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1. Thrombotic Thrombocytopenic Purpura  
Thrombotic thrombocytopenic purpura (TTP) is a very rare disease with an incidence 
of 4-11 cases/106 per year, according to the OKLAHOMA TTP-HUS registry (1). When 
left untreated, it is a life-threatening thrombotic microangiopathic disorder (TMA), 
characterized by severe thrombocytopenia and microangiopathic hemolytic anemia, 
with symptoms including microthrombosis in capillaries and arterioles, presence of 
fragmented red blood cells (RBC) (schistocytes) and low hematocrit levels. Other less 
specific symptoms are fever, neurological dysfunction and renal impairment (2). To 
understand the pathophysiology of TTP, basic principles of blood, platelets, 
hemostasis and von Willebrand Factor (VWF) will be discussed in the following 
paragraphs. 
1.1. Blood 
The human body contains approximately 5 liters of blood of which the main component 
is plasma (55%), consisting mainly of water, but also of nutrients, oxygen, waste 
products, salts and proteins. The remaining 45% of the blood is formed by the blood 
cells, including red blood cells (RBC) or erythrocytes, white blood cells (WBC) or 
leukocytes and blood platelets or thrombocytes. These cells have various specific 
functions and are the final product of hematopoiesis, a highly regulated process 
originating in the bone marrow. RBC bind oxygen via hemoglobin and transport it from 
the lungs to the tissues (3). The volume of RBC in whole blood, expressed in 
percentage, is termed hematocrit and is normally around 45% in both men and mice 
(Table 1). It is a measure for the effectiveness of oxygen delivery to the tissues and 
low hematocrit levels are related to anemia (4).  
3 
WBC consist of neutrophils, eosinophils, basophils, monocytes, macrophages and 
lymphocytes. These cells protect the body from infectious diseases and foreign 
invaders, and thus are important in innate and acquired immunity (5).  
The primary function of platelets is coagulation or blood clotting, but they are also 
involved in other processes such as tissue repair, host defense and production of 
inflammatory cytokines (6). 
1.1.1. Platelets 
Every day, 1011 blood platelets are produced in and removed from the human body to 
maintain a steady state with an average platelet count of 150-400 x 103 platelets per 
microliter of blood. Human platelets are anuclear, very small (1.5-3 µm) cells, with a 
discoid shape (lens shaped) because of the highly specialized cytoskeleton (7, 8). Two-
thirds of the platelets circulate through the body whereas the rest is stored in the 
spleen. Platelets have a plasma membrane rich in specific glycoprotein (GP) surface 
receptors regulating platelet adhesion, activation and aggregation (9). The most 
abundant surface receptor is the αIIbβ3 integrin of which there are 40-80 x 103 per 
platelet, even further increasing after platelet activation (10). Furthermore, platelets 
contain secretory α- and dense granules storing biologically active molecules. 
Especially the α-granules, which contain proteins involved in platelet adhesion such as 
von Willebrand factor (VWF) and αIIbβ3, are well represented (40-80/platelet) (11, 12). 
Factors released after platelet activation such as serotonin, adenosine diphosphate 
(ADP), adenosine triphosphate (ATP) and calcium are stored in the dense granules 
(13). 
The average survival time of blood platelets in humans is between 8 and 10 days. 
When platelet counts are lower than 150 x 103 platelets per microliter of blood, this 
condition is called thrombocytopenia and is associated with bleeding at platelet 
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numbers below 30 x 103 platelets per microliter. There are significant differences 
between human and murine platelets (Table 1). In mice, normal platelet counts are 4 
to 6 times higher than in humans and can reach levels up to 1600 x 103 platelets per 
microliter of blood. Additionally, platelets in mice are much smaller than in humans and 
their survival time is 2 to 3 times shorter. Moreover, the α-granules in murine platelets 
are more heterogeneous in size and shape (circular or elongated) and there are fewer 
dense granules than in human platelets (14). 
Table 1: Normal values for the blood cell count and platelet characteristics of male human and 
murine (C57BL/6; age 8-10 weeks) blood and platelets. 
 Human Murine 
Red blood cell count (x106/µL) 4.0 - 6.0 9.5 
Hematocrit (%) 47 47 
Hemoglobin (g/dL) 13.5 - 16.5 14.2 
White blood cell count (x103/µL) 4.8 - 10.8 8.9 
Platelet count (x103/µL) 150 - 400 900 - 1600 
Mean platelet volume (fL) 9.7 - 12.8 5.0 
Platelet diameter (µm) 1.5 - 3.0 0.50 
Platelet lifespan (days) ± 10 ± 4.0 
 
Source: Charles River Mouse Hematology; Anatomy and Philology (15, 16). 
 
Platelet production and clearance are strictly regulated processes, in both 
physiological and pathological conditions, monitoring constant numbers of platelets in 
order to prevent spontaneous bleeding or thrombus formation and subsequent organ 
damage (7). 
The most prominent player in regulation of platelet production is thrombopoietin (TPO), 
which is produced mainly by hepatocytes, bone marrow and kidneys. Platelet 
precursors in the bone marrow, the megakaryocytes, mature under influence of diverse 
chemokines and cytokines (e.g. TPO, interleukin (IL)-6, IL-3, IL-11, colony-stimulating 
factor) and become polynuclear during a process called endomitosis. While 
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megakaryocytes mature, their cytoplasm increases in size and is filled with platelet-
specific α- and dense granules (8). In a next step, polynuclear megakaryocytes 
develop extensions and form proplatelets that extend through or between sinusoidal 
cells into the blood circulation. These proplatelets fragment into anuclear, sialylated 
platelets, which are released into the blood stream (Figure 1) (17).  
 
Figure 1: Platelet production from megakaryocytes in the bone marrow.  
From hematopoietic stem cells (HSC) in the bone marrow, megakaryocytes are formed regulated 
by thrombopoietin (megakaryopoiesis). Megakaryocytes mature and become polynuclear, form 
long extensions (proplatelets) and release sialylated platelets into the circulation. Figure based 
on (7).  
 
After being split off from the megakaryocytes and released into the blood stream, 
platelets will eventually be consumed in a hematopoietic process or cleared from the 
circulation. Platelet clearance occurs through the liver and the spleen, and is regulated 
by different mechanisms: intrinsic apoptosis (a), clearance by antibodies (b), ageing-
induced (senescence) (c) or cold-induced (d) (by storage for platelet transfusion) 
clearance (7).  
a) Although platelets are anuclear, the intrinsic apoptotis pathway is involved in 
platelet clearance. B-cell lymphoma 2 (Bcl-2) family members are present in 
human platelets, driving clearance through apoptosis. Pro-survival proteins of 
the Bcl-2 family protect healthy platelets from apoptosis. However, these 
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proteins can be inhibited leading to mitochondrial damage, cytochrome C 
release and ultimately caspase activation resulting in apoptosis and clearance 
via scavenger receptors (Figure 2.1). It was shown that ex vivo inhibition of the 
Bcl-2 family member Bcl-xL in platelets resulted in mitochondrial damage, 
caspase activation and externalization of phosphatidylserine, which is typical for 
dying nucleated cells (18, 19). Furthermore, thrombocytopenia was caused in 
mice and dogs within 2 hours after administration of a Bcl-xL inhibitor (20). The 
triggering event leading to activation of the apoptotic pathway remains unclear 
(18). Moreover, it is unknown whether Bcl-2 family members influence sialic acid 
content on the platelet surface. It is possible that sialic acid loss could trigger 
intrinsic apoptosis, thereby affecting platelet survival (7).  
b) In immune thrombocytopenic purpura, also known as immune 
thrombocytopenia (ITP), autoantibodies directed against different surface 
receptors on platelets e.g. αIIbβ3 or GPIb-IX-V are produced by B cells after 
interaction of reactive T cells with memory B cells (21). It is thought that the first 
antigenic response occurs in the spleen and is followed by stimulation of other 
antibody-producing tissues, particularly the bone marrow (22). When passing 
through the sinusoids of the spleen, macrophages will recognize and 
phagocytose auto-antibody-coated platelets, leading to destruction (23) (Figure 
2.2).   
c) Platelet surface glycoproteins, e.g. GPIb, are important in glycan-lectin 
mediated platelet clearance. In ageing (senescent) circulating platelets, the 
VWF-binding GPIbα subunit is desialylated by platelet sialidases. Due to the 
removal of the sialic acids, galactose residues become exposed, which leads to 
recognition of the platelets by specific liver lectins called the Ashwell-Morell 
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receptors (AMR), resulting in clearance of the senescent platelets (24) (Figure 
2.3). Recently, it became clear that elimination of senescent platelets by the 
hepatic AMR drives TPO production in the liver followed by increased 
megakaryocyte and platelet production, assuring an equilibrium between 
production and clearance (25). 
d) Refrigerated platelets used for platelet transfusion are cleared more rapidly from 
the circulation than room temperature stored platelets, because cooled platelets 
lose, apart from the sialic acids groups, also the underlying galactose residues, 
whereby N-acetyl D-glucosamine (GlcNac) groups become exposed. After 
transfusion of cooled platelets, these monosaccharides cluster and are 
recognized as foreign by the αMβ2 integrin on the hepatic Kupffer cells, followed 
by phagocytosis and removal of the transfused platelets (26) (Figure 2.3). 
Consequently, platelets for transfusion are stored at room temperature risking 
bacterial contamination and loss of platelet functionality, limiting the storage 
time to maximum 5 days (27). 
Hence, platelet counts are regulated in a complex way. Production and clearance of 
platelets seem interrelated as shown by the regulation of TPO after senescent platelet 
clearance by the hepatic AMR. Under pathological conditions, platelets are cleared via 
spleen macrophages, while senescent platelets are removed from the circulation by 
liver cells or apoptosis, regulated partly by desialylation of platelet surface 
glycoproteins. 
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Figure 2: Mechanisms of platelet clearance in the liver and spleen.  
1) Clearance mediated by programmed cell death (apoptosis) via the intrinsic apoptotic pathway: 
the balance between pro- and anti-apoptotic Bcl-2 family members is disturbed leading to 
discontinuation of the inhibition of Bak and Bax resulting in apoptosis. The triggering factor is 
still unknown. 2) Auto-antibody mediated clearance: antibodies against αIIbβ3 or GPIb leading 
to phagocytosis or platelet desialylation, respectively. 3) Glycan-lectin mediated clearance: due 
to ageing, desialylation results in recognition and clearance of the platelet by the AMR on 
hepatocytes. In addition, stored platelets can lose galactose thereby exposing GlcNAc that will 
be recognized by the Kupffer cell αMβ2 integrin in the liver leading to phagocytosis of the 
platelet. Figure based on (7).  
Abbreviations: GPIb: glycoprotein I b; Bcl-2: B-cell lymphoma 2; AMR: Ashwell-Morell receptor; 
GlcNac: N-acetyl D-glucosamine. 
 
1.1.2. Circulatory system and shear stress 
Blood is pumped from the heart through the body by a network of arteries, arterioles, 
capillaries, venules and veins. These blood vessels are built of three distinct layers: 
tunica intima, tunica media and tunica adventitia. The tunica intima contains 
endothelial cells surrounded by a basal membrane: the subendothelium that is 
surrounded by the internal elastic lamina. The tunica media is formed by a layer of 
smooth muscle cells together with connective tissue. Beneath the smooth muscle cells, 
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a second elastic layer, the external elastic lamina, is located. The outer layer is the 
tunica adventitia built of connective tissue that consists of collagen and fibroblasts. The 
vessel size and type determines the thickness and composition of these three layers. 
Arteries and arterioles have a thicker layer of smooth muscle cells than veins and 
venules and can therefore resist higher pressures. The pressure in veins and venules 
is much lower than in arteries and arterioles. Veins and venules also lack the elastic 
laminas. Nevertheless, because of the presence of valves in the central venous 
circulation, it is possible to bring the blood back to the heart. The capillaries form the 
connection between arterioles and venules and are located in the tissues. These 
consist only of a thin layer of endothelial cells to facilitate diffusion and supply the 
tissues with oxygen and nutrients (3). 
Blood is a viscous fluid and can flow because of a pressure gradient resulting in 
tangential forces generated at the vessel wall in the direction of the flow, which is called 
shear stress (28). The blood flow is laminar in a cylindrical vessel and therefore the 
velocity of the blood stream is highest in the middle of a blood vessel and decreases 
towards zero at the blood vessel wall. In contrast, the shear stress is highest at the 
vessel wall and in small vessels such as arterioles and capillaries (29, 30).  
1.1.3. Hemostasis 
Hemostasis is the resting condition in which pro-coagulant and anti-coagulant 
processes are balanced. Disturbed hemostasis will lead to thrombosis or bleeding, 
which can be life-threatening. When a vessel is damaged, platelets react immediately 
by binding to the injured vessel wall, leading to the formation of a blood clot preventing 
excessive blood loss. To form and dissolve a clot, three mechanisms are important: 
primary and secondary hemostasis and fibrinolysis.   
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Primary hemostasis comprises three phases in which platelets play a prominent role, 
namely adhesion, activation and aggregation (Figure 3) (31-33).  
 
Figure 3: (Primary) hemostasis after vessel injury.   
1. The intact blood stream. 2. Blood vessel damage leading to VWF release from the Weibel 
Palade bodies in the endothelial cells. 3. VWF can bind with its A3 domain to the exposed 
collagen of the subendothelium and will unfold due to shear stress. Platelets are now able to 
bind to VWF with their GPIb receptor. This binding is reversible and the platelets start to roll over 
VWF. 4. During the rolling phase, platelets bind with the GPIaIIa and GPVI receptors to collagen 
and platelets become activated. Step 3 and 4 are called adhesion. 5. In the next step, the 
activation phase, the conformation of αIIbβ3 receptor on platelets changes, 6. allowing 
fibrinogen binding and thus crosslinking αIIbβ3 on adjacent platelets resulting in aggregation 
and blood clot formation. The platelet clot formed during primary hemostasis can be stabilized 
further in the secondary hemostasis by fibrin and thrombin. Ultimately, in wound healing the 
blood clot is removed by plasmin during fibrinolysis.  
Abbreviations: VWF: von Willebrand Factor; GP: glycoprotein. 
 
During the adhesion phase (Figure 3.3 and 3.4), platelets will adhere to the vessel wall 
by binding with their GPIb receptor to VWF that in a previous step already bound to 
the naked collagen of the subendothelium of the injured vessel and consequently 
unfolded due to shear stress (Figure 3.2 and 3.3) (31). This platelet-VWF binding is 
transient and therefore, platelets will roll over the damaged vessel wall, which slows 
down the platelets allowing them to interact with collagen via integrin α2β1 (GPIaIIa) 
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and GPVI (34). Subsequently, platelets become activated, characterized by a 
conformational change and spreading of platelets (Figure 3.5). In addition, the content 
of the α- and dense granules is secreted resulting in further activation of rolling 
platelets. Activated platelets express the activated αIIbβ3 receptor, which makes it 
possible to form platelet aggregates (clots) in the aggregation phase (Figure 3.6) (33).  
This platelet aggregate would, however, quickly dissolve and only postpone bleeding. 
Therefore, the clot is simultaneously stabilized by a fibrin network involving the 
coagulation cascade or secondary hemostasis cascade in which thrombin plays a 
major role (35) (Figure 4). Tissue factor (TF), the key initiator of the coagulation 
cascade, circulates in blood at low concentrations (100-150 pg/mL plasma) and is 
active or can be activated. Furthermore, TF is expressed by cells surrounding blood 
vessels. When a blood vessel is damaged, blood will leak into the extravascular tissues 
and will be exposed to TF. This will initiate the extrinsic coagulation cascade in which 
thrombin is formed after a number of enzymatic reactions. Apart from the extrinsic 
pathway, the coagulation cascade can be amplified by activating coagulation factor XII, 
but especially factor XI by negatively charged surfaces such as glass (in vitro) or 
negatively charged phosphatidylserine (in vivo); this is called intrinsic coagulation. 
Thrombin formed in the early extrinsic pathway can also activate factor XI. Ultimately, 
both the extrinsic and intrinsic coagulation share a common pathway in which 
prothrombin is converted into thrombin that will convert fibrinogen into insoluble fibrin 
and can further activate platelets. In addition, thrombin will interact with the GPIb 
receptor on platelets, thereby activating factor IX, factor VIII and factor V, resulting in 
high levels of thrombin. During primary hemostasis, luminal (inside the vessel) 
activated platelets and endothelial cells will release P-selectin that will bind to P-
selectin glycoprotein ligand-1 (PSGL-1) on monocytes. This results in induction of TF-
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rich microvesicles transported to the thrombus ultimately leading to generation of 
thrombin (36, 37). 
 
Figure 4: The secondary hemostasis or coagulation cascade. 
In the extrinsic pathway (red), trauma leads to exposure of tissue factor (TF) and activated factor 
VII (FVIIa). Together, this complex activates factor X (FX). The intrinsic pathway (blue), after a 
cascade of enzymatic reactions, also leads to activation of FX by the tenase complex. 
Subsequently, the common pathway (green) results in formation of thrombin from prothrombin, 
which will also bind to the GPIb receptor on platelets, activate FVIII and FV leading to a thrombin 
burst. Thrombin converts fibrinogen to insoluble fibrin that will stabilize the platelet plug formed 
during primary hemostasis. In addition, thrombin is able to activate platelets leading to further 
secretion of coagulation cascade factors (e.g. prothrombin). At the inside of the vessel, P-
selectin secreted from activated platelets and endothelial cells will bind to PSGL-1 on monocytes 
resulting in TF positive MP generation and increased thrombin generation. MP can also be 
formed by platelets and endothelial cells.  
Abbreviations: F: factor; a: activated; TF: tissue factor; GP: glycoprotein; PSGL-1: P-selectin 
glycoprotein ligand-1; MP: microparticles.  
 
When activated, platelets also secrete several factors of the coagulation cascade (e.g. 
prothrombin) and negatively charged phosphatidylserine becomes exteriorized (38), 
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forming a surface on which coagulation can proceed. Moreover, VWF is the carrier 
protein of coagulation factor VIII. Thus, primary and secondary hemostasis collaborate 
to form a stable thrombus, which happens very rapidly after vessel injury (32, 35). 
The traditional classification into extrinsic and intrinsic pathway of the coagulation 
cascade is still valid, but nowadays coagulation is often subdivided into initiation, 
amplification, propagation and stabilization. During the initiation phase, thrombin is 
generated, which further activates factor V and VIII to activate the prothrombinase 
complex leading to a thrombin burst in several positive feedback loops during the 
amplification phase. In the propagation phase, the tenase and prothrombinase 
complexes assure continuous generation of thrombin and fibrin to form a large clot. 
Thrombin generation results in factor XIII activation covalently linking fibrin polymers 
resulting in a stable platelet clot during the stabilization phase (39).  
In the third process, i.e. fibrinolysis (Figure 5), plasmin breaks down fibrin in order to 
dissolve the blood clot. Furthermore, the fibrinolytic system is important in protecting 
the body from thrombus formation in healthy vessels (32). The fibrinolytic system 
contains several cofactors, receptors and inhibitors, and is therefore highly regulated 
and controlled. The precursor of plasmin, plasminogen, is produced by the liver and 
activated by tissue-type plasminogen activator (tPA) or urokinase (uPA) that are 
secreted by endothelial cells or urinary epithelium. Inhibitors of the fibrinolytic system 
are important to prevent hyperactivity of plasmin. Plasminogen activator inhibitor (PAI)-
1 and -2 can inhibit tPA and uPA, whereas α2-antiplasmin (α2-AP) inhibits plasmin in 
a 1:1 ratio. However, plasmin generated at the fibrin surface is protected from rapid 
inhibition by α2-AP. In addition, α2-AP can also bind to fibrin protecting it from cleavage 
by plasmin and protecting the clot from fibrinolysis. Thrombin activatable fibrinolysis 
inhibitor (TAFI) exerts anti-fibrinolytic activity by eliminating C-terminal lysines on fibrin, 
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leading to a strongly decreased binding of plasminogen to fibrin (40). Thus, fibrinolysis 
is a regulated enzymatic process preventing unneeded fibrin clot formation, assuring 
balanced hemostasis and breakdown of platelet-fibrin plugs when necessary (41, 42).  
Figure 5: The fibrinolytic system.  
Plasmin can cleave fibrin into fibrin degradation products leading to clot breakdown, thus 
dissolving a blood clot. The precursor plasminogen is activated to plasmin by tPA or uPA, which 
can be inhibited by PAI-1 and PAI-2. Furthermore, α2-AP can inhibit plasmin or bind to fibrin to 
delay its cleavage.   
Abbreviations: tPA: tissue-type plasminogen activator; uPA: urokinase; PAI: plasminogen 
activator inhibitor; α2-AP: α2-antiplasmin. 
 
1.2. von Willebrand Factor  
VWF is a multimeric plasma glycoprotein that plays a major role in primary hemostasis 
(as described above). VWF is produced by endothelial cells and megakaryocytes and 
can be stored in Weibel Palade bodies or α-granules in either endothelial cells or 
platelets, respectively. The blood VWF concentration is 5-15 µg/mL blood (43). 
1.2.1. Synthesis, release and clearance 
The VWF encoding gene is located at chromosome 12. After transcription, the VWF 
mRNA is translocated to the cytoplasm where it is translated to the pre-pro-VWF 
precursor consisting of a signal peptide, propeptide and the mature VWF subunit. 
Thereafter, the signal peptide is responsible for the translocation of pre-pro-VWF to 
the endoplasmatic reticulum where the pre-peptide is cleaved and VWF dimers, also 
known as protomers, are formed by a disulfide bond between two pro-VWF moieties. 
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Further multimerization occurs in the Golgi complex via additional disulfide bridges 
resulting in multimers consisting of 2 to 60 subunits (44). The pro-peptides are released 
by furin after glycosylation and the mature ultra-large VWF (UL-VWF) is transported to 
the α-granules of megakaryocytes or platelets, to Weibel Palade bodies of endothelial 
cells, or is secreted directly into the blood stream (Figure 6) (45, 46). The formation of 
Weibel Palade bodies in the endothelial cells is VWF dependent, whereas α-granules 
in platelets will be generated regardless of VWF.  
Release of VWF from endothelial cells into the blood stream can be either constitutively 
or in a regulated process, whereas VWF secretion from α-granules requires platelet 
activation (45). Consequently, all the VWF in circulation comes from the endothelium. 
Most of the VWF secreted by endothelial cells arises from the constitutive secretory 
pathway. Endothelial stimulation (as upon vascular injury) leads to massive release of 
Weibel Palade bodies and the production of longer hyperactive VWF multimers that 
anchor to endothelial cells and induce spontaneous microaggregate formation. 
Consequently, platelets will be recruited and primary hemostasis occurs (47). 
The half-life of therapeutic VWF antigen in humans is approximately 16 hours, but the 
half-life of endogenous VWF is very variable depending on its glycosylation pattern. 
Since VWF is a carrier protein of the coagulation cascade factor VIII, also the half-life 
of the latter will depend on the individual half-life of VWF (48). 
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Figure 6: Synthesis of VWF in endothelial cells.  
1. The gene that encodes VWF is located on chromosome 12. 2. The VWF mRNA is translocated 
to the cytoplasm where it is translated to the pre-pro-VWF protein, which is translocated to the 
endoplasmatic reticulum (ER) via its signal peptide. 3. The pre-peptide is cleaved in the ER, VWF 
dimers (protomers) are formed by a disulfide bond between two pro-VWF moieties. 4. Further 
multimerization occurs in the Golgi complex. 5. The propeptides are released and the mature 
ultra-large VWF is transported to the Weibel Palade bodies of the endothelial cell or secreted 
into the blood stream. Figure based on (48).  
Abbreviations: ER: endoplasmatic reticulum; VWF: von Willebrand Factor; mRNA: messenger 
RNA; UL-VWF: ultra-large VWF; WB: Weibel Palade. 
 
Since VWF and macrophages generally co-localize and after depletion of 
macrophages endogenous VWF levels increase strikingly, the major elimination route 
of VWF is via macrophages in the liver and spleen (49). It is believed that VWF is 
cleared by receptor-mediated endocytosis, possibly involving the Ashwell receptor, low 
density lipoprotein receptor-related protein 1 (LRP1), sialic acid binding Ig like lectin 5 
(Siglec-5) or C-type lectin domain family 4 member M (CLEC4M) receptors; in 
particular the LRP1 receptor appears to be important in VWF clearance. However, 
since deficiency of this receptor leads to only a twofold increase of the VWF half-life it 
is plausible that other, up until now unknown, receptors could also play a role (50). 
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1.2.2. Structure, function and activity  
VWF multimers consist of monomers of 250 kDa built of 2050 amino acids that form 
different domains, more specifically D1-D2-D’-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-
CK (Figure 7).  
Figure 7: Domain structure of VWF.  
The pre-pro-VWF protein contains the signal peptide of 22 amino acids (aa), the pro-peptide of 
741 aa that contains the D1 and D2 domain, and the mature monomer of 2050 aa. The mature 
monomer contains different domains. Figure based on (48) and (50). Abbreviations: aa: amino 
acids; VWD: von Willebrand Factor D; C8: cysteine 8; TIL: trypsin-inhibitor-like; E: E module; 
FVIII: factor 8; GP: glycoprotein; ADAMTS13: a disintegrin and metalloproteinase with 
thrombospondin-1 repeat, member 13; VWF: von Willebrand Factor. 
 
Recently it has been discovered that the D1, D2 and D3 domains contain von 
Willebrand Factor D (VWD), cysteine 8 (C8), trypsin-inhibitor-like (TIL) structures and 
an E module. D4 domains lack E modules, but enclose a unique D4N domain. The D’ 
domains do not contain VWD or C8 domains (Figure 7) (50, 51). The D1-D2 domains 
form the pro-peptide and the remaining protein is the mature VWF subunit. Each 
mature monomer contains 12 N-linked and 10 O-linked glycosylation sites essential for 
the secretion, clearance and folding of VWF. The A1 domain is able to bind platelets 
via the GPIb receptor, the A2 domain contains the cleavage site where ADAMTS13 (a 
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disintegrin and metalloproteinase with thrombospondin-1 repeat, member 13) can bind 
and the A3 domain contains the major physiological binding site for fibrillar collagens I 
and III, whereas the A1 domain can bind to collagen VI (52). The platelet receptor 
αIIbβ3 interacts with the C1 domain of VWF, resulting in a stable platelet binding.  
In normal physiologic conditions, VWF is in its folded, inactive globular form in order to 
prevent spontaneous platelet binding to circulating VWF. While circulating, the A3 
domain is constitutively accessible and able to bind to exposed collagen at sites of 
vascular injury. Subsequently, mechanical shear forces will induce the conformational 
change of VWF, uncovering the A1 and A2 domains leading to binding with platelets 
and/or cleavage by ADAMTS13, respectively (45, 53) (Figure 8).  
 
Figure 8: Unfolding and activation of VWF. 
 In normal physiologic conditions, VWF is in its globular, folded conformation. Shear stress 
leads to unfolding, thereby exposing the A1 and A2 domains of VWF. Platelets can bind to the 
A1 domain; ADAMTS13 can bind and cleave VWF in its A2 domain decreasing the activity of 
VWF. Figure adapted from (45).   
Abbreviations: VWF: von Willebrand Factor; ADAMTS13: a disintegrin and metalloproteinase 
with thrombospondin-1 repeat, member 13. 
 
The activity of VWF is determined by its multimeric composition. The largest VWF 
multimers, ultra-large (UL)-VWF, are the most hemostatically active in binding with 
blood platelets. These UL-VWF multimers unfold better under high shear rates as 
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present in arterioles and capillaries and can spontaneously interact with platelets, 
resulting in intravascular platelet plugs. However, normally ADAMTS13 will cleave, 
fragment and thereby inactivate VWF to prevent unwanted platelet plug formation (45, 
46, 50). The domain structure and functions of ADAMTS13 are described in section 2 
of this general introduction. 
Besides ADAMTS13, VWF can be cleaved in vitro by thrombin, plasmin, proteinase 3, 
cathepsin G, elastase and granzyme B. However, the significance of these factors for 
proteolysis of VWF in vivo is still questionable (47, 54).  
1.3. Types of TTP 
TTP is caused by a deficiency or total absence of the VWF cleaving proteinase 
ADAMTS13 resulting in uncleaved UL-VWF multimers leading to platelet aggregation 
and microthrombosis, especially in arterioles and capillaries (the microcirculation) 
(Figure 9). Most TTP patients develop their first TTP episode during adolescence or 
even later in life. Therefore, it is thought that besides a lack or absence of ADAMTS13, 
a secondary triggering factor generating shear stress or endothelial activation is 
needed to evoke acute TTP. Known triggers are pregnancy, alcohol abuse, HIV, 
surgery, etc. (55). However, in most cases the trigger remains undiscovered, and 
therefore the exact etiology of TTP is still unknown.  
The two main types of TTP are the congenital and acquired form. Congenital TTP, also 
known as Upshaw-Schulman Syndrome, is provoked by a recessively inherited 
mutation in the ADAMTS13 gene resulting in disturbed synthesis, secretion or 
activation of the proteinase. Consequently, ADAMTS13 activity is severely reduced. 
Notwithstanding that there are more than 140 different mutations in the ADAMTS13 
gene described, congenital TTP is extremely rare and represents less than 5% of all 
TTP cases (56). Patients with congenital TTP generally develop their first attack in 
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early childhood and tend to relapse, but in uncommon cases the disease state remains 
undetected until adolescence. Acquired TTP, on the other hand, is the most common 
form of TTP and is caused by autoantibodies directed against ADAMTS13, thereby 
clearing it from the circulation or inhibiting its function. Thus, acquired TTP is an 
autoimmune disease. The predominant binding sites for the antibodies are the spacer 
and cysteine-rich domains of ADAMTS13 (45). Acquired TTP may be secondary to 
specific conditions such as pregnancy, infections, certain pharmacological therapies, 
autoimmune diseases and alcohol abuse, but is usually idiopathic (55). 
 
Figure 9: Pathophysiology of TTP.  
Triggering factors may activate the endothelium, resulting in release of platelet activating factors 
and UL-VWF from the WP bodies. When ADAMTS13 activity is normal, the UL-VWF multimers 
will be cleaved and inactivated. However, in TTP, ADAMTS13 is deficient or absent. 
Consequently, the UL-VWF multimers will not be cleaved and remain hyperactive leading to 
platelet binding and activation, which results in the formation of VWF/platelet-rich blood clots 
especially in the microcirculation where the shear stress is highest. Figure based on (56).  
Abbreviations: UL-VWF: ultra-large von Willebrand Factor multimers; WP: Weibel Palade; 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin-1 repeat, member 13; 
TTP: thrombotic thrombocytopenic purpura. 
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1.4. Diagnosis and treatment of TTP 
As already mentioned above, TTP is originally characterized by a pentad of symptoms, 
more specifically: severe thrombocytopenia (< 50 000 platelets/µL of blood), 
microangiopathic hemolytic anemia (formation of microthrombi, schistocytes in blood 
smears and a low hematocrit), fever, neurological signs and kidney failure. These five 
symptoms are not always present altogether, and TTP also shows overlap with other 
TMA’s. However, the sooner the treatment is started, the better the prognosis will be 
(55). Therefore, when a patient presents with severe thrombocytopenia and signs of 
hemolytic anemia, the patient should be diagnosed for TTP and treatment should be 
started immediately without unnecessary delay. Plasma, serum and blood cells are to 
be checked for ADAMTS13 and VWF levels. Since TTP is a rare disease, it is not 
always easy to recognize and is therefore a challenging hematological emergency. 
Nowadays, the overall survival rate of a TTP episode is over 80%, but 40% of the 
patients will relapse with possibly a fatal outcome (57).  
Congenital TTP is treated by plasma infusion therapy in which 20-40 mL/kg body 
weight of fresh frozen donor plasma is infused, thereby administering donor 
ADAMTS13. Acquired TTP cannot be treated by plasma infusion therapy, because the 
administered donor ADAMTS13 would be neutralized by the autoantibodies. 
Consequently, plasma exchange therapy will be used instead in order to remove the 
autoantibodies. The plasma infusion or exchange therapy for, respectively, congenital 
or acquired TTP is given on a daily basis until platelet counts and lactate 
dehydrogenase (LDH) activity levels (marker of organ damage related to 
microthrombosis) normalize, and signs of hemolysis and organ damage improve (55). 
Other options to treat acquired TTP are immunosuppressive therapy to limit further 
synthesis of autoantibodies, or Rituximab, a monoclonal antibody against the CD20 
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antigen of B-cells to destroy the antibody producing B-cells. Rituximab is now generally 
used in patients that do not react well to treatment and occasionally even as first line 
therapy. For patients with refractory or frequently relapsing TTP, splenectomy could 
also be helpful (55, 57). 
TTP therapy should be improved further to ameliorate the response rate in TTP 
episodes and prevent relapses. Therefore, international clinical trials are currently 
performed to evaluate new therapeutics such as Caplacizumab. This nano-body 
against the A1 domain of VWF (in a phase two clinical trial) prevents binding of 
platelets to VWF (58). Another very promising treatment is recombinant ADAMTS13 
(rADAMTS13) that can substitute the deficient or inhibited proteinase (59). 
1.5. Animal models for TTP 
As the exact etiology of TTP is still unclear, animal models are of great value to 
investigate the etiology of this rare disease, and thereby develop new, more specific 
treatments or strategies to prevent TTP (60).  
1.5.1.  Mouse models 
The first ADAMTS13 deficient (Adamts13-/-) mouse was generated by Motto et al. in 
2005 (61). Exons 1-6 of the ADAMTS13 gene were replaced by a neomycin resistant 
cassette in a mouse on a C57BL/6J and 129X1/SvJ mixed genetic background. 
Despite complete loss of ADAMTS13 activity, this Adamts13-/- mouse was healthy and 
did not show any signs of TTP. Another research group developed an Adamts13-/- 
mouse on a pure 129/Sv background by eliminating exon 3-6 of the ADAMTS13 gene. 
Similar to the Adamts13-/- mice on the mixed background, ADAMTS13 activity was 
completely lost, but the mice were healthy (62). Thus, deficiency of ADAMTS13 is not 
sufficient to develop TTP symptoms in mice.   
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Interestingly, mice on a CASA/Rk background have 5- to 10-fold higher VWF levels as 
compared to mice on a mixed C57BL/6J and 129X1/SvJ background (63). In this 
context, Motto et al. tried to improve their Adamts13-/- mouse TTP model by 
backcrossing it into the CASA/Rk background and thereby obtaining higher VWF levels 
that could induce TTP. However, even though some mice showed a lower platelet 
count and reduced survival, spontaneous TTP development was exceptional (61).  
In a following step, based on the second hit theory for evoking an acute TTP event, 
several triggering factors were suggested to elicit TTP symptoms in genetically 
predisposed Adamts13-/- mice. For instance, infection with bacterial Shigatoxin (Stx), 
produced by Shigella dysenteriae and Escherichia coli, can cause Hemolytic Uremic 
Syndrome (HUS), which shows similarities with TTP. Injection of Stx in Adamts13-/- 
mice in a CASA/Rk background induced TTP-like symptoms such as severe 
thrombocytopenia, severe anemia, microangiopathic hemolytic anemia and VWF-rich 
thrombi in the microcirculation. However, these signs were not present in all mice that 
were treated with the toxin (61). Another TTP triggering factor in mice is high dose 
(2000 U/kg) recombinant human VWF (rVWF) containing highly active UL-VWF 
multimers. Intravascular injection of this rVWF resulted in severe thrombocytopenia in 
all treated animals, a decreased hematocrit, increased LDH activity indicating organ 
damage and schistocytes in the blood smears. Nevertheless, none of the animals died 
since end-stage TTP was not attained (64).  
1.5.2.  Baboon model 
Baboons are non-human primates, and when injected with neutralizing monoclonal 
ADAMTS13 antibodies (3H9, inhibitory monoclonal anti-ADAMTS13 antibody directed 
against a metalloproteinase epitope; 5C11 non-inhibitory anti-ADAMTS13 antibody 
directed against the second thrombospondin-1 (TSP-1) repeat as control antibody) can 
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serve as model for acquired TTP. Administration of the antibody resulted in 
ADAMTS13 activity levels below the detection limit (< 5%) and the baboons suffered 
from severe thrombocytopenia and hemolytic anemia. In addition, they had increased 
LDH levels, schistocytes in their blood smears and microthrombi in the 
microvasculature. However, since none of the animals died, it was defined as early 
stage TTP (65). 
2. ADAMTS13 
ADAMTS13 is a constitutively active Zn2+- and Ca2+-dependent metalloproteinase (66). 
It is produced and secreted by the hepatic stellate cells (67) and to a lesser extent by 
vascular endothelial cells (68). ADAMTS13 is able to cleave VWF, its only known 
substrate, in the A2 domain, more specifically between amino acid 1605 (Tyr) and 1606 
(Met).  
2.1. Domain structure 
ADAMTS13 is a glycoprotein with a plasma concentration of 1 µg/mL and a half-life of 
2-3 days in man. It consists of different domains: the metalloproteinase (MP), 
disintegrin (D), cysteine-rich (Cys), spacer (S), TSP-1 repeat (TSR) and 2 CUB 
(Complement component C1r/C1s, Urinary epidermal growth factor (Uegf), and Bone 
morphogenic protein-1) domains (Figure 10) (69). The interaction of the MP-D-TSP-1-
Cys-S domains with VWF is well described, but the role of the C-terminal tail domains 
(7 TSP-1 and 2 CUB domains) is still largely unknown. The MP domain is the catalytic 
domain, whereas the D-TSP-1-Cys-S domains are especially involved in the correct 
positioning of ADAMTS13 on VWF. The MP-D-TSP-1-Cys-S domains as such can 
degrade VWF multimers in vitro and in vivo to the same extent as the complete 
ADAMTS13 proteinase. However, deletion of the Cys or S domain markedly decreases 
the ADAMTS13 activity (70). In humans, but not in mice, it is believed that the distal 
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domains inhibit the MP domain until it is bound to unfolded VWF that will support its 
own destruction by activating ADAMTS13 (71). VWF strings are UL-VWF multimers 
secreted from the endothelium that remain anchored to the activated endothelial cell 
surface. These multimers can unravel due to shear stress and bind to platelets, 
resulting in string-like structures that wave in the direction of the flow (47). The 
proteolysis of these strings is regulated positively by the TSR2-8-CUB domains, 
probably because these domains can serve as docking site for VWF multimers (70). 
 
Figure 10: Domain structure of ADAMTS13.   
The VWF cleaving proteinase ADAMTS13 is built of different domains: metalloproteinase, 
disintegrin, cysteine-rich, spacer, TSP-1 repeat and 2 CUB domains.  
Abbreviations: MP: metalloproteinase; D: disintegrin; Cys: cysteine-rich; S: spacer; TSR: 
thrombospondin-1 repeat; CUB: Complement component C1r/C1s, Urinary epidermal growth 
factor (Uegf), and Bone morphogenic protein-1. 
 
2.2. Functions of ADAMTS13 
ADAMTS13 is able to bind to VWF in its globular form, but cannot cleave it because 
the A2 domain is buried in the globular conformation. Therefore, cleavage is only 
possible when VWF is in its active, unfolded conformation (72). Moreover, the A2 
domains in the middle of a larger VWF multimer are more prone to unfolding due to 
shear stress and therefore to cleavage by ADAMTS13, as compared to shorter VWF 
multimers or non-centered A2 domains of the multimers (73). Due to its potential to 
cleave VWF, ADAMTS13 has anti-thrombotic capacities. 
There is no known specific inhibitor of ADAMTS13 and the proteolytic activity is 
dependent on the availability of the VWF cleavage site. ADAMTS13 cleaves unfolded 
26 
VWF in circulation, at sites of platelet clot formation and newly secreted VWF from 
endothelial cells (45). Thrombin and collagen, both present upon vessel damage and 
coagulation, counteract cleavage of VWF by ADAMTS13, thereby allowing clot 
formation. VWF can easily bind to the exposed collagen, unfolds in response to shear 
stress and activates platelets leading to stable clot formation. Additional platelets will 
be recruited and activated independently of VWF and can therefore become resistant 
to the effects of ADAMTS13-regulated cleavage of VWF. The platelet plug grows, but 
formation occurs more efficiently in presence of collagen and thrombin, which are only 
present at the site of injury. Therefore, beyond the injury, VWF-platelet binding is less 
pronounced, probably allowing efficient cleavage of VWF by ADAMTS13. Thus, 
platelet plug growth remains restricted to the site of vessel damage (45). In contrast, 
large VWF multimers present in the circulation can unfold naturally. However, since 
collagen and thrombin are absent in this situation and ADAMTS13 will cleave the 
unraveled VWF multimer in the A2 domain, the formation of platelet-rich microthrombi 
is prevented (45).  
High VWF/ADAMTS13 ratios are of significant importance in stroke development. 
Recently it was shown that rADAMTS13 could be administered as pontential 
pharmacological therapy in stroke, especially in tPA resistant cases. Ischemic stroke 
thrombi are indeed VWF-rich. Thus, in an Adamts13-/- mouse model with VWF-rich 
thrombotic occlusion, administration of rADAMTS13 led to recanalization of the 
occluded vessel, implying thrombolytic potential of the proteinase (74). 
UL-VWF multimers are important in thrombus formation, but also play a role in 
inflammation. Thrombosis and inflammation share an analogous first step in which 
VWF is involved: platelet adhesion. Thus, apart from its antithrombotic role, 
ADAMTS13 affects inflammatory-related processes: it prevents rolling of leukocytes in 
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unstimulated veins, and decreases adhesion and extravasation of leukocytes in 
inflammatory conditions (75, 76).  
ADAMTS13 is part of the ADAM/ADAMTS family that consists of 21 ADAM and 19 
ADAMTS proteinases. They can regulate cell adhesion and migration (disintegrin 
domain) and degrade extracellular matrix components (metalloproteinase domain), 
and consequently play a role in cell proliferation and angiogenesis (77). TSP-1 
domains, however, inhibit angiogenesis. In vitro, rADAMTS13 as such has pro-
angiogenic capacities, but after addition of vascular endothelial growth factor (VEGF), 
VEGF-induced angiogenesis is inhibited by ADAMTS13 due to the TSP-1 domains that 
affect VEGF receptor (VEGFR) 2 phosphorylation (78, 79). Thus, the angiogenic 
capacities of ADAMTS13 depend on its TSP-1 repeats, that can mediate pro- or anti-
angiogenic effects on VEGF levels and VEGFR2 phosphorylation (76).  
2.3. Plasmin as backup for ADAMTS13 
Probably because of oscillating ADAMTS13 levels, TTP is a disease characterized by 
recurrent acute episodes of microangiopathic hemolytic anemia alternated by periods 
of remission. Strikingly, human subjects with very low levels or complete absence of 
ADAMTS13 activity can present without symptoms of microangiopathy, suggesting 
that other factors can compensate for ADAMTS13 (80). Plasmin, the protagonist of 
fibrinolysis, is proposed as a candidate for ADAMTS13 substitution to degrade 
platelet/VWF complexes during thrombotic microangiopathic episodes (81). In vitro, 
plasmin is able to cleave VWF, but in human subjects, the results are less clear. During 
an acute TTP episode in patients, plasma plasmin-α2-antiplasmin (PAP) complexes, a 
measure of plasminogen activation, are increased predominantly in patients with 
severe microangiopathy and undetectable ADAMTS13 activity. This implies that 
thrombolysis is increased in TTP patients, which is rather counterintuitive. It was 
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hypothesized that hypoxia, resulting from microthrombi, triggers plasminogen 
activation on the endothelium of ischemic tissue. Consequently, VWF degradation by 
plasmin leads to destruction of the microthrombi and clinical symptoms will not 
develop. Only when microthrombi formation exceeds the endogenous plasmin 
formation, TTP symptoms will appear due to the inability to clear the obstructions (54, 
81).  
3. Obesity 
3.1. Definition and prevalence of obesity 
According to the World Health Organization (WHO), obesity is defined as an excessive 
accumulation of adipose tissue impairing health. The body mass index (BMI) is 
calculated as weight (kg) divided by the square of the length (m²) and is the most used 
index to classify obesity (Table 2) (82). 
Table 2: WHO classification of BMI. 
BMI (kg/m²) classification 
<18.5 Underweight 
18.5-24.9 Healthy, normal 
25-29.9 Overweight 
30-34.9 Obese class I 
35-39.9 Obese class II 
≥ 40 Obese class III or morbidly obese 
 
The BMI does, however, not correspond to the same degree of fatness in different 
individuals, because it cannot distinguish weight associated with muscle from weight 
associated with fat (83). Hence, other indices such as waist-to-hip ratio (WHR), waist 
circumference (WC) and waist-to-height ratio (WHtR) are also used (84-87). The WC 
is an integral feature to diagnose the metabolic syndrome (88, 89), which is a cluster 
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of metabolic disorders that enhance the risk of heart disease, impaired glucose 
tolerance and insulin resistance (90).  
Obesity is a multifactorial disease, as both genetic and environmental factors play a 
role in its etiology (91). However, the WHO reported that dietary and nutritional 
changes, especially the increased intake of foods rich in fat and sugar, in combination 
with a sedentary lifestyle are the major causes of the obesity pandemic. The most 
recent data state that worldwide more than 1.9 billion adults are overweight and 600 
million people are obese (June 2016) (82). The obesity problem is not confined to 
Western societies, but has a global impact, even touching continents threatened by 
starvation (92).  
In 2010, 54% of the Belgian adults were overweight and 15% were obese; in 2014, the 
mean BMI of a Belgian adult was 25.5 kg/m² and 21% of the Belgian adults were 
obese. In 2012, 21% of Belgian children between 10 and 12 years old were overweight 
(93). Obesity has become the second most important cause of early death, after 
smoking. In the USA 112,000 people die from obesity-related causes every year (94). 
As a consequence, the health care costs related to overweight, obesity and 
comorbidities are substantial (95). In Western European countries, the estimated 
obesity-related health care costs range from 0.09% to 0.61% of total annual gross 
domestic product (GDP). The highest annual costs were reported in Germany and 
corresponded to 10.4 billion Euros in 2002 (96). Similar data were reported in studies 
from Canada and New Zealand, where obesity-related costs ranged from 0.2% to 0.6% 
of the GDP (97-99). In the future, further increases are expected. 
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3.2. (White) adipose tissue 
Obesity is characterized by an excessive accumulation of adipose or fat tissue. 
Adipocytes form 90% of the adipose tissue volume, but only 20-40% of the cellular 
content (100). In addition to adipocytes, fat tissue consists of the stromal vascular 
fraction (SVF) containing pre-adipocytes, fibroblasts, vascular smooth muscle cells, 
endothelial cells, neurons, macrophages and lymphocytes. There are different types 
of adipose tissue including brown and beige (101), but the white adipose tissue (WAT) 
is the most abundant. 
3.2.1.  Unlimited growth potential of white adipose tissue 
WAT protects the internal and delicate organs from mechanical stress and functions 
as insulator against heat loss. However, its most important function is its role in 
nutritional homeostasis, especially as energy storing organ. When energy intake 
exceeds expenditure, the excess of energy is stored in white adipocytes in the form of 
triglycerides. The storing capacity of white adipocytes for lipids has an almost unlimited 
potential, which is a unique feature in comparison with other organs. Adipocytes have 
a unilocular morphology and are able to grow. The latter process is called hypertrophy 
and thereby adipocytes can have various sizes (25-200 µm in diameter). Apart from 
growing adipocytes, adipose tissue mass can also increase by de novo formation of 
mature adipocytes differentiated from committed pre-adipocytes, a process known as 
hyperplasia (101). In order to expand, adipocytes need to be in close proximity to at 
least one blood vessel for the supply of oxygen, nutrients and fatty acids from the blood 
stream and for the elimination of waste products. Therefore, new blood vessels are 
formed from pre-existing blood vessels (angiogenesis) in obese adipose tissue (102). 
Especially hypertrophy is related with cardiometabolic risks, insulin resistance and 
hepatic fibrosis (103). However, 30% of obese subjects are metabolically healthy. 
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These “benign obese” people have smaller adipocytes than metabolically unhealthy 
subjects of comparable weight, and the size of adipocytes correlates with insulin 
sensitivity. Thus, adipocyte size may be more important than adipose tissue mass for 
the metabolic health profile of obese people (104).  
3.2.2.  Inflammatory state of obese adipose tissue 
Adipose tissue produces and secretes bioactive proteins, called adipokines, including 
leptin, adiponectin and tumor necrosis factor-α (TNF-α) into the circulation and thus 
functions as an endocrine organ regulating metabolism and inflammation. Because of 
these endocrine mediators, the adipose tissue can interact and communicate with 
other organs, such as the pancreas, liver and muscle thereby controlling glucose 
metabolism, insulin sensitivity, immunological processes etc. (105). 
In obese individuals, leptin levels are increased in parallel with body fat mass, while 
adiponectin levels are negatively correlated with adipose tissue mass. In contrast to 
most other adipokines, adiponectin exerts anti-inflammatory actions (106). The lower 
levels of adiponectin in obesity are important in the development of insulin resistance 
since it is an insulin-sensitizing hormone. It stimulates release of anti-inflammatory 
cytokines e.g. IL-4 and IL-10, and inhibits phagocytotic activity and production of TNF-
α in macrophages, the differentiation of monocyte precursors, and the formation of 
foam cells (related to cardiovascular disease). Leptin is a satiety hormone that can 
sense the state of energy storage in the body and stimulate satiety or energy 
expenditure. It is a pro-inflammatory adipokine stimulating monocyte proliferation and 
differentiation into macrophages and induces the production of pro-inflammatory 
cytokines such as TNF-α, IL-6 and IL-8 (107).  
Due to the presence of immune cells (especially leukocytes), cytokines and 
chemokines including TNF-α and IL-6 are prominent in adipose tissue. These 
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cytokines can be pro- or anti-inflammatory. The majority of these cytokines is produced 
by adipose tissue resident macrophages of which there are two main groups, the M1 
or pro-inflammatory classically activated and M2 or anti-inflammatory alternatively 
activated macrophages. M1, but particularly M2 macrophages are present in lean 
adipose tissue. However, while becoming obese there is a switch to a greater M1/M2 
ratio, as the amount of M1 macrophages increases whereas the number of M2 
macrophages remains unchanged (108). Moreover, other white blood cells such as 
neutrophils, B- and T-cells also produce pro-inflammatory cytokines in obese adipose 
tissue. Consequently, obesity is characterized by a chronic low-grade pro-inflammatory 
state of the adipose tissue.  
The pro-inflammatory state is maintained by the combination of an excessive uptake 
of saturated fatty acids (SFA) from the diet, oxidative stress and hypoxia coming 
together in a vicious circle (Figure 11). Lean adipose tissue has mainly anti-
inflammatory capacities due to M2 macrophages and anti-inflammatory adipokines as 
adiponectin and IL-10. An excess of nutrients, as often seen in obesity, leads to 
increased release of free fatty acids (FFA) of which especially the SFA are involved in 
inflammation. SFA bind to Toll-like receptors (TLR) on macrophages leading to 
secretion of pro-inflammatory cytokines and increase in leptin production (109). 
Furthermore, the excess of nutrients and subsequent cell expansion (hypertrophy) in 
obesity causes cellular stress leading to the production of reactive oxygen species 
(ROS) and stronger activation of pro-inflammatory pathways. Moreover, macrophages 
are attracted to these stressed adipocytes and recruited into the white adipose tissue, 
which will lead to enhanced production of pro-inflammatory cytokines. Furthermore, 
stressed adipocytes are dysfunctional and can go into apoptosis leading to formation 
of crown-like structures (CLS), which are dead adipocytes surrounded by 
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macrophages. Altogether, this leads to enhanced stress, adipocyte death and further 
stress signaling (110, 111). Despite obesity-related angiogenesis, the vascular 
availability for adipocytes can still be limited due to extreme expansion of the adipose 
tissue leading to hypoxia. This causes increased leptin, decreased adiponectin, lactate 
production and ultimately adipocyte apoptosis. Consequently, macrophages are 
recruited to the hypoxic areas resulting in a higher level of inflammation, stressed and 
dysfunctional adipocytes (112). Since apoptosis of adipocytes plays a major role in 
development of insulin resistance and hepatic steatosis, inflammation of white adipose 
tissue resulting from excess of SFA, oxidative stress and hypoxia, is involved in the 
development of metabolic disorders, thus comorbidities related to obesity (113). 
3.2.3. Anatomical location of white fat is of considerable concern 
Fat depots are anatomically localized at different regions in the body and therefore 
have different characteristics. A major distinction is made between subcutaneous (SC) 
and visceral adipose tissue. However, visceral adipose tissue can be further 
subdivided into, among others, gonadal (GN), mesenteric, retroperitoneal, epicardial 
and omental fat. Interestingly, visceral fat depots are distinct in humans and rodents. 
Whereas the epididymal fat mass is considerable and the omental fat hardly exists in 
mice, these depots are nonexistent and well represented, respectively, in human 
visceral fat (114). However, in both rodents and men, visceral adiposity, in contrast to 
SC fat, is associated with a metabolically unhealthy profile.  
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Figure 11: Obesity, a state of low-grade chronic inflammation in the adipose tissue.  
Lean adipose tissue contains low levels of pro-inflammatory IL-6, IL-8, TNF-α and leptin, whereas 
adiponectin levels are relatively high (font size corresponds to amount). Resident macrophages 
are primarily anti-inflammatory M2 macrophages (green). While becoming obese, adipocytes 
grow (hypertrophy) and increase in number (hyperplasia). Moreover, new blood vessels will 
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develop (angiogenesis) to supply the new and larger adipocytes with nutrients and oxygen (O2). 
However, local hypoxia (O2↓) can still occur leading to lactate production. Together with an 
excess of saturated fatty acids (SFA) from the diet and the development of oxidative stress, this 
leads to the activation of pro-inflammatory pathways. Leptin production increases and pro-
inflammatory M1 macrophages (orange) are attracted to the adipose tissue thereby secreting 
cytokines and chemokines. The obese adipocytes become dysfunctional causing more stress 
and inflammation resulting in apoptotic adipocytes and formation of crown-like structures (CLS) 
that will lead to further inflammation and stress. Therefore, obesity is a condition of low-grade 
chronic inflammation of the adipose tissue in which the adipocytes are trapped in a vicious circle 
of pro-inflammatory macrophage chemotaxis, cytokine production and stress.  
Abbreviations: Mφ1: pro-inflammatory classically activated M1 macrophages; Mφ2: anti-
inflammatory alternatively activated M2 macrophages; IL: interleukin; TNF-α: tumor necrosis 
factor-α; ROS: reactive oxygen species; SFA: saturated fatty acids; TLR: Toll-like receptors; 
CLS: crown-like structures. 
 
Visceral and SC depots show differences in adipokine production and secretion, 
inflammatory profile and adipocyte behavior (115). For instance, more infiltration of 
macrophages and lower secretion of the anti-inflammatory adipokine adiponectin is 
observed in obese visceral fat, leading to a more pro-inflammatory profile as compared 
to SC adipose tissue. Furthermore, adiposity is reduced and glucose homeostasis 
improved when SC adipose tissue is transplanted to the visceral area, indicating that 
SC fat has potentially favorable metabolic effects (116). 
3.3. Comorbidities 
Obesity is associated with a variety of life-threatening comorbidities, including 
cardiovascular diseases, insulin resistance and type 2 diabetes, non-alcoholic fatty 
liver disease (NAFLD), cancer and respiratory diseases. 
Normally, fat storage is limited to the adipose tissue, but in obesity, the overload of fat 
will also accumulate in other organs throughout the body. This ectopic lipid deposition 
can give rise to organ dysfunction, as in NAFLD and insulin resistance.  
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NAFLD is a spectrum of diseases ranging from fat accumulation in the liver (liver 
steatosis) to non-alcoholic steatohepatitis (NASH). Liver steatosis mostly persists 
without symptoms and thus remains unnoticed. NASH is characterized by 
inflammation, hepatocellular injury and fibrosis and is therefore a risk for liver cirrhosis 
and cancer (117). However, subjects suffering from NASH develop cardiovascular 
diseases sooner and more frequently than the liver-related side effects. NAFLD is the 
most frequent liver disease in Western countries and is considered the hepatic 
manifestation of the metabolic syndrome of which the risk factors are very similar. More 
specifically, insulin resistance, type 2 diabetes, central obesity and dyslipidemia are 
the major players in development of NAFLD as well as of the metabolic syndrome 
(118). 
Fat accumulation in the liver, but also in muscle and pancreas, is linked to insulin 
resistance. Insulin is released from β-cells in the pancreas after nutrient ingestion and 
is the major regulator of glucose homeostasis. It decreases appetite and stimulates 
storage and uptake of energy, whereas the breakdown of macromolecules to glucose 
as well as de novo glucose production in the liver is blocked. Insulin resistance is one 
of the most common comorbidities related to obesity. The β-cells are still capable to 
produce and secrete sufficient insulin, but the cells are unable to react to the hormone 
resulting in hyperglycemia. As a response, β-cells increase their insulin secretion, FFA 
are released from the adipose tissue, production of FFA and hepatic glucose 
increases, glucose uptake by skeletal muscles is decreased, and β-cells become 
eventually dysfunctional (119, 120) and type 2 diabetes develops. Furthermore, insulin 
resistance together with hypercholesterolemia, ectopic fat deposition in the heart and 
blood vessels, endothelial dysfunction and an inflammatory state as seen in obesity 
are risk factors for cardiovascular diseases related to atherothrombotic events (121).  
37 
Since human platelets express insulin receptors, insulin has an anti-aggregating 
function in insulin-sensitive subjects, while in insulin-resistant conditions as obesity, 
the anti-aggregating effects are largely reduced (122). Moreover, in obese subjects, 
platelet activation, thrombin and fibrinogen levels are increased. Because of coronary 
artery disease as seen in many obese people, other coagulation factors and anti-
fibrinolytic agents, such as TF and PAI-1 are also enhanced, resulting in increased clot 
formation. Therefore, obesity is a pro-thrombotic state, as a consequence of the 
obesity-related insulin resistance and inflammation (123). 
4. Obesity as risk factor for TTP  
The exact etiology of TTP is still unclear. It is generally accepted that mostly 
ADAMTS13 deficiency plays an important part in the pathophysiology of TTP, but a 
second triggering event is needed to evoke an acute TTP episode. Recent data 
suggest that obesity might be such a triggering event and therefore might be a risk 
factor for TTP.  
Multiple independent studies indicated that ADAMTS13 and obesity could possibly 
interact. Firstly, ADAMTS13 plasma antigen levels and BMI are positively correlated in 
humans, as observed in a case-control study of patients with myocardial infarction 
(124). Furthermore, ADAMTS13 expression levels in the liver are higher in obese as 
compared to lean mice (125). Thus, both in humans and in mice, ADAMTS13 antigen 
levels and body weight are positively correlated.  
As explained above, obesity is a state of chronic inflammation and is, in addition, 
described as a potential risk factor for TTP development, while ADAMTS13, on the 
other hand, has anti-inflammatory capacities (75). Since body weight and ADAMTS13 
levels are positively correlated, this is rather paradoxical. Furthermore, it would be 
expected that an increase of ADAMTS13 would protect against TTP and thus that 
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obesity would be protective against TTP instead of being a risk factor. However, 
despite these contradictions, there are several indications that obesity is indeed a risk 
factor for TTP, as observed in the Oklahoma TTP cohort study. This is a population-
based inception cohort of 376 patients recruited from 1989 to 2008, with an initial TTP 
episode that required plasma exchange. This study showed that the prevalence of 
obesity, especially morbid obesity (BMI of at least 40 kg/m²) was increased in TTP 
patients (126). Furthermore, half of the patients with severe ADAMTS13 deficiency 
were obese. Thus, the relative frequency of obesity increased in patients diagnosed 
with TTP and TTP patients with ADAMTS13 levels lower than 10% were more obese 
(127). In addition, obesity was associated with TTP development and identified as an 
independent risk factor for TTP with an odds ratio of 7.6 in a retrospective study with 
108 TTP patients (128). In the context of acquired TTP, Lombardi et al. found (non-
inhibitory) autoantibodies against ADAMTS13 in obese subjects stating that obesity 
could be a risk factor for acquired TTP (129). 
The pathophysiological mechanisms regulating the interaction between obesity and 
TTP remain, however, unknown.  
 
 
  
 
 
 
 
 
 
Chapter 2 
Aims of the study 
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The exact etiology of TTP remains unclear. It is thought that a (genetic) predisposition 
is underlying TTP development, but that an extra, undefined trigger is required to evoke 
an acute TTP episode. Despite some controversies, there is evidence that obesity is a 
possible risk factor for TTP. Moreover, since ADAMTS13 levels and BMI are positively 
correlated, ADAMTS13 (mainly produced and secreted by the liver) could play a role 
in adipose tissue expansion. In this project:  
1. We investigated whether ADAMTS13 is involved in adipose tissue expansion. 
Therefore, we kept wild-type (WT) and ADAMTS13 deficient (Adamts13-/-) mice 
on a diet high in fat and sugar (HFD) to nutritionally induce obesity, or on a 
standard diet (SFD) (Chapter 3).  
2. We studied whether ADAMTS13 deficiency and obesity are synergistic risk 
factors for microthrombi formation in the liver, and whether plasmin could 
compensate for the absence of ADAMTS13 in Adamts13-/- mice (Chapter 4).  
3. We investigated a potential role for ADAMTS13 in liver steatosis in two different 
mouse models for NAFLD, i.e. a diet-induced obesity model (Chapter 4) 
and a steatosis model induced by a diet deficient in methionine and choline 
(Chapter 5).  
4. We evaluated whether obesity is indeed a risk factor for TTP and explored 
potential underlying mechanisms (Chapter 6). 
5. We tried to develop a new murine TTP model by using obese Adamts13-/- mice. 
A new animal model for TTP would be very useful to further unravel the 
pathophysiology or etiology of TTP, thereby identifying triggering factors, and to 
develop potential strategies for treatment/prevention of acute TTP episodes 
(Chapter 6).  
  
  
 
 
 
 
 
 
Chapter 3 
No functional role of ADAMTS13 in adiposity in mice 
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ABSTRACT 
Background: BMI and ADAMTS13 levels are positively correlated in man. 
Development of obesity is associated with angiogenesis and inflammation, and 
increased ADAMTS13 synthesis in the liver. 
Methods: Male wild-type (WT) and ADAMTS13 deficient (Adamts13-/-) mice were kept 
on normal chow (SFD) or high fat diet (HFD) for 15 weeks.  
Results: HFD feeding of WT mice resulted in significantly enhanced levels of 
ADAMTS13 antigen and activity as compared to SFD feeding. ADAMTS13 deficiency 
had no significant effect on body weight gain, subcutaneous (SC) or gonadal (GN) 
adipose tissue mass, or on adipocyte size. In GN fat of obese (HFD) Adamts13-/- mice, 
adipocyte density was higher and blood vessel density lower as compared to obese 
WT mice. No marked effects of genotype were observed on mRNA expression of 
adipogenic, endothelial, inflammatory or oxidative stress markers in adipose tissue. 
Analysis of metabolic parameters and of glucose and insulin tolerance did not reveal 
significant differences between both obese genotypes, except for higher adiponectin 
and cholesterol levels in obese Adamts13-/- as compared to WT mice.  
Conclusion: Our data do not support a functional role of ADAMTS13 in adiposity, nor 
in associated angiogenesis or inflammation in mice.  
General significance: ADAMTS13 deficiency may cause thrombotic 
thrombocytopenic purpura (TTP). Obesity, which is associated with enhanced 
ADAMTS13 levels, is nevertheless considered an independent risk factor for TTP. To 
resolve this apparent contradiction, we show that ADAMTS13 does not directly 
promote development of adipose tissue in a mouse model.  
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INTRODUCTION 
Metabolic disturbances such as obesity and diabetes and their associated 
complications are a main cause of mortality and morbidity. Development of adipose 
tissue is a complex process in which extensive modifications occur in adipogenesis, 
angiogenesis and proteolytic remodeling of extracellular matrix (1). Matrix 
metalloproteinases are known to play a role in these processes, but little is known on 
a potential contribution of related classes of proteinases (2, 3). 
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin-1 repeat, 
member 13) is the proteinase that degrades large multimers of von Willebrand Factor 
in plasma, thereby preventing development of thrombotic thrombocytopenic purpura 
(TTP), a life-threatening multisystem disease characterized by the formation of 
microthrombi in capillaries and arterioles (4). It was suggested that obesity may be a 
risk factor or trigger for acquired TTP (5); obesity is indeed more frequent in the 
population of TTP patients than in the general population and represents an 
independent risk factor for TTP (6). In addition, it has been suggested that ADAMTS13 
itself may play a role in adiposity. Indeed, ADAMTS13 plasma levels correlate 
positively with body mass index (7), and its synthesis is significantly increased in the 
liver of obese mice (8), likely due to low-grade chronic inflammation (9). However, an 
inhibitory effect of ADAMTS13 on inflammation has been reported in mouse models of 
atherosclerosis and cerebral ischemia (10, 11). Furthermore, the thrombospondin-1 
(TSP-1) domain of ADAMTS proteinases, such as ADAMTS5, has anti-angiogenic 
properties (12). Indeed, ADAMTS13 inhibits VEGF-induced angiogenesis by binding 
to VEGF via its TSP-1 domain (13). However, recently Lee et al. found ADAMTS13 to 
have pro-angiogenic features in vitro by upregulating VEGF and VEGFR2 (14).  
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Because of these apparently contradictory data and the known association of 
angiogenesis and inflammation with obesity, we have investigated a potential role of 
ADAMTS13 in development of adipose tissue and associated angiogenesis and 
inflammation, using an established model of diet-induced obesity in WT and 
ADAMTS13 deficient mice.  
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MATERIALS & METHODS  
Nutritionally induced obesity model 
Male Adamts13-/- (n = 20) and WT littermates (n = 18) (genetic background, C57Bl6/J 
x 129X1/Sv x CASA/RK) (15), from the age of 5 weeks on, were kept in individual 
micro-isolation cages on a 12h day/night cycle and fed for 15 weeks with a HFD (42% 
kcal as fat, caloric value 22 kJ/g; E15721-34; Ssniff, Soest, Germany) (n = 17) or a 
standard fat diet (SFD) (13% kcal as fat, caloric value 10.9 kJ/g; KM-04-k12, Muracon, 
Carfil, Oud-Turnhout, Belgium) (n = 21). Water was always available ad libitum. Body 
weight and food intake were measured at weekly intervals.  
The mice were sedated and blood was taken from the retro-orbital sinus on trisodium 
citrate (0.01 M), before they were killed by cervical dislocation. Inguinal subcutaneous 
(SC) and intra-abdominal gonadal (GN) adipose tissues were removed and weighed. 
Portions were used for RNA or protein extraction or were fixed in 1% formaldehyde for 
histological analysis. Other organs were also removed and weighed. 
All animal experiments were approved by the KU Leuven ethical committee (P082-
2011) and performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (1996) and carried out in accordance with the EU Directive 
2010/63/EU for animal experiments. 
ADAMTS13 determinations 
Murine ADAMTS13 antigen levels in plasma were measured using a home-made 
ELISA. A 96-well microtiter plate was coated overnight with the in-house developed 
murine anti-mADAMTS13 monoclonal antibody 20A10 at 5 µg/ml in PBS. After 
blocking, plasma was diluted in PBS, 0.3% (m/v) skimmed milk and the plate was 
incubated at 37°C for 1h. An in-house developed polyclonal rabbit anti-mADAMTS13 
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(5 µg/ml) was incubated for 1h. Bound antibody was detected with HRP-labeled goat 
anti-rabbit antibody (Jackson Immunoresearch Laboratories Inc., West Grove, PA) 
(1/25,000 in dilution buffer). A pool of normal murine plasma was used as a reference 
and set as 100% mADAMTS13 antigen. 
The activity of murine ADAMTS13 was measured using the FRETS-VWF73 method 
(16). Briefly, murine ADAMTS13 in plasma (20 µl) was incubated with 2 µM FRETS-
VWF73 in a HEPES buffered saline solution (50 mM HEPES, 5 mM CaCl2, 1 µM ZnCl2, 
150 mM NaCl, pH 7.4; HBS), containing 1 mg/ml bovine serum albumin (Sigma, St 
Louis, MO). Digestion of FRETS-VWF by murine ADAMTS13 generates a fluorescent 
signal that is measured using the FLUOstar OPTIMA reader (BMG Labtech GmbH, 
Offenburg, Germany). ADAMTS13 mRNA levels in liver extracts were determined by 
quantitative real-time PCR using the primers and 6-carboxy-fluorescein (FAM) labeled 
probes, shown in Table 3. 
Metabolic and inflammatory parameters 
At the end of the diet, blood was obtained from the tail of unanesthetized mice after 
fasting for 6h. Blood glucose concentrations were measured using the Accu-chek 
performa meter and blood glucose test strips (Roche Diagnostics, Basel, Switserland). 
Total and HDL cholesterol levels were evaluated using routine clinical assays. Leptin 
and adiponectin levels in plasma were determined with specific ELISA’s (R&D 
Systems, Minneapolis, USA). 
Extracts of SC and GN adipose tissues were prepared as described (17), and the 
protein concentration was determined using the BCA protein assay. IL-6 and TNF- 
levels in plasma or extracts were measured using commercially available ELISA’s 
(ELISA Ready-SET-Go!, Affymetrix eBioscience, San Diego, CA). 
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Table 3: Markers detected by qPCR using TaqMan gene expression assays. 
Gene Assay† Gene Assay† 
GLUT4 Mm00436615_m1 IL-6 Mm00446190_m1 
PPAR- Mm01184322_m1 MCP-1 Mm00441242_m1 
Adiponectin Mm00456425_m1 Arginase Mm00475988_m1 
CD36 Mm00432403_m1 Mannose receptor Mm00485148_m1 
VEGF-A Mm00437304_m1 Catalase Mm00437992_m1 
VE-cadherin Mm00486938_m1 SOD1 Mm01700393_g1 
endoglin Mm00468256_m1 GPX1 Mm00656767_g1 
F4/80 Mm00802529_m1 XDH1 Mm00442110_m1 
TNF- Mm00443258_m1 -actin Mm01205647_g1 
 
 FW primer RV primer probe 
ADAMTS13 GGAGCCCAAGGATG
TGTGTCTT 
TCTCTGGAGGTGAG
AGGGAGGAT 
6FAM 
CTTGGCCACCATGC
T MGBNFQ 
 
 
†Assays purchased from Life Technologies (Carlsbad, CA). 
 
Gene expression studies 
mRNA expression levels in adipose tissue extracts were determined by quantitative 
real-time PCR, as described elsewhere (18). qPCR was done in the ABI 7500 Fast 
Sequence detector (Life Technologies) to detect the markers listed in Table 3. 
Transcript levels were determined in duplicate by qPCR reaction using a gene 
expression assay with specific primers, probes and the Fast mastermix (Life 
Technologies, Carlsbad, CA). Analyses were performed with the CT method using 
the 7500 System SDS software (Life Technologies). Normalization was carried out to 
correct for fluctuations caused by sample differences. Fold changes were calculated 
as 2-∆∆CT relative to the mice fed a SFD for the obese mice (effect of diet), and relative 
to WT mice for the Adamts13-/- mice (effect of genotype). -actin was used as 
housekeeping gene. 
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Histological analysis 
Paraffin sections (8 µm) for histology were prepared from isolated SC and GN fat pads. 
The size and density of adipocytes in the SCAT and GNAT were determined by 
staining with haematoxylin/eosin (H&E) under standard conditions. The blood vessels 
in the adipose tissues were analyzed by staining with Bandeiraea simplicifolia lectin 
(19). Analyses were performed by using a Zeiss Axioplan 2 microscope with the 
AxioVision release 4.8 software (Carl Zeiss, Oberkochen, Germany).  
Insulin and glucose tolerance tests 
In separate experiments, after 10 weeks of HFD, WT and Adamts13-/- mice (n = 10 
each) were fasted for 6h and a bolus of 0.1 U/kg human insulin (Eli Lilly Benelux S.A., 
Brussels, Belgium) or 2 mg/g glucose was administered i.p. Blood glucose levels were 
determined, as described above, before and 30, 60, 90 and 120 minutes after insulin 
or glucose injection. 
Statistics 
Data are presented as means ± standard error of the means (SEM). Statistical 
significance between groups was analyzed with the non-parametric Mann-Whitney U 
test, one-way or two-way ANOVA. Correlation analysis was performed using the 
Spearman rank test. Analysis of the data was performed using Prism 6 (GraphPad 
Software Inc., San Diego, CA). Values of p < 0.05 are considered statistically 
significant. 
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RESULTS 
Effect of ADAMTS13 deficiency on adiposity 
Five weeks old Adamts13-/- and WT mice had comparable body weight and showed a 
very similar weight gain when kept on either SFD (lean) or HFD (obese) for 15 weeks 
(Figure 12A) (Table 4). Food intake over this period was also comparable for both 
genotypes (Figure 12B).  
Figure 12: Body weight and food intake of WT and Adamts13-/- mice. 
Evolution of body weight (A) or food intake (B) of WT (closed symbols) and Adamts13-/- (open 
symbols) mice kept on SFD (circles) or HFD (squares) for 15 weeks. Data are means ± SEM of 8 
to 11 experiments in each group. No significant differences were observed between both 
genotypes (One-way ANOVA). 
 
In plasma of WT mice, significantly elevated levels of both ADAMTS13 antigen and 
activity were observed after 15 weeks of HFD feeding (Figure 13). ADAMTS13 mRNA 
expression in the liver was not different between lean or obese WT mice (p = 0.52, 
data not shown). Isolated SC or GN fat mass were not significantly different for WT or 
Adamts13-/- mice on either diet. Adipocytes were markedly enlarged on HFD as 
compared to SFD, but adipocyte size was similar for both genotypes (Table 4). 
Adipocyte density in SC adipose tissue was similar for WT and Adamts13-/- mice on 
either SFD or HFD, whereas it was higher in GN fat of obese Adamts13-/- versus obese 
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WT mice (Table 4). The weight of other organs, including liver, heart, spleen, lungs, 
pancreas, kidneys and hypothalamus was also not different between both genotypes 
either on SFD or HFD (data not shown). 
Table 4: Body weight, adipose tissue mass, adipocyte size and density, blood vessel size and 
density in GN and SC adipose tissue of WT and Adamts13-/- mice fed a SFD or HFD for 15 weeks. 
 
SFD HFD 
WT Adamts13-/- WT Adamts13-/- 
n 10 11 8 9 
Body weight start (g) 22.3 ± 0.49 22.6 ± 0.65 20.8 ± 0.45 22.4 ± 0.65† 
Body weight end (a) (g) 31.3 ± 0.48 31.3 ± 0.86 40.9 ± 1.2 40.3 ± 1.7 
Body weight gain (g) 8.3 ± 0.28 8.8 ± 0.44 19.8 ± 0.90 17.9 ± 1.3 
SC 
weight (mg) 338 ± 15 384 ± 45 1279 ± 80 1096 ± 92 
adipocyte size (µm²) 1055 ± 100 1279 ± 156 3092 ± 312 2591 ± 261 
adipocyte density (x10-6/µm2) 1042 ± 70 900 ± 86 362 ± 42 446± 53 
vessel size (µm²) 24.6 ± 1.9 24.5 ± 1.1 29.5 ± 1.9 24.2 ± 1.2† 
vessel density (x10-6/µm²) 657 ± 58 510 ± 62 386 ± 43 417 ± 27 
vessel n°/adipocyte n° 0.62 ± 0.04 0.60 ± 0.06 1.2 ± 0.17 1.0 ± 0.09 
GN 
weight (mg) 791 ± 43 855 ± 87 2672 ± 147 2454 ± 241 
adipocyte size (µm²) 2229 ± 63 2391 ± 155 5626 ± 266 4519 ± 335 
adipocyte density (x10-6/ µm2) 456 ± 13 441 ± 30 182 ± 9.6 234 ± 19† 
vessel size (µm²) 29.5 ± 1.8 27.6 ± 1.5 34.7 ± 1.3 30.9 ± 3.1 
vessel density (x10-6/µm²) 337 ± 13 301 ± 20 266 ± 12 203 ± 15†† 
vessel n°/adipocyte n° 0.78 ± 0.04 0.70 ± 0.04 1.4 ± 0.14 0.95 ± 0.12† 
 
Data are means ± SEM of n experiments in each group. †p < 0.05, †† p < 0.01 as compared to WT 
mice on HFD (Mann-Whitney U test). (a) Body weight after 6h of fasting.   
Abbreviations: SFD: standard fat diet; HFD: high fat diet; WT: wild-type; Adamts13-/-: ADAMTS13 
deficient; SC: subcutaneous adipose tissue; GN: gonadal adipose tissue. 
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Figure 13: ADAMTS13 antigen and activity levels in plasma of WT mice. 
ADAMTS13 antigen (A) and activity (B) levels in plasma (to normal mouse plasma) of WT mice 
at the start and the end of SFD or HFD feeding for 15 weeks. *, *** p < 0.05, p < 0.001. 
 
Table 5: Adiponectin, leptin, total and HDL cholesterol levels in plasma and glucose levels 
measured in whole blood of WT and Adamts13-/- mice fed a SFD or HFD for 15 weeks. 
 
 
SFD HFD 
WT Adamts13-/- WT Adamts13-/- 
n 10 11 8 9 
Adiponectin (µg/ml) 4.1 ± 0.15 4.3 ± 0.33 3.5 ± 0.13** 4.6 ± 0.35†† 
Leptin (ng/ml) 1.8 ± 0.40 3.4 ± 0.7 18.7 ± 1.2*** 16.3 ± 3.7# 
Total cholesterol (mg/dl) 56.3 ± 1.1 59.7 ± 3.5 100 ± 7.5*** 126 ± 7.9###† 
HDL cholesterol (mg/dl) 45.6 ± 2.4 47.2 ± 2.8 93.4 ± 6.4*** 108 ± 7.3### 
Glucose (mg/dl) 124 ± 7.8 129 ± 7.0 152 ± 8.8 169 ± 4.1 
 
Data are means ± SEM of n experiments in each group. †p < 0.05, †† p < 0.01 as compared to WT 
mice on HFD. ** p < 0.01, *** p < 0.001 as compared to WT mice fed a SFD. # p < 0.05, ### p < 
0.001 as compared to Adamts13-/- mice fed a SFD (Mann-Whitney U test).   
Abbreviations: SFD: standard fat diet; HFD: high fat diet; WT: wild-type; Adamts13-/-: ADAMTS13 
deficient. 
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Gene expression analysis of the adipogenic markers GLUT4, PPAR-, adiponectin and 
CD36 in adipose tissues did not reveal effects of ADAMTS13 deficiency in lean or 
obese mice, with the exception of lower GLUT4 expression in SC fat of lean  
Adamts13-/- mice (0.80 ± 0.05 versus 1.03 ± 0.09 for lean WT mice, p < 0.05 by Mann-
Whitney U test) (data not shown). Determination of plasma adiponectin levels by ELISA 
(Table 5) revealed lower levels in obese versus lean WT mice, but not in obese versus 
lean Adamts13-/- mice. Higher levels were observed in obese Adamts13-/- versus obese 
WT mice. 
Effect of ADAMTS13 deficiency on adipose tissue related angiogenesis 
Quantitative analysis of blood vessel size and density in SC and GN adipose tissues 
of WT and Adamts13-/- mice on HFD revealed a few significant differences for obese 
Adamts13-/- as compared to obese WT mice (Table 4):  
1) blood vessels in SC adipose tissue were smaller 
2) blood vessel density in GN adipose tissue was lower 
3) blood vessel density normalized to adipocyte density was lower in GN fat  
On SFD, no differences were observed between WT and Adamts13-/- adipose tissues. 
For WT mice, no correlations were observed between plasma ADAMTS13 antigen or 
activity levels and blood vessel size or density in SC or GN adipose tissues.  
We also monitored expression of some endothelial markers by qPCR. This revealed 
no effects of either diet or genotype on relative expression in GN adipose tissue of 
endoglin (1.01 ± 0.09 for lean Adamts13-/- versus 1.02 ± 0.04 for lean WT mice, with 
corresponding values of 1.0 ± 0.06 versus 0.89 ± 0.08 for obese Adamts13-/- versus 
obese WT mice). Expression of VEGF-A was lower for obese as compared to lean GN 
fat for both WT (0.60 ± 0.07 versus 1.05 ± 0.11; p < 0.01) and Adamts13-/- (0.58 ± 0.06 
versus 0.99 ± 0.10; p < 0.01 by Mann-Whitney U test) mice, but was not different 
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between genotypes. Expression of VE-cadherin was higher for obese as compared to 
lean GN fat for both WT (1.60 ± 0.17 versus 1.02 ± 0.05; p < 0.01) and Adamts13-/- 
(1.64 ± 0.17 versus 1.13 ± 0.06; p<0.01 by Mann-Whitney U) mice, but was also not 
different between genotypes.  
Effect of ADAMTS13 deficiency on adipose tissue related inflammation or 
oxidative stress 
Analysis of the effect of diet on expression of inflammatory gene markers in SC adipose 
tissues of WT mice revealed significantly reduced expression of IL-6 on HFD as 
compared to SFD, whereas expression of F4/80, TNF-, MCP-1, arginase or  
mannose R was not different (Figure 14A, I). In GN adipose tissue of WT mice, 
expression of IL-6 was also significantly reduced on HFD as compared to SFD, 
whereas F4/80, TNF- and mannose R expression was enhanced (Figure 14A, II). In 
SC adipose tissue of Adamts13-/- mice on HFD versus SFD, enhanced expression of 
F4/80, arginase and mannose R, and reduced expression of IL-6 was observed  
(Figure 14A, I). Similarly, in GN adipose tissue of obese versus lean Adamts13-/- mice, 
expression of IL-6 was significantly reduced and expression of F4/80 and arginase was 
enhanced (Figure 14A, II).  
Analysis of the effect of genotype on expression of inflammatory gene markers 
revealed significantly lower expression of F4/80, TNF-, IL-6 and mannose R in SC 
fat, and of F4/80 in GN fat of lean Adamts13-/- versus WT mice. For obese  
Adamts13 -/- mice as compared to obese WT mice, only higher expression of arginase 
in SC fat was observed (albeit not statistically different) (Figure 14B, I). Expression of 
MCP-1 in SC or GN adipose tissues was not affected by diet or genotype. 
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Figure 14: Gene expression of inflammatory markers in SC and GN adipose tissue. 
(A) Effect of diet on expression of inflammatory markers in SC (I) or GN (II) adipose tissues. Gene 
expression is shown for obese relative to lean WT (white bars) or obese relative to lean 
Adamts13-/- (black bars) mice. *, **, *** p < 0.05, p < 0.01 and p < 0.001 for obese versus lean mice. 
(B) Effect of genotype on expression of inflammatory markers in SC (I) or GN (II) adipose tissues. 
Gene expression is shown for lean (white bars) or obese (black bars) ADAMTS13-/- relative to WT 
mice. *, **, *** p < 0.05, p < 0.01 and p < 0.001 for Adamts13-/- versus WT mice (Mann-Whitney U 
test). 
 
In protein extracts of SC and GN adipose tissues as well as plasma of lean and obese 
WT and Adamts13-/- mice TNF- and IL-6 could not be detected (detection limit of 78 
pg/ml and 145 pg/ml, respectively) by ELISA.  
Analysis of the effect of diet on expression of oxidative stress markers in SC adipose 
tissues revealed enhanced expression of NOX4 for obese Adamts13-/- and reduced 
expression of XDH1 for obese WT mice (Figure 15A, I). In GN adipose tissues, NOX4 
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expression was enhanced for obese WT as well as Adamts13-/- mice, whereas SOD1 
and GPX1 expression were reduced in obese as compared to lean WT mice (Figure 
15A, II).   
 
Figure 15: Gene expression of oxidative stress markers in SC and GN adipose tissue. 
(A) Effect of diet on expression of oxidative stress markers in SC (I) or GN (II) adipose tissues. 
Gene expression is shown for obese relative to lean WT (white bars) or obese relative to lean 
Adamts13-/- (black bars) mice. *, **, *** p < 0.05, p < 0.01 and p < 0.001 for obese versus lean mice. 
(B) Effect of genotype on expression of oxidative stress markers in SC (I) or GN (II) adipose 
tissues. Gene expression is shown for lean (white bars) or obese (black bars) Adamts13-/- relative 
to WT mice. *, **, *** p < 0.05, p < 0.01 and p < 0.001 for Adamts13-/- versus WT mice (Mann-
Whitney U test). 
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Analysis of the effect of genotype on expression of oxidative stress markers in SC 
adipose tissues revealed reduced expression of NOX4 and SOD1 for lean  
Adamts13-/- versus lean WT mice, and enhanced expression of GPX1 for obese 
Adamts13-/- versus obese WT mice (Figure 15B, I). In GN adipose tissues, only 
reduced expression of NOX4 for obese Adamts13-/- versus obese WT mice was 
observed (Figure 15B, II). Expression of catalase in SC or GN adipose tissues was not 
affected by diet or genotype.  
Effect of ADAMTS13 deficiency on metabolic parameters 
Analysis of plasma metabolic parameters evidenced the effects of HFD versus SFD, 
as shown by enhanced leptin, total cholesterol and HDL cholesterol levels in WT as 
well as Adamts13-/- mice (Table 5). No significant effects of genotype were observed 
on these metabolic parameters, except for higher total cholesterol levels for obese 
Adamts13-/- versus WT mice. Total plasma cholesterol levels for WT mice were strongly 
positively correlated with both ADAMTS13 antigen (r = 0.81, p < 0.0001) and activity  
(r = 0.67, p = 0.002). Glucose levels for obese Adamts13-/- mice were not significantly 
different as compared to obese WT mice. In separate experiments glucose tolerance 
and insulin sensitivity tests were performed with obese WT and Adamts13-/- mice. No 
significant differences were observed between WT (n = 10) and Adamts13-/- (n = 10) 
mice (Figure 16). 
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Figure 16: Insulin and glucose tolerance in WT and Adamts13-/- mice after a HFD. 
Insulin sensitivity (A) and glucose tolerance (B) test of WT (closed symbols) or Adamts13-/- (open 
symbols) mice kept on HFD. Data are means ± SEM of 10 experiments in each group. No 
significant differences were observed between both genotypes (Two-way ANOVA).  
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DISCUSSION 
The rationale for this study was based on several published observations relating to a 
potential functional role of ADAMTS13 in adiposity (7), angiogenesis (13), and 
oxidative stress/inflammation (20). Therefore, we have investigated a potential role of 
ADAMTS13 in adipose tissue development and associated angiogenesis and 
inflammation using an established mouse model of nutritionally induced obesity (21). 
The difference in body weight, weight of SC and GN fat depots, adipocyte size and 
density between mice fed a SFD or HFD and the enhanced levels of leptin and 
cholesterol, confirm that the HFD was effective in inducing obesity in both genotypes. 
However, no differences were found in body weight, food intake, adipocyte size or 
expression of adipogenic markers between the two genotypes. These data indicate 
that there is no relevant functional role of ADAMTS13 in adiposity in mice. The 
enhanced plasma ADAMTS13 levels in obese as compared to lean WT mice could not 
be explained by increased expression in the liver, the main organ of its synthesis (22), 
but may be due to enhanced release. 
For adipose tissue to expand, each adipocyte needs to be in close proximity to blood 
vessels for the supply of nutrients and oxygen, for the transport of lipids and signaling 
molecules and for the elimination of waste products (23). It was previously established 
that adipogenesis is related to angiogenesis (24). Thus, ADAMTS13 inhibits  
VEGF-induced angiogenesis by binding to VEGF via its TSP-1 domain (14). In our 
study, obese Adamts13-/- mice showed smaller blood vessels in their SC fat depots as 
compared to WT mice and had fewer blood vessels in their GN adipose tissue. There 
were, however, no differences in gene expression of endoglin, VEGF-A or VE-cadherin 
in GN adipose tissues of WT or Adamts13-/- mice. It is generally accepted that adipose 
tissue associated angiogenesis is mainly regulated by VEGF (23). Thus, the  
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anti-angiogenic effect of ADAMTS13 in adipose tissue related angiogenesis is at best 
marginal and does not affect in vivo adipose tissue development.  
Obesity is associated with a state of low-grade chronic inflammation, which triggers 
some related comorbidities. Pro-inflammatory cytokines are secreted and leptin 
production by dysfunctional adipocytes is increased leading to insulin resistance. 
Adiponectin is an anti-inflammatory insulin-sensitizing hormone that inhibits several 
obesity-related processes such as formation of foam cells and production of TNF- in 
macrophages (25). It is known that adiponectin concentrations decrease with 
increasing body weight in mice as well as in humans (26). Interestingly, in our study 
adiponectin levels were comparable in lean and obese Adamts13-/- mice, but were 
higher in obese Adamts13-/- mice as compared to their WT counterparts. The fact that 
adiponectin levels in Adamts13-/- mice do not decrease upon HFD feeding may suggest 
a somewhat improved metabolic profile.  
In agreement with a previous study of Crawley et al. (7) in man, we observed a strong 
positive correlation between cholesterol levels and ADAMTS13 levels in WT mice. 
However, total plasma cholesterol levels were higher in obese Adamts13-/- versus 
obese WT mice. This apparent contradiction questions the functional association 
between ADAMTS13 and cholesterol levels. Furthermore, insulin and glucose 
tolerance tests on obese mice did not reveal differences between the two genotypes 
and blood glucose levels at the start of the tests were comparable for obese WT and 
Adamts13-/- mice. These findings indicate that there is no direct effect of ADAMTS13 
on glycemia in nutritionally induced obese mice.   
Reactive oxygen species and oxidative stress are involved in adipocyte dysfunction. 
Stressed adipocytes send out signals that recruit macrophages in white adipose tissue 
leading to production of pro-inflammatory cytokines resulting in further enhanced 
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stress and adipocyte death (27). Based on the literature it was anticipated that obesity 
(28) as well as ADAMTS13 deficiency (20) would be associated with enhanced 
inflammation. Therefore, we monitored expression of pro- and anti-inflammatory gene 
markers in SC and GN adipose tissues of lean and obese WT and Adamts13-/- mice. 
More specifically, as general macrophage markers F4/80 and MCP-1 were used.  
TNF-α and mannose receptor or arginase were used as markers for M1 (classically 
activated, pro-inflammatory) or M2 (alternatively activated, anti-inflammatory) 
macrophages, respectively. IL-6 can act as a pro-inflammatory as well as an anti-
inflammatory cytokine (29). It is secreted by adipocytes in obese subjects (30). The 
major changes that were observed (≥ 2-fold difference; p < 0.05) for the effect of diet 
(HFD versus SFD) were: 1) reduced expression of IL-6 in SC and GN fat of both WT 
and Adamts13-/- mice; 2) enhanced expression of the macrophage marker F4/80 in GN 
fat of Adamts13-/- mice (as expected); and 3) enhanced expression of anti-inflammatory 
arginase and mannose receptor in SC fat of Adamts13-/- mice (reduction was 
expected). For the effect of genotype (Adamts13-/- versus WT), we observed: 1) in SC 
fat of lean mice reduced expression of TNF- (increase expected), of IL-6 and of 
mannose receptor; 2) enhanced arginase expression in SC fat of obese Adamts13-/- 
mice and 3) reduced expression of F4/80 in both SC and GN adipose tissue of lean 
Adamts13-/- versus WT mice. In obese adipose tissues, no relevant effects of genotype 
were observed on expression of inflammatory gene markers. In lean SC adipose 
tissues, however, expression of pro-inflammatory TNF- and F4/80 and of anti-
inflammatory mannose receptor was significantly reduced in Adamts13-/- as compared 
to WT mice. These differences were not consistently detected in lean GN adipose 
tissues, except for lower expression of F4/80 in Adamts13-/- tissues. Because of the 
confounding effects of the combination of obesity and ADAMTS13 deficiency, and the 
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differences between SC and GN adipose tissues, these data do not allow to predict 
whether ADAMTS13 is pro- or anti-inflammatory in adipose tissue. In any case, the 
observed changes in expression of inflammatory markers are not reflected in 
differences in adipose tissue development between WT and Adamts13-/- mice. Similar 
analysis for expression of oxidative stress gene markers revealed only an effect of 
HFD on enhanced expression of NOX4 in Adamts13-/- mice (as expected), and no 
effects of genotype. As chronic inflammation and enhanced oxidative stress are 
considered consequences of obesity, and ADAMTS13 deficiency did not affect 
adiposity, significant differences in associated inflammation or oxidative stress 
between both obese genotypes would not be expected. 
Thus, despite several indications from previous studies, our study does not support a 
functional role of ADAMTS13 in obesity nor in associated angiogenesis or 
inflammation, at least in mice. However, it cannot be excluded that ADAMTS13 plays 
a more prominent role in adipose tissue development in humans. 
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ABSTRACT 
ADAMTS13 cleaves ultra-large multimeric von Willebrand Factor (VWF), thereby 
preventing formation of platelet-rich microthrombi. ADAMTS13 is mainly produced by 
hepatic stellate cells, and numerous studies have suggested a functional role of 
ADAMTS13 in the pathogenesis of liver diseases. We used a model of high fat diet-
induced steatosis in ADAMTS13 deficient (Adamts13-/-) and wild-type (WT) control 
mice to investigate a potential role of ADAMTS13 in formation of hepatic microthrombi 
and development of non-alcoholic steatohepatitis (NASH).  
Microthrombi were more abundant in the liver of obese Adamts13-/- as compared to 
obese WT or to lean Adamts13-/- mice. Obese Adamts13-/- mice displayed lower 
platelet counts and higher prevalence of ultra-large VWF multimers. Hepatic  
plasmin-2-antiplasmin complex levels were comparable for obese WT and 
Adamts13-/- mice and were lower for lean Adamts13-/- than WT mice, not supporting 
marked activation of the fibrinolytic system. High fat diet feeding, as compared to 
normal chow, resulted in enhanced liver triglyceride levels for both genotypes  
(p < 0.0001) and steatosis (p < 0.0001 for WT mice, p = 0.002 for Adamts13-/- mice) 
without differences between the genotypes. Expression of markers of inflammation, 
oxidative stress, steatosis and fibrosis was affected by diet, but not by genotype.  
Thus, our data confirm that obesity promotes NASH, but do not support a detrimental 
role of ADAMTS13 in its development. However, ADAMTS13 deficiency in obese mice 
promotes hepatic microthrombosis, whereas a compensatory role of plasmin in 
removal of microthrombi in the absence of ADAMTS13 could not be demonstrated. 
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INTRODUCTION 
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type-1 repeat, 
member 13) specifically cleaves multimeric von Willebrand Factor (VWF), hereby 
preventing accumulation of ultra-large VWF (UL-VWF) multimers and the subsequent 
platelet clumping and formation of microthrombi that disturbs the microcirculation and 
impairs oxygen supply to organs (1). Hence, ADAMTS13 deficiency, caused by 
mutations in the ADAMTS13 gene (2-6) or by inhibitory autoantibodies (7, 8) may result 
in development of thrombotic thrombocytopenic purpura (TTP), a rare but  
life-threatening disease (1). Recently, it was reported that plasmin might function as a 
backup for ADAMTS13 in the degradation of complexes between platelets and  
UL-VWF multimers in patients with TTP (9). On the basis of these findings, it was 
suggested that plasmin may also be involved in the removal of microthrombi in patients 
with liver disease (10). ADAMTS13 is mainly produced by stellate cells in the liver (11), 
and numerous studies have suggested a functional role of ADAMTS13 in the 
pathogenesis of liver diseases (reviewed in (12)). A beneficial effect of ADAMTS13 
activity was observed on liver disease severity, and increased ADAMTS13 activity is 
related with a better prognosis of liver cirrhosis (13), alcoholic hepatitis (14) and hepatic 
veno-occlusive disease (15). However, a detrimental effect of ADAMTS13 was also 
reported on hepatocellular carcinoma risk in patients suffering from chronic liver 
disease (16). In rats, steatohepatitis and liver fibrosis are associated with enhanced 
systemic ADAMTS13 antigen and activity levels (17). In addition, we previously found 
enhanced ADAMTS13 levels in obese mice (18). Therefore, in this study, we have 
used a model of diet-induced non-alcoholic steatohepatitis (NASH) in ADAMTS13 
deficient mice to elucidate a potential role of ADAMTS13 and obesity in hepatic 
microthrombosis and steatosis.  
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MATERIALS & METHODS 
Animal models 
Male Adamts13-/- and wild-type (WT) littermate mice (genetic background, C57Bl6/J x 
129X1/Sv x CASA/RK) were used and genotyped as described (19). The mice were 
kept from the age of 5 weeks on in individual micro-isolation cages on a 12h day/night 
cycle and fed for 15 weeks with a high fat diet (HFD) (42% kcal as fat, caloric value 22 
kJ/g; E15721-34; Ssniff, Soest, Germany) (n = 9 or 8 for Adamts13-/- or WT) or a 
standard fat diet (SFD) (13% kcal as fat, caloric value 10.9 kJ/g; KM-04-k12; Muracon, 
Carfil, Oud-Turnhout, Belgium) (n = 11 or 10 for Adamts13-/- or WT). Water was always 
available ad libitum. Body weight and food intake were measured at weekly intervals 
(18). At the end of the diet, after fasting for 6h, blood was taken from the tail of 
unanesthetized mice. Blood glucose concentrations were measured using the  
Accu-chek performa meter (Roche diagnostics, Roche, Basel, Switserland) and blood 
glucose test strips (Roche diagnostics). At the end of the experiment, the mice were 
sedated and blood was taken from the retro-orbital sinus on trisodium citrate (0.01 M), 
before they were perfused by saline and killed by cervical dislocation. Livers were 
removed and weighed. Portions were used for RNA or protein extraction or were fixed 
in 4% formaldehyde for histological analysis.  
All animal experiments were approved by the KU Leuven ethical committee (P158-
2011) and performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (1996) and the EU Directive 2010/63/EU for animal experiments. 
Metabolic and inflammatory parameters 
Total triglyceride, alkaline phosphatases, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels in plasma were evaluated using routine 
clinical assays. Mouse plasminogen activator inhibitor 1 (PAI-1) antigen levels in 
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plasma were measured by a combined monoclonal-polyclonal antibody assay 
calibrated with recombinant mouse PAI-1, as described previously (18, 20). C-reactive 
protein (CRP) levels in plasma were determined by ELISA (Quantikine ELISA kit, R&D 
Systems, Minneapolis, USA). Liver tissue extracts were prepared by adding alcoholic 
KOH (30%) to a sample of 30 mg. Samples were incubated overnight at 55°C to digest 
the tissue, and 1M MgCl2 was added to the digested sample (1:1 vol/vol), mixed well, 
incubated on ice for 10 minutes and centrifuged for 30 minutes. The supernatant was 
analyzed using the triglycerides FS* kit (Diasys, Holzheim, Germany).  
Plasmin-2-antiplasmin (PAP) and thrombin-antithrombin III (TAT) complex levels 
were determined in plasma and liver extracts by home-made ELISA (21) or by a 
commercial ELISA (ab137994, Abcam, Cambridge, Great-Britain), respectively. 
Protein extraction of liver tissue was performed in 10 L/g tissue of a 10 mM sodium 
phosphate buffer, pH 7.2, containing 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% 
sodium deoxycholate and 0.2% NaN3. After centrifugation, the protein concentration of 
the supernatant was determined (BCA assay, Thermofisher Scientific Waltham, MA).
RNA extraction and expression analysis 
RNA extraction from livers was performed using the RNeasy mini kit (Qiagen, Basel, 
Switzerland) according to the manufacturer’s protocol. Therefore, the livers were 
transferred in RLT buffer (lysis buffer) before homogenizing (FastPrep-24; MP 
Biomedicals, Illkirch, France). To prevent the lipids from obstructing the membrane of 
the RNeasy column, the lysates were centrifuged for 3 minutes at 13,000 rpm. The 
resulting supernatant was transferred to a new tube. An equal volume of 50% ethanol 
was added to all samples to allow binding of the RNA on the membrane of the RNeasy 
spin column. DNAse treatment was performed to prevent contamination with genomic 
DNA. RNA was eluted in 60 µL RNAse-free water. RNA concentrations were measured 
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using a nanodrop spectrometer (ThermoFisher Scientific) and samples were stored at 
-80°C. Next, 10 ng/µL RNA was reverse transcribed into cDNA using the MultiscribeTM 
Reverse Transcriptase kit, according to the manufacturer’s protocol (Life 
Technologies, Carlsbad, CA). Quantitative real-time PCR (qPCR) was performed to 
amplify the isolated RNA. qPCR was done in the ABI 7500 Fast Sequence detector 
(Life Technologies) to detect the markers listed in Table 6.  
Table 6: Markers detected by qPCR using TaqMan gene expression assays 
 
Gene Assay† Gene Assay† 
F4/80 Mm00802529_m1 FATP Mm00449511_m1 
TNF-α Mm00443258_m1 MCAD Mm01323360_g1 
MCP-1 Mm00441242_m1 CD36 Mm00432403_m1 
IL-6 Mm 00446190_m1 PPAR-γ Mm00440939_m1 
IL-1 Mm 01336189_m1 TIMP-1 Mm 00441818_m1 
Arginase Mm00475988_m1 PAI-1 Mm 00435860_m1 
Mannose receptor Mm00485148_m1 α-SMA Mm00725412_s1 
SREBP-1 Mm00550338_m1 Col1a1 Mm00801666_g1 
FAS Mm01253300_g1 TGF-β Mm01178820_m1 
β-actin Mm01205647_g1   
 
†Assays purchased from Life Technologies (Carlsbad, CA). 
 
Transcript levels were determined in duplicate by qPCR reaction using a gene 
expression assay with specific primers, probes and the Fast mastermix (Life 
Technologies). Analyses were performed with the CT method using the 7500 
System SDS software (Life Technologies). Normalization was carried out to correct for 
fluctuations caused by sample differences. Fold changes were calculated as 2-CT 
relative to the mice fed a SFD for obese mice (effect of diet) and relative to WT mice 
for the Adamts13-/- mice (effect of genotype). -actin was used as housekeeping gene 
(18). 
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Histological analysis 
Paraffin sections (4 m) for histology were prepared from isolated livers. The degree 
of steatosis was visualized by staining with haematoxylin/eosin (H&E) under standard 
conditions, and sections were inspected for the presence of microthrombi. These were 
further evaluated by staining for VWF, TSP-1 and fibrin. Antigens were unmasked 
using trypsin treatment for 7 minutes or antigen retrieval solution (Dako) for VWF or 
TSP-1 and fibrin stainings, respectively. To remove endogenous peroxidase activity, 
sections were incubated in 0.3% hydrogen peroxide in PBS. The sections were 
incubated overnight with a polyclonal rabbit anti-human VWF antibody (DAKO, code 
A0082, Heverlee, Belgium) at a dilution of 1/500 in blocking buffer, a TSP-1 (0.87 
µg/mL in-house rabbit anti-human TSP-1, preadsorbed with liver extract from Tsp1-/- 
mice, to eliminate interfering TSP-2 signals) or a goat anti-human fibrinogen 1/200 
antibody (Nordic Immunology cat no: GAHu/Fbg/7S stock 10 mg/ml) in blocking buffer. 
Afterwards, a biotin labeled goat-anti-rabbit antibody (DAKO, E0432) or rabbit anti-
goat-HRP (P0449) was used as secondary antibody (1/300 dilution). VWF and TSP-1 
were visualized by the ABC-kit (Vector Laboratories, CA, USA) and DAB, whereas 
fibrin was visualized using DAB. Microthrombi in the liver were quantitated as blood 
vessels of 15-100 µm obstructed with VWF positive thrombi relative to total blood 
vessels of 15-100 µm. In addition, the size was scored (+, ++, or +++, corresponding 
to respectively less than 2/3, 2/3 or totally obstructing blood vessels) in 2 to 3 sections 
taken throughout the liver of 3-6 mice in each group. 
Analyses were performed with a Zeiss Axioplan 2 microscope and the AxioVision 
release 4.8 software (Carl Zeiss, Oberkochen, Germany) and Image J. 
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VWF antigen and multimers 
Murine VWF antigen levels were measured in plasma using a home-made ELISA. A 
96-well microtiter plate was coated overnight with a polyclonal rabbit anti-human VWF 
antibody (Dako). After blocking, plasma was diluted in PBS, 0.3% non-fat milk and the 
plate was incubated at 37°C for 1.5h. Bound antigen was detected with 2 biotinylated 
in-house developed murine anti-mVWF monoclonal antibodies (2C12-bio, 15H7-bio). 
HRP-labeled streptavidin (Sigma Aldrich) was added (1/10 000 in PBS 0.3% non-fat 
milk).  
The multimeric pattern of plasma VWF was analyzed by gel electrophoresis as 
described by Lotta et al. (22). Low (L), medium (M) and high (H) molecular weight (MW) 
multimers were visualized using an in-house developed anti-VWF antibody. 
Statistical analysis 
Data are presented as means ± standard error of the means (SEM). Statistical 
significance between groups was analyzed with the non-parametric Mann-Whitney U 
test. Scores of microthrombi in liver sections were analyzed by one-way ANOVA. 
Analysis of the data was performed using Prism 6 (GraphPad Software Inc., San 
Diego, CA). Values of p < 0.05 are considered statistically significant. 
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RESULTS 
Effect of diet and genotype on microthrombosis and fibrinolysis 
When mice were kept on a SFD or HFD for 15 weeks, total body weight (Figure 17A) 
as well as liver weight (Figure 17B) were markedly enhanced for both obese 
Adamts13-/- and WT mice as compared to lean (SFD) mice, but there were no 
significant differences between genotypes.  
B
o
d
y
 w
e
ig
h
t 
(g
)
0
1 0
2 0
3 0
4 0
5 0
* * *
W T A d a m ts 1 3
- / -
* * *
L
iv
e
r
 w
e
ig
h
t 
(g
)
0
1
2
3 * * *
* * *
W T A d a m ts 1 3
- / -
A B
Figure 17: Body weight (A) and liver weight (B) are shown for wild-type (WT) and Adamts13-/- 
mice kept on standard fat diet (white bars) or high fat diet (black bars). Data represent means ± 
SEM of 8 to 10 experiments. *** p < 0.001. 
 
Staining of liver sections indicated the presence of fibrin, whereas TSP-1 staining 
showed abundance of platelets for obese Adamts13-/- as compared to WT mice (Figure 
18). Furthermore, VWF-staining (Figure 19A) and quantitative analyses revealed 
significantly higher prevalence of microthrombi for Adamts13-/- mice on HFD as 
compared to WT mice on HFD (p = 0.001) or SFD (p = 0.05) (Figure 19B). Scoring of 
microthrombi size confirmed a significant abundance for obese Adamts13-/- versus 
obese WT mice (p = 0.02) or versus lean Adamts13-/- mice (p = 0.001) (Figure 19C). 
No significant difference was observed between SFD and HFD feeding of WT mice, or 
between WT and Adamts13-/- mice on SFD. 
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Figure 18: Characterization of hepatic microthrombi.  
Fibrin (A) and TSP-1 (B) staining of liver sections of obese (HFD) WT (panels I) and Adamts13-/- 
mice (panels II). Scale bars represent 50 µm. 
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Figure 19: Quantitation of microthrombi in the liver of WT and Adamts13-/- mice.   
(A) VWF staining of liver sections of a lean WT mouse (I) (score +) and an obese Adamts13-/- 
mouse (II) (score +++). Scale bars represent 50 µm. (B) Total number of thrombi normalized to 
total number of blood vessels in WT and Adamts13-/- mice fed a SFD (white bars) or HFD (black 
bars). (C) Number of thrombi normalized to total number of blood vessels between 15 and 100 
µm that are totally obstructing (+++), 2/3 obstructing (++) or less than 2/3 obstructing (+) blood 
vessels. Data represent means ± SEM of 4 experiments. * p < 0.05, ** p < 0.01. 
 
TAT levels in plasma (Table 7) or in liver extracts (Figure 20A) were somewhat higher 
upon HFD as compared to SFD feeding. For liver extracts, TAT levels were significantly 
different between lean WT and Adamts13-/- mice, whereas, in plasma no significant 
differences were found between the genotypes.  
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Figure 20: Thrombin-antithrombin III (TAT) complex levels (A) and plasmin-2-antiplasmin (PAP) 
complex levels (B) in liver extracts. Data represent means ± SEM of 8 to 10 experiments. * p < 
0.05, ** p < 0.01, *** p < 0.001. 
 
Platelet counts at the end of the diet were lower for obese Adamts13-/- mice versus 
obese WT or lean Adamts13-/- mice (Figure 21A). VWF antigen levels were higher for 
lean, but not for obese Adamts13-/- versus WT mice (Figure 21B). Analysis of VWF 
multimer composition in plasma (Figure 21C) revealed more abundant HMW multimers 
for both lean and obese Adamts13-/- versus WT mice.  
To examine whether plasmin compensates for the absence of ADAMTS13 as 
previously suggested (9), plasmin-α2-antiplasmin (PAP) complex levels were 
measured. This is a sensitive parameter to monitor activation of the fibrinolytic system. 
PAP complex levels in plasma were below 5 nM in all samples and were not different 
between genotypes. As compared to WT mice, PAP complex levels in liver extracts 
were lower for Adamts13-/- mice on SFD and were not enhanced on HFD (Figure 20B), 
not supporting marked activation of the fibrinolytic system in the absence of 
ADAMTS13. 
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Figure 21: Effect of diet and genotype on platelet counts and VWF composition.  
(A) platelet count, (B) plasma levels of VWF antigen and (C) VWF multimers are shown for wild-
type (WT) and ADAMTS13 deficient (Adamts13-/-) mice kept on standard fat diet (white bars) or 
high fat diet (black bars). Data represent means ± SEM of 8 to 10 experiments. * p < 0.05,  
** p < 0.01. 
 
Effect of diet and genotype on liver steatosis 
Plasma levels of the liver enzymes alkaline phosphatases and ALT were elevated for 
obese versus lean Adamts13-/- mice, but not for WT mice. AST levels were not affected 
by either diet or genotype. Plasma PAI-1 and CRP levels were significantly elevated 
after HFD feeding in both genotypes (Table 7). Histological analysis of liver steatosis 
by H&E staining (Figure 22A) revealed a higher degree of steatosis in obese as 
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compared to lean mice, without however, significant difference between genotypes. 
Quantitative analysis revealed that HFD feeding significantly enhanced liver steatosis 
in both genotypes, but showed no difference between genotypes (Figure 22B). 
Determination of triglycerides in liver extracts confirmed significantly higher levels after 
HFD as compared to SFD feeding, but did not show a difference between genotypes 
(Figure 22C). Determination of plasma triglyceride levels did not reveal significant 
effects of diet or genotype (Table 7). Glucose levels correlated positively with liver 
weight for WT mice (r = 0.81; p < 0.0001) and for Adamts13-/- mice (r = 0.54; p < 0.01). 
Obese Adamts13-/- mice had lower glucose levels than obese WT mice. 
 Table 7: Plasma levels of liver enzymes and inflammatory markers of WT and Adamts13-/- mice. 
 
Data are means ± SEM of 8 to 10 experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 for HFD versus 
SFD fed mice; ## p < 0.01 for Adamts13-/- versus WT mice. 
Abbreviations: WT: wild-type; SFD: standard fat diet; HFD: high fat diet; AST: aspartate 
aminotransaminase; ALT: alanine aminotransferase; PAI: plasminogen activator inhibitor; CRP: 
C-reactive protein; PAP: plasmin-α2-antiplasmin complex; TAT: thrombin-antithrombin III 
complex. 
 
 
 
 
 WT Adamts13-/- 
SFD HFD SFD HFD 
Glucose (mg/dl) 124 ± 7.99 211 ± 16.2*** 129 ± 7.95 156 ± 7.68*## 
Triglycerides (mg/dl) 42 ± 1.8 40 ± 7.0 38 ± 1.4 33 ± 2.1 
Alkaline phosphates (U/l) 41 ± 1.9 47 ± 5.2 39 ± 2.1 55 ± 5.8 ** 
AST (U/l) 191 ± 29 151 ± 21.1 167 ± 21.3 237 ± 39.4 
ALT (U/l) 72 ± 9.1 95 ± 12 59 ± 3.9 122 ± 27.3** 
PAI-1 (ng/ml) 7.4 ± 2.2 30 ± 11* 13 ± 5.2 42 ± 18 
CRP (µg/ml) 5.8 ± 0.33 9.4 ± 1.3* 5.6 ± 0.52 6.4 ± 0.89** 
PAP (ng/ml) 437 ± 50.4 559 ± 48.2 331 ± 38.8 483 ± 65.3 
TAT (ng/ml) 93 ± 34 115 ± 39 60 ± 15 118 ± 30 
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Figure 22: Effect of diet-induced obesity and ADAMTS13 deficiency on liver steatosis.  
(A) Haematoxylin/eosin staining (40x) of liver sections of WT mice on SFD (I) or HFD (II) and of 
Adamts13-/- mice on SFD (III) or HFD (IV). The scale bars correspond to 50 µm. (B) Quantitative 
analysis of steatosis of liver sections and (C) triglycerides (TG). Data represent means ± SEM of 
8 to 10 experiments. *** p < 0.001. 
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Effect of diet and genotype on expression of macrophage/inflammatory, 
steatosis, fibrosis and oxidative stress markers   
Gene expression analysis in liver tissues was performed to evaluate the effects of diet 
or genotype on markers of macrophages/inflammation, oxidative stress, 
steatosis/triglyceride metabolism and fibrosis (Figure 23). Analysis of the effect of diet 
on expression of inflammatory gene markers in the liver of Adamts13-/- mice revealed 
significantly enhanced expression of F4/80, TNF-α and MCP-1 (as expected) and 
reduced expression of IL-6, IL-1 and arginase in mice on HFD compared to SFD. 
Essentially similar observations were made for obese as compared to lean WT mice 
(Figure 23A). Analysis of the effect of genotype showed reduced expression of F4/80, 
MCP-1 and IL-6 and enhanced expression of TNF-α for lean Adamts13-/- versus lean 
WT mice, whereas on HFD only TNF-α expression was elevated for Adamts13-/- versus 
WT mice. Expression of Mannose R was not affected by either diet or genotype.  
Analysis of the effect of diet on expression of oxidative stress markers in the liver 
revealed markedly reduced expression of catalase, SOD1, NOX4 and XDH1 for obese 
versus lean mice, but no marked differences between genotypes (data not shown). 
Analysis of the effect of diet on expression of markers of triglyceride metabolism in the 
liver revealed markedly enhanced expression of CD36 on HFD versus SFD for 
Adamts13-/- as well as WT mice. Expression of SREBP-1, FAS, FATP, MCAD and 
PPAR-α were not drastically different between both genotypes (Figure 23B). Analysis 
of the effect of diet on expression of fibrosis markers showed higher levels of TIMP-1, 
col1a1 and TGF-β after a HFD in both Adamts13-/- and WT mice, but no differences 
between genotypes (Figure 23C). 
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Figure 23: Effect of diet and genotype on expression of markers of macrophages/inflammation, 
steatosis/ triglyceride metabolism and fibrosis in the liver.  
Relative gene expression is shown for WT and Adamts13-/- mice fed a SFD (lean, white bars) or a 
HFD (obese, black bars). * p < 0.05, ** p < 0.01, *** p < 0.001 for obese versus lean mice. # p < 
0.05, ## p < 0.01, for Adamts13-/- versus WT mice on the same diet. Markers of 
macrophages/inflammation in panel A, markers of steatosis/triglyceride metabolism in panel B 
and markers of fibrosis in panel C. 
 
Thus, the combination of obesity and ADAMTS13 deficiency (Adamts13-/- mice on HFD 
versus WT mice on SFD) resulted for the inflammatory makers in significantly higher 
expression of TNF-α and MCP-1 and lower expression of IL-6, IL-1 and arginase, for 
the oxidative stress markers in reduced expression of NOX4 and XDH1, for fibrosis 
markers in higher expression levels of TIMP-1, col1a1 and TGF-β and for the markers 
of triglyceride metabolism in reduced expression of SREBP-1, MCAD and PPAR-α and 
enhanced expression of CD36. Most of these differences are, however, due to the HFD 
feeding and not to the genotype. 
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DISCUSSION 
An apparent paradox with respect to the potential role of ADAMTS13 in development 
of acute liver failure has recently been recognized. On the one hand, ADAMTS13 
activity was found to be inversely related to disease severity and outcome, possibly 
due to formation of platelet-rich thrombi in the diseased liver. On the other hand, 
however, no UL-VWF multimers were found in the systemic circulation, and high 
molecular weight (HMW) VWF levels and VWF function were even reduced as 
compared to healthy controls (23). We have in the present study directly investigated 
a potential role of ADAMTS13 in liver steatosis and monitored activation of the 
fibrinolytic system. Therefore, we used ADAMTS13 deficient mice with diet-induced 
steatosis, achieved by feeding mice with a HFD for 15 weeks. 
In a previous study, we have shown that obesity in WT mice is associated with 
enhanced ADAMTS13 antigen and activity levels, but that ADAMTS13 deficiency does 
not markedly affect adipose tissue development (18). In the present study, 
histopathological examination of liver sections revealed a more abundant presence of 
microthrombi for obese versus lean ADAMTS13 deficient mice, but not for obese WT 
mice. This finding is compatible with higher prevalence of HMW VWF multimers (lack 
of cleavage by ADAMTS13), promoting microthrombi and with lower platelet count 
(incorporated in microthrombi) for obese Adamts13-/- mice. These thrombi indeed were 
predominantly platelet-rich as shown by TSP-1 staining. Enhanced microthrombosis is 
observed only with the combination of obesity and ADAMTS13 deficiency, indicating 
that both conditions are required. Circulating PAP levels were comparable for both 
genotypes, but lower levels were found in the liver of ADAMTS13 deficient mice on 
SFD (no differences between obese WT and obese Adamts13-/- mice). These findings 
do not support more extensive activation of the fibrinolytic system in the obese 
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ADAMTS13 deficient mice, and are not compatible with a compensatory action of 
plasmin to remove hepatic microthrombi in absence of ADAMTS13. This, therefore, 
could suggest that more extensive endothelial damage is required for activation of the 
fibrinolytic system, and subsequent degradation of UL-VWF multimers.  
Common liver diseases include syndromes ranging from isolated steatosis to  
non-alcoholic steatohepatitis (NASH), characterized by fat accumulation in the liver in 
combination with hepatocyte ballooning, inflammation and liver damage, with or 
without fibrosis (14). Increasing age, obesity and diabetes are known risk factors for 
development of NASH (15). It is also recognized that the increased prevalence of 
obesity and metabolic syndrome is paralleled by an increase in non-alcoholic fatty liver 
disease (NAFLD) (16, 17). NASH is an independent risk factor for cardiovascular 
diseases (18), and is associated with an increased risk for development of cirrhosis 
and liver-related deaths (15); it is becoming a major indication for liver transplantation 
(24). Our present data indicate that obesity triggers NAFLD, but that ADAMTS13 
deficiency does not distinctly affects its development. Liver steatosis was indeed found 
to be significantly more pronounced upon HFD as compared to SFD feeding, but was 
overall not different between Adamts13-/- and WT mice. Indeed, similar levels of 
triglycerides in the liver and comparable hepatic expression of steatosis and fibrosis 
markers were observed for both genotypes on either diet. Analysis of the liver enzymes 
alkaline phosphatases, AST and ALT did reveal effects of the diet, but no marked 
differences between genotypes. Park et al. (25) reported that enhanced production of 
the cytokines TNF-α and IL-6 plays a central role in liver inflammation in dietary and 
genetic obesity. We also observed enhanced liver expression of TNF-α upon HFD 
feeding of WT and ADAMTS13 deficient mice, but lower expression of IL-6. It was 
previously recognized that the role of IL-6 in obesity may be more complex than 
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anticipated (26). Thus, whereas obesity promotes liver steatosis in both genotypes, 
ADAMTS13 deficiency does not appear to aggravate it for lean or obese mice. 
Furthermore, our finding of more pronounced microthrombosis in obese Adamts13-/- 
mice without aggravating steatohepatitis does not suggest a causative relation 
between both processes.  
In summary, our study shows that ADAMTS13 deficiency in obese mice promotes 
formation of hepatic microthrombi, and does not support a compensatory role of 
plasmin in removal of microthrombi in the absence of ADAMTS13. Our data 
furthermore confirm that obesity promotes NASH, but do not support a detrimental role 
of ADAMTS13 in development of liver steatosis in obese mice. 
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ABSTRACT 
Previous studies, mainly based on increased or decreased plasma levels, have 
reported conflicting data on a potential functional role of ADAMTS13 in the 
pathogenesis of liver diseases, including non-alcoholic steatohepatitis (NASH). The 
aim of this study was to evaluate whether ADAMTS13 deficiency affects development 
of NASH.   
Therefore, male wild-type (WT) and ADAMTS13 deficient (Adamts13-/-) mice were kept 
on a steatosis-inducing diet devoid of methionine and choline (MCD) or a control diet 
(MCC) for 4 weeks. Induction of NASH did not affect plasma ADAMTS13 antigen levels 
of WT mice. MCD as compared to MCC feeding resulted in lower body and liver weight 
without, however, differences between genotypes. Plasma levels of the liver enzymes 
AST and ALT were significantly higher for MCD versus MCC fed Adamts13-/- and WT 
mice, but were not different between genotypes. Liver triglyceride levels were also 
higher after MCD feeding, but were not different between WT and Adamts13-/- mice. 
Adamts13-/- mice on both diets displayed higher insulin sensitivity as compared to WT 
mice. On the MCC diet, neither genotype showed clear histological abnormalities in 
the liver, whereas severe steatosis and fibrosis were observed on MCD diet, but 
comparable for both genotypes. This was supported by comparably enhanced hepatic 
expression in both genotypes on MCD diet of the steatosis marker CD36 and of the 
fibrosis marker TIMP-1.  
Thus, our data do not support a functional role of ADAMTS13 in this murine model of 
NASH. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat 
accumulation in the liver of patients without a history of alcohol abuse. NAFLD is 
classified into simple steatosis and non-alcoholic steatohepatitis (NASH). In patients 
with NASH, in addition to steatosis, also intralobular inflammation and hepatocellular 
ballooning are observed, frequently with progressive fibrosis (1). Over time, NASH may 
progress to liver cirrhosis and hepatocellular carcinoma (2-4). It is recognized that the 
increased prevalence of obesity and metabolic syndrome is paralleled by an increase 
in NAFLD (5, 6), as up to 80% of obese subjects suffer from NAFLD (7). Worldwide 
about 20% of all adults have NAFLD and 2 to 3% suffer from NASH (8). 
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin-1 repeat, 
member 13) is a proteinase that specifically cleaves multimeric von Willebrand factor 
(VWF), thereby preventing accumulation of ultra-large VWF (UL-VWF) multimers and 
subsequent platelet clumping and formation of microthrombi that disturb the 
microcirculation and impair oxygen supply to organs (9). ADAMTS13 is mainly 
produced by stellate cells in the liver (10), of which proliferation contributes to 
steatohepatitis and fibrosis. This is compatible with enhanced ADAMTS13 antigen and 
activity levels observed in rats suffering from diet-induced steatosis and fibrosis (11). 
Several previous studies have, however, reported conflicting data on a potential 
functional role of ADAMTS13 in the pathogenesis of liver diseases (reviewed in (12)). 
A beneficial effect of ADAMTS13 activity was observed on liver disease severity, and 
increased ADAMTS13 activity was related with a better prognosis of liver cirrhosis (13), 
alcoholic hepatitis (14) and hepatic veno-occlusive disease (15). In contrast, a 
detrimental effect of ADAMTS13 was reported on hepatocellular carcinoma risk in 
patients suffering from chronic liver disease (16). Thus, it is not clear whether NASH is 
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related with increased or decreased levels of ADAMTS13, nor whether ADAMTS13 
plays a functional role in its development. In order to resolve these apparent 
contradictions, we have subjected wild-type and ADAMTS13 deficient mice to a 
steatosis-inducing diet. 
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MATERIALS & METHODS 
Animal model 
Male ADAMTS13 deficient (Adamts13-/-) and wild-type (WT) mice (genetic background, 
C57Bl6/J x 129X1/Sv x CASA/RK) were used and genotyped as described (17, 18). 
The mice were kept from the age of 5 weeks on in individual micro-isolation cages on 
a 12h day/night cycle and fed for 4 weeks with a lipogenic diet devoid of methionine 
and choline (MCD; #02960034, MPbiomedicals, Illkirch Cedex, France) or the MCD 
diet supplemented with 3 g/kg DL-methionine and 2 g/kg choline chloride (control diet, 
MCC; #02960414, MPbiomedicals) (n = 10 or 5 for Adamts13-/- or WT mice on each 
diet). Water was always available ad libitum. Body weight and food intake were 
measured at weekly intervals. At the end of the diet, after fasting for 6h, blood was 
taken from the tail of unanesthetized mice for determination of blood glucose 
concentrations using the Accu-chek performa meter and blood glucose test strips 
(Roche diagnostics, Roche, Basel, Switserland). At the end of the experiment, the mice 
were sedated and blood was taken from the retro-orbital sinus on trisodium citrate  
(0.01 M), before they were killed by cervical dislocation. Platelets were counted (Cell 
Dyn 3200R, Abbott Diagnostics, Illinois, USA). Livers, SC and GN adipose tissues 
were removed and weighed. Portions were used for RNA or protein extraction or were 
fixed in 4% formaldehyde for histological analysis.   
All animal experiments were approved by the KU Leuven ethical committee (P158-
2011) and performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (1996) and the EU Directive 2010/63/EU for animal experiments. 
Metabolic and inflammatory parameters 
Total, HDL and LDL cholesterol, triglycerides, alkaline phosphatases, alanine 
aminotransferase (ALT) and aspartate aminotransaminase (AST) levels in plasma 
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were evaluated using routine clinical assays. Insulin levels in plasma were determined 
by ELISA (Ultrasensitive mouse insulin ELISA 10-1249-01; Mercodia AB, Uppsala, 
Sweden). The homeostasis model assessment of insulin resistance (HOMA-IR) was 
determined using the formula: [fasting plasma insulin (ng/ml) × fasting blood glucose 
(mg/dl)]/405. Liver tissue extracts were prepared by adding alcoholic KOH (30%) to a 
sample of 30 mg. Samples were incubated overnight at 55°C to digest the tissue, and 
1 M MgCl2 was added to the digested sample (1:1 vol/vol), mixed well, incubated on 
ice for 10 minutes and centrifuged for 30 minutes. The supernatant was analyzed using 
the triglycerides FS* kit (Diasys, Holzheim, Germany).  
Histological and microscopic analysis 
Liver samples were fixed in 4% buffered formaldehyde and embedded in paraffin. 
Sections (4 µm) were stained with haematoxylin/eosin (H&E) or picrosirius red to 
assess steatosis or fibrosis, respectively. All liver biopsies were analyzed by an expert 
liver pathologist, blinded to the genotype and diet. Steatosis and fibrosis were 
diagnosed and semiquantitatively scored according to the NASH-Clinical Research 
Network criteria (19, 20). Hepatocyte ballooning was classified as 0 (none), 1 (few) or 
2 (many cells/prominent ballooning). Foci of lobular inflammation were scored as 0 (no 
foci), 1 (< 2 foci per 200× field), 2 (2–4 foci per 200× field) and 3 (> 4 foci per 200× 
field). Fibrosis was scored as stage F0 (no fibrosis), stage F1a (mild, zone 3, 
perisinusoidal fibrosis), stage F1b (moderate, zone 3, perisinusoidal fibrosis), stage 
F1c (portal/periportal fibrosis), stage F2 (perisinusoidal and portal/periportal fibrosis), 
stage F3 (bridging fibrosis) and stage F4 (cirrhosis). Severity of the disease was 
assessed using the NAS (NAFLD activity score) as the unweighted sum of scores of 
steatosis, hepatocyte ballooning and lobular inflammation (21). Percentage of fibrosis 
was quantitated by morphometry from digitalized sirius red stained sections (22). 
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RNA extraction and expression analysis 
RNA extraction from livers was performed using the RNeasy mini kit (Qiagen, Basel, 
Switzerland) according to the manufacturer’s protocol. Ten ng/µl RNA was reverse 
transcribed into cDNA using the MultiscribeTM Reverse Transcriptase kit (Life 
Technologies, Carlsbad, CA). RT-qPCR was done in the ABI 7500 Fast Sequence 
detector (Life Technologies) to detect the markers listed in Table 8. Analyses were 
performed with the ∆∆CT method (23) using the 7500 System SDS software (Life 
Technologies). Normalization was carried out to correct for fluctuations caused by 
sample differences. Fold changes for MCD diet fed mice were calculated as 2-∆∆CT 
relative to MCC diet. β-actin was used as housekeeping gene. 
VWF and ADAMTS13 antigen 
Murine VWF and ADAMTS13 antigen levels were measured in plasma using home-
made ELISA’s (24, 25).  
Statistical analysis 
Data are presented as means ± standard error of the means (SEM). Statistical 
significance between groups was analyzed with the non-parametric Mann-Whitney U 
test. Analysis of the data was performed using Prism 6 (GraphPad Software Inc., San 
Diego, CA). Values of p < 0.05 are considered statistically significant. 
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Table 8: Markers detected by qPCR using TaqMan gene expression assays. 
Gene Assay† Gene Assay† 
F4/80 Mm00802529_m1 PPAR-α Mm00440939_m1 
TNF-α Mm00443258_m1 TIMP-1 Mm0441818_m1 
MCP-1 Mm00441242_m1 PAI-1 Mm0435860_m1 
IL-6 Mm0446190_m1 α-SMA Mm00725412_s1 
Arginase Mm00475988_m1 Col1a1 Mm00801666_g1 
Mannose receptor Mm00485148_m1 TGF-β Mm01178820_m1 
FAS Mm01253300_g1 β-actin Mm01205647_g1 
CD36 Mm00432403_m1 
 
 FW primer RV primer probe 
ADAMTS13 GGAGCCCAAGGATG
TGTGTCTT 
TCTCTGGAGGTGAG
AGGGAGGAT 
6FAM 
CTTGGCCACCATGC
T MGBNFQ 
 
 
†Assays purchased from Life Technologies (Carlsbad, CA).  
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RESULTS 
Feeding WT and Adamts13-/- mice with the MCD diet for 4 weeks as compared to the 
control MCC diet, resulted in rapid and progressive weight loss for both genotypes 
(Figure 24A). Food intake was comparable for WT and Adamts13-/- mice kept on MCC 
(3.3 versus 3.0 g/mouse/day) or on MCD diet (2.4 versus 2.2 g/mouse/day). At the end 
of the diets, total body weight was comparable for WT and Adamts13-/- mice on MCC 
diet (30.0 ± 1.4 versus 27.4 ± 0.6 g) as well as on MCD diet (17.2 ± 0.4 versus 17 ± 
0.4 g). As expected, subcutaneous (SC) and gonadal (GN) fat mass were markedly 
lower for both genotypes when kept on MCD versus MCC diet (Figure 24B, C).  
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Figure 24: Effect of MCD and MCC diets on body and fat mass of wild-type (WT) and ADAMTS13 
deficient (Adamts13-/-) mice.  
Body weight evolution (A) and weight of subcutaneous (SC) fat (B) and gonadal (GN) fat (C) of 
mice kept on MCD (black symbols and bars) or MCC (white symbols and bars) diet for 4 weeks. 
Data are means ± SEM of 10 (Adamts13-/-) (squares) or 5 (WT) (circles) experiments for each diet. 
*, **, *** p < 0.05, p < 0.01, p < 0.001. 
 
For WT mice, plasma ADAMTS13 antigen levels were not significantly different on 
MCC or MCD diet (183 ± 12 versus 205 ± 17 % of pooled plasma), and relative 
expression of ADAMTS13 mRNA in the liver was comparable on both diets (0.91 ± 
0.07 versus 1.0 ± 0.05). VWF antigen levels were comparable for both genotypes on 
either diet (Table 9). However, platelet counts were significantly lower for Adamts13-/- 
mice fed the MCD versus MCC, but this was not seen in WT mice (Table 9). Analysis 
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of plasma metabolic parameters (Table 9) revealed for MCD versus MCC diets for both 
genotypes: 1) lower glucose levels; 2) lower total and HDL cholesterol levels; 3) higher 
LDL cholesterol levels (p < 0.05 for Adamts13-/- mice; trend for WT mice, as for the 
MCC diet n = 2, because of undetectable levels of LDL cholesterol in other samples); 
and 4) comparable triglyceride levels. Insulin levels were markedly lower on MCD 
versus MCC diet (only significant for the Adamts13-/- mice due to small sample sizes 
for WT mice), and were reduced for Adamts13-/- versus WT mice on MCC. Thus, 
HOMA-IR revealed higher insulin sensitivity for Adamts13-/- mice on MCC diet (Table 
9). 
 Total liver weight was reduced upon MCD feeding, but was not affected by genotype 
(Figure 25A). Liver enzymes AST and ALT were markedly higher in MCD fed as 
compared to MCC fed mice, but were not different between genotypes (Table 9). Liver 
triglyceride levels were also enhanced upon MCD feeding, but not affected by 
genotype (Figure 25B). 
H&E staining of liver sections revealed more pronounced steatosis in MCD as 
compared to MCC fed mice of both genotypes (Figure 26A), as confirmed by 
quantitative analysis (Figure 25C).  
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Figure 25: Effect of MCD and MCC diets on liver of wild-type (WT) and ADAMTS13 deficient 
(Adamts13-/-) mice.  
Weight of liver (A) of mice kept on MCD (black bars) or MCC (white bars) diet for 4 weeks. Liver 
triglyceride (TG) levels (B) and quantitation of liver steatosis (C). Data are means ± SEM of 10 
(Adamts13-/-) or 5 (WT) experiments for each diet. *, **, *** p < 0.05, p < 0.01, p < 0.001 for MCD 
versus MCC. 
 
Further histological analysis of liver sections revealed that after 4 weeks of MCC diet 
feeding, both WT (3/5 with score 1) and Adamts13-/- (3/10 with score 1) mice showed 
only mild steatosis, whereas they all scored 0 for hepatocyte ballooning, lobular 
inflammation, and fibrosis (Figure 26A and Table 10). However, after MCD feeding, 
both WT and Adamts13-/- mice presented with histological abnormalities with markedly 
enhanced scores for steatosis, ballooning, lobular inflammation and NAS without, 
however, significant differences between genotypes (Figure 26C). Also fibrosis stage 
and score were deteriorated in MCD versus MCC fed mice, but did not show a clear 
genotype effect (Figure 26B and Table 10). 
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Table 9: Plasma levels of metabolic parameters, liver enzymes, endogenous VWF and platelet 
count of WT and Adamts13-/- mice kept on MCC or MCD diet for 4 weeks. 
 
Data are means ± SEM of 10 (Adamts13-/-) or 5 (WT) experiments for each diet. * p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001 for MCD versus MCC fed mice; # p < 0.05 for Adamts13-/- 
versus WT mice.   
Abbreviations: WT: wild-type; Adamts13-/-: ADAMTS13 deficient; MCD: methionine and choline 
deficient diet; MCC: control diet; HOMA-IR: Homeostasis Model Assessment of Insulin 
Resistance; HDL: high density lipoprotein; LDL: low density lipoprotein; AST: aspartate 
aminotransaminase; ALT: alanine aminotransferase; mVWF: murine von Willebrand factor; NMP: 
normal mouse plasma. 
 
Relative expression of markers of triglyceride metabolism, fibrosis and inflammation 
were not markedly affected by genotype on either diet (data not shown). Histological 
observations on steatosis and fibrosis were compatible with markedly enhanced gene 
expression of the steatosis maker CD36 and the fibrosis marker TIMP-1 for MCD 
versus MCC fed mice of both genotypes (Figure 27A, B). Analysis of hepatic 
inflammatory markers revealed enhanced expression of TNF-α for WT mice on MCD 
versus MCC feeding (Figure 27C).  
 WT Adamts13-/- 
MCC MCD MCC MCD 
Glucose (mg/dl) 194 ± 20.4 94 ± 8.98** 177 ± 6.09 93 ± 3.86**** 
Insulin (ng/ml) 0.58 ± 0.12  0.17 ± 0.07 0.26 ± 0.06# 0.05 ± 0.01* 
HOMA-IR 0.30 ± 0.06 0.05 ± 0.02* 0.12 ± 0.03# 0.01 ± 0.002** 
Triglycerides (mg/dl) 45 ± 4.6 36 ± 0.95 35 ± 1.7 31 ± 1.0# 
Cholesterol (mg/dl) 89 ± 14 31 ± 5* 84 ± 5 30 ± 1*** 
HDL cholesterol (mg/dl) 82 ± 13 22 ± 2* 75 ± 4# 17 ± 1*** 
LDL cholesterol (mg/dl) 1.5 ± 1.5 7.5 ± 0.9 3.8 ± 0.9 7.0 ± 0.9* 
Alkaline phosphatases (U/l) 63 ± 7.6 76 ± 12 56 ± 3.2 77 ± 3.0* 
AST (U/l) 58 ± 13 185 ± 62.0* 78 ± 12 173 ± 14.4*** 
ALT (U/l) 22 ± 2.0 193 ± 53.4** 39 ± 9.0 227 ± 24.0**** 
Platelet count (x10³/µl) 917 ± 84.3 752 ± 117 829 ± 25 565 ± 65** 
mVWF (% to NMP) 302 ± 2.53 250 ± 38.9 247 ± 40.3 168 ± 37.5 
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Figure 26: MCD diet-induced steatohepatitis in WT and Adamts13-/- mice.  
H&E (A) and sirius red (B) stainings of liver sections of WT (a, b) and Adamts13-/- (c, d) mice kept 
on MCC (a, c) or MCD (b, d) diet for 4 weeks. Scale bars represent 100 µm. (C) Histological scoring 
of steatosis, hepatocyte ballooning, inflammation, fibrosis and NAS for mice kept on MCD diet. 
Data are means ± SEM of 10 (Adamts13-/-, black bars) or 5 (WT, white bars) determinations. 
 
DISCUSSION 
Deficiency of ADAMTS13, the VWF cleaving proteinase, causes thrombotic 
thrombocytopenic purpura (TTP), a rare but severe thrombotic disease (26). A 
functional role of ADAMTS13 has also been suggested in liver diseases, but available 
data are controversial (12). We have previously shown that ADAMTS13 antigen and 
activity levels are enhanced in obese mice, whereas ADAMTS13 deficiency did not 
affect development of NASH in obese mice (27, 28). In the present study, we show 
that a steatosis-inducing diet, independent of obesity, induces NASH to a comparable 
extent in ADAMTS13 deficient and WT mice.  
In patients, visceral obesity is frequently associated with NAFLD and NASH. These 
conditions may be associated with reduced ADAMTS13 activity, as reported in an 
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obese patient with recurrent TTP; defective ADAMTS13 synthesis was suggested as 
a possible consequence of NASH (29).  
Table 10: Histological scoring* of liver sections of mice kept on MCC or MCD diet for 4 weeks.  
 
*See Materials & Methods  
Abbreviations: MCD: methionine and choline deficient diet; MCC: control diet; WT: wild-type; 
Adamts13-/-: ADAMTS13 deficient.  
 
Furthermore, an apparent paradox with respect to the potential role of ADAMTS13 in 
development of acute liver failure has recently been recognized. On the one hand, 
ADAMTS13 activity was found to be inversely related to disease severity and outcome, 
whereas on the other hand, no UL-VWF multimers were found in the systemic 
 MCC MCD 
WT Adamts13-/- WT Adamts13-/- 
Microvesicular steatosis     
Score 0 (<5%) 2/5 7/10 0/5 0/10 
Score 1 (5-33%) 3/5 3/10 1/5 1/10 
Score 2 (33–66%) 0/5 0/10 2/5 6/10 
Score 3 (>66%) 0/5 0/10 2/5 3/10 
Hepatocyte ballooning     
Score 0 5/5 10/10 2/5 9/10 
Score 1 0/5 0/10 2/5 1/10 
Score 2 0/5 0/10 1/5 0/10 
Lobular inflammation     
Score 0 5/5 10/10 0/5 0/10 
Score 1 0/5 0/10 4/5 8/10 
Score 2 0/5 0/10 1/5 2/10 
Score 3 0/5 0/10 0/5 0/10 
Fibrosis     
F0 5/5 10/10 1/5 1/10 
Stage F1a 0/5 0/10 0/5 6/10 
Stage F1b 0/5 0/10 4/5 2/10 
Stage F1c 0/5 0/10 0/5 0/10 
Stage F2 0/5 0/10 0/5 1/10 
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circulation, and high molecular weight VWF levels and VWF function were even 
reduced in patients with acute liver failure as compared to healthy controls (30). 
Since NASH is difficult to study in humans because of the slow progression of the 
disease and of ethical considerations, animal models of NASH are crucial to better 
understand the pathogenesis of the disease. The model of feeding rodents with a diet 
deficient in both methionine and choline (MCD) used in this study, is one of the most 
common in NASH research (31-34). It is characterized by macrovesicular steatosis, 
hepatocellular death, inflammation, oxidative stress and fibrosis. Due to this diet, the 
mice lose weight and the metabolic profile is opposite to that of typical human NASH, 
e.g. the mice do not develop hyperlipidemia or hypertriglyceridemia and do not present 
with insulin resistance. However, liver injury and steatohepatitis are histologically 
similar to humans (35-37). The severity of NASH induced in rodents by the MCD diet 
depends on the administration scheme, but also on species, gender and strain of the 
animal (38, 39). With the administration scheme used in this study, 4 weeks of 
MCD/MCC, we have previously observed a protective effect of ADAMTS5 deficiency 
(C57Bl/6J background) on development of NASH (40). A similar administration 
scheme was used by Rinella et al. (34). Although we have not performed a time course, 
different effects of ADAMTS13 deficiency at earlier time points (e.g. 2 weeks) cannot 
be totally excluded. 
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Figure 27: Effect of MCD diet on expression of hepatic markers of steatosis/triglyceride 
metabolism (A), fibrosis (B) and inflammation (C).   
Gene expression relative to the MCC diet is shown for MCD fed mice. Data represent means ± 
SEM of 10 (Adamts13-/-) or 5 (WT) experiments for each diet. *, **, *** p < 0.05, p < 0.01, p < 0.001 
for MCD versus MCC.  
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It was reported that steatosis in mice kept on the MCD diet develops within 2 to 4 
weeks and progression to fibrosis by 8 to 10 weeks (41-43). Our mice indeed 
developed steatosis on the 4-weeks diet, which was not restricted to centrolobular or 
periportal liver portions, but was diffusely spread throughout the liver tissue. More 
pronounced steatosis and higher liver triglyceride levels were found upon MCD feeding 
of both genotypes, but without differences between genotypes. None of the mice 
developed severe fibrosis, although mRNA expression of the fibrosis markers TIMP-1 
and TGF-β in liver tissue was enhanced after the short-term MCD diet. These findings 
were supported by similar hepatic expression profiles of steatosis and fibrosis markers 
for both genotypes. The liver enzymes alkaline phosphatases, AST and ALT were 
enhanced on the MCD diet, indicating liver damage, but without marked differences 
between genotypes. Platelet counts tended to be lower after MCD diet feeding, most 
pronounced in Adamts13-/- mice. To our knowledge, this has not been reported 
previously and remains unexplained.  
In the present study, we observed that both the WT and the ADAMTS13 deficient mice 
fed with the MCD diet lose weight and present with low fasting blood glucose, but do 
not develop insulin resistance, in agreement with previous studies (31, 32, 37). 
Actually, we observed improved insulin sensitivity upon MCD feeding of both 
genotypes, whereas the HOMA-IR on either diet was lower for Adamts13-/- versus WT 
mice. In contrast, in mice with high fat induced obesity, glucose and insulin sensitivity 
were not different between WT and Adamts13-/- mice (27).  
Taken together, our present and previous (27) data do not support a functional role for 
ADAMTS13 in the development of steatohepatitis in mouse models of diet-induced 
steatosis. This is in agreement with a recent study in patients with NASH, showing that 
plasma ADAMTS13 levels were not different from controls (44). 
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Chapter 6 
ADAMTS13 deficiency and obesity as risk factors for 
Thrombotic Thrombocytopenic Purpura in mice 
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ABSTRACT 
Background: Thrombotic thrombocytopenic purpura (TTP) is caused by absence of 
ADAMTS13 activity. Thrombocytopenia is presumably related to formation of 
microthrombi rich in von Willebrand Factor (VWF) and platelets. Obesity may be a risk 
factor for TTP; it is associated with abundance of macrophages that may phagocytose 
platelets. 
Aims: To evaluate the role of obesity and ADAMTS13 deficiency in TTP, and to 
establish whether macrophages contribute to thrombocytopenia. 
Methods: Lean or obese ADAMTS13 deficient (Adamts13-/-) and wild-type (WT) mice 
(n = 10 in each group) were triggered with 250 U/kg of recombinant human VWF 
(rVWF), and TTP characteristics were evaluated 24h later. In separate experiments, 
macrophages were depleted in the liver and spleen of lean and obese WT or 
Adamts13-/- mice (n = 5 in each group) by injection of clodronate liposomes, 48h before 
injection of rVWF.  
Results: Obese Adamts13-/- mice had a lower platelet count than their lean 
counterparts (894 ± 35 x 10³ versus 1010 ± 35 x 10³ platelets/µL; p < 0.05) suggesting 
that they might be more susceptible to TTP development. Lean Adamts13-/- mice 
triggered with rVWF did not develop TTP, while typical TTP symptoms developed in 
obese Adamts13-/- mice, including severe thrombocytopenia (35 ± 13 x 103 versus 803 
± 113 x 103 platelets/µL; p = 0.0001) and higher LDH levels (630 ± 123 versus 329 ± 
57 mU/mL; p < 0.05). Removal of hepatic and splenic macrophages by clodronate 
injection in obese Adamts13-/- mice before treatment with rVWF resulted in 
preservation of platelet counts measured 24h after the trigger (1327 ± 80 x 103/µL 
versus 187 ± 47 x 103/µL for control PBS liposomes; p = 0.008). In vitro experiments 
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with cultured macrophages confirmed VWF dose-dependent increase of platelet 
phagocytosis (p = 0.001). 
Conclusions: Obese Adamts13-/- mice are more susceptible to induction of acute 
episodes of TTP than lean mice. Phagocytosis of platelets by macrophages contributes 
to thrombocytopenia after rVWF injection in this model.  
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INTRODUCTION 
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease caused by 
absence of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin-type 
1 repeat, member 13) activity, which cleaves pro-thrombotic ultra-large von Willebrand 
Factor (UL-VWF) multimers. Consequently, TTP is characterized by formation of 
platelet-rich microthrombi in capillaries and arterioles that can lead to organ failure and 
death. Other symptoms are severe thrombocytopenia, microangiopathic hemolytic 
anemia, fever and neurological dysfunctions (1). Pregnancy, alcohol abuse, infections 
and surgery are common risk factors for TTP development (2). However, investigation 
of potential triggers for TTP development is hampered by the lack of suitable animal 
models. Indeed, Adamts13-/- mice do not spontaneously develop TTP, but this can be 
triggered by injection of high dose recombinant VWF (rVWF) (3) or of Shiga toxin (Stx) 
(4). We previously observed higher levels of ADAMTS13 antigen and activity in obese 
as compared to lean mice (5). This is in agreement with higher expression levels of 
ADAMTS13 in livers of obese mice (6). Therefore, obesity would not be expected to 
be a risk factor for TTP, as it is associated with higher levels of the VWF cleaving 
proteinase ADAMTS13. Moreover, ADAMTS13 has anti-inflammatory potential (7), 
whereas obesity is a state of low-grade chronic inflammation (8). Recent emerging 
data, however, suggest that obesity may be a trigger for acute TTP in humans. Thus, 
in patients with BMI > 30 kg/m2 obesity was identified as a potential inducer of TTP 
with an odds ratio of 7.6 (9), and in the Oklahoma Registry of TTP patients more than 
25% were morbidly obese (BMI > 40 kg/m2) (10). Furthermore, a positive correlation 
was established between ADAMTS13 levels and BMI in humans (11). In the present 
study, we have evaluated the combined effect of obesity and ADAMTS13 deficiency in 
mice on development of a TTP phenotype. 
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It was also reported that macrophages play a role in thrombocytopenia associated with 
von Willebrand Disease (12). In TTP patients, it is assumed that severe 
thrombocytopenia is a consequence of the formation of microthrombi that are VWF 
and platelet-rich (13). Since macrophages are able to phagocytose and clear platelets 
from the circulation (14), we have also investigated whether platelet clearance in the 
liver and spleen by macrophages could contribute to TTP-related thrombocytopenia.  
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MATERIALS & METHODS 
Animal model 
Male ADAMTS13 deficient (Adamts13-/-) and wild-type (WT) littermate mice (genetic 
background: C57Bl6/J x 129X1/Sv x CASA/RK) (4) were kept on a standard fat diet 
(SFD) (KM-04-k12, Muracon, Carfil, Oud-Turnhout, Belgium; 13% kcal as fat, caloric 
value 10.9 kJ/g) or a high fat diet (HFD) (E15721–34, Ssniff, Soest, Germany; 42 % 
kcal as fat, caloric value 22 kJ/g) (n = 20 WT and Adamts13-/- mice each for both diets) 
for 15 weeks from the age of 5 weeks on. Body weight was measured weekly. At the 
start and end of the diet, blood was taken from the retro-orbital plexus on trisodium 
citrate (0.01 M) or EDTA (0.5 M) under anesthesia with isoflurane, and whole blood 
cell analysis was performed (Cell Dyn 3200R, Abbott Diagnostics, Illinois, USA). At the 
end of the diet, mice (n = 9-11 per group) were injected in the tail vein with a threshold 
dose of rVWF (250 U/kg) (Baxalta Innovations GmbH, Vienna, Austria) to trigger TTP 
(see below). Twenty-four hours later, blood was taken and organs were harvested after 
anesthetizing with pentobarbital. Blood smears were stained with May-Grünwald-
Giemsa to visualize schistocytes, and photographed on a Zeiss Axioplan 2 microscope 
(Carl Zeiss, Oberkochen, Germany). In separate experiments, obese (HFD) and lean 
(SFD) WT as well as Adamts13-/- mice were injected i.v. with 10 µL/g body weight 
liposome-encapsulated dichloromethylene bisphosphonate (clodronate) or control 
PBS liposomes (n = 5 with clodronate and PBS each) 48h before injection with rVWF 
(250 U/kg). In vivo platelet clearance was monitored in obese Adamts13-/- mice injected 
with clodronate or PBS 24h before injection with rVWF (250 U/kg).  
All animal experiments were approved by the KU Leuven ethical committee (P153–
2015) and performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (1996) and the EU Directive 2010/63/EU for animal experiments. 
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Determination of threshold dose of rVWF  
To determine the threshold dose that does not reduce platelet counts below 600 x 
10³/µL (level of thrombocytopenia), lean Adamts13-/- mice were injected with different 
doses (0, 100, 250, 500, 1000, 1300 and 2000 U/kg) of rVWF (3). Blood was taken via 
the retro-orbital plexus under anesthesia with isoflurane at several time points (24, 48, 
72, 96 and 120h) after injection to measure the platelet count.  
Analysis 
Murine ADAMTS13 and VWF levels in plasma were determined by ELISA as described 
previously (5, 15). Pooled plasma of WT mice was used as reference. Macrophages 
were stained with a F4/80 antibody (Serotec, Raleigh, NC), followed by signal 
amplification with the tyramide signal amplification biotin system (Perkin Elmer, 
Waltham, MA) and visualization with a streptavidin-enzyme conjugate, followed by 
DAB. Data are quantitatively expressed as percentage staining of section area. 
Analyses were performed with a Zeiss Axioplan 2 microscope and the AxioVision 
release 4.8 software (Carl Zeiss). Gene expression analysis of F4/80, MRC-1, IL-1β 
and TNF-α in liver tissue was analyzed by qPCR as described previously (5). Lactate 
dehydrogenase (LDH) activity levels were measured in plasma by the Lactate 
Dehydrogenase Activity Assay according to manufacturer’s protocol (BioVision 
Incorporated, Milpitas, CA). 
Platelet isolation and labeling 
For the in vitro study, lean WT mice were anesthetized with pentobarbital and blood 
was obtained by cardiac puncture, diluted (6/1) in ACD buffer (93 mM sodium citrate, 
7 mM citric acid, 14 mM dextrose, pH 6.8 supplemented with apyrase (100 mU/mL) 
(A6410, Sigma: Darmstadt, Germany); platelet-rich plasma (PRP) was obtained by 
centrifugation at 1600g for 30s followed immediately by centrifugation at 115g for 5 
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minutes. The PRP was diluted in ACD (1/3) and centrifuged at 950g for 5 minutes, 
followed by resuspension of the platelet pellet in Tyrode buffer (137 mM NaCl, 12 mM 
NaHCO3, 2 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM glucose, 
and 5 mM HEPES [N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid], pH 7.4). 
Washed platelets were labeled with CMFDA-Green (10 µM for 30 min at 37°C) 
(Molecular Probes, Life Technologies). Afterwards 1 µM prostaglandin E1 (PGE1; 
Sigma Aldrich, Saint‐Quentin, France) was added before centrifugation (to remove 
non-incorporated dye), to suppress platelet activation. 
For the in vivo study, obese WT mice were anesthetized with pentobarbital and blood 
was obtained by cardiac puncture in ACD-C buffer (124 mM tri‐sodium citrate, 130 mM 
citric acid, 110 mM dextrose, pH 6.5), washed in wash buffer (140 mM NaCl, 5 mM 
KCl, 12 mM tri‐sodium citrate, pH 6.5, supplemented with 100 mU/mL apyrase and  
1 µM PGE1). PRP, obtained by centrifugation at 1600g for 30s followed immediately 
by centrifugation at 115g for 5 minutes. was supplemented by ACD (1/10), 100 mU/mL 
apyrase and 1 µM PGE1, and washed in wash buffer and centrifuged for 5 minutes at 
950g; platelets were finally diluted in Tyrode buffer (10 mM HEPES, 140 mM NaCl,  
3 mM KCl, 5 mM NaHCO3, 0.5 mM MgCl2, and 10 mM glucose, pH 7.4). Washed 
platelets were labeled with CMTMR-Orange (10 µM for 30 min at 37°C) (Molecular 
Probes, Life Technologies) in Tyrode buffer supplemented with 100 mU/mL apyrase 
and 1 µM PGE1. To remove non-incorporated dye, platelets were centrifuged for 5 
minutes at 950g. 
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In vitro platelet phagocytosis by macrophages 
Four days after i.p. injection of 4% thioglycollate, peritoneal macrophages were 
harvested in RPMI medium (Thermofisher Scientific, Gent, Belgium) and incubated 
with red blood cell (RBC) lysis buffer (eBioscience, San Diego, USA) for 5 minutes. 
Cells were counted and seeded at a density of 500 x 10³ cells per well (3.8 cm²) in 
RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (PenStrep; Invitrogen, Paisly, UK). After attaching overnight, 
macrophages were washed with PBS to remove non-adherent cells and incubated for 
45 minutes in an atmosphere of 95% humidified air–5 % CO2 at 37°C with 5 µM Cell 
Tracker Orange CMTMR in DMEM/F12 (Thermofisher Scientific) supplemented with 
10 mM L-glutamine (Thermofisher Scientific) and 1% PenStrep. Afterwards, remaining 
dye was removed by washing with PBS. CMFDA-Green labeled washed murine 
platelets were added at a density of 5 platelets per macrophage, together with 
increasing doses of rVWF (0-15 U/mL) and botrocetin (3 µg/mL/U rVWF; Sigma-
Aldrich, Overijse, Belgium) to promote  rVWF binding to platelets. Cells were incubated 
for 20h in DMEM/F12 medium supplemented with 10 mM L-glutamine, 10% FBS and 
1% PenStrep at 37°C after which they were washed and fixed with 4% formaldehyde 
(Thermofisher Scientific) in PBS. Phagocytosis was analyzed and quantitated by using 
a fluorescence Zeiss Axioplan 2 microscope (Carl Zeiss). For each condition, total 
amount of macrophages, total amount of platelets, macrophages with phagocytosed 
platelets (yellow) and total number of phagocytosed platelets were assessed.  
In vivo platelet clearance/aggregation 
Obese Adamts13-/- mice were injected with 10 µL/g body weight PBS or clodronate 
liposomes. Twenty-four hours later, 200 µL of washed fluorescently labeled (CMTMR-
Orange) platelets obtained from obese WT mice (diluted in Tyrode buffer 
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supplemented with 1 µM PGE1 to a final concentration of 500 x 103 platelets/µL) was 
injected via the tail vein in obese Adamts13-/- mice. Threshold dose of rVWF (250 U/kg) 
was injected i.v. 1h after injection of fluorescent-labeled platelets. Twenty-four hours 
later, blood was taken via retro-orbital bleeding (0.5 M EDTA), platelets were counted 
and blood smears were prepared with 4 µL of blood. Mice were perfused by saline and 
killed by cervical translocation, before liver and spleen were removed. 
Microaggregates/single platelets were qualitatively visualized using the fluorescence 
Zeiss Axioplan 2 microscope (Carl Zeiss).  
Statistical analysis 
Data are presented as means ± standard error of the means (SEM). Statistical 
significance between groups was analyzed with the non-parametric Mann-Whitney U 
or non-parametric Wilcoxon test. Analysis of the data was performed using Prism 7 
(GraphPad Software Inc., San Diego, CA). Values of p < 0.05 are considered 
statistically significant.  
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RESULTS  
Obese Adamts13-/- mice do not develop TTP 
After 15 weeks of HFD, both WT and Adamts13-/- mice gained significantly more weight 
as compared to SFD feeding (Figure 28A). This was associated with significantly 
enhanced ADAMTS13 antigen levels after HFD feeding of WT mice, but with reduced 
levels after SFD feeding (Figure 28B).  
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Figure 28: Phenotype of wild-type (WT) and ADAMTS13 deficient (Adamts13-/-) mice kept on a 
standard fat (SFD) or high fat diet (HFD).   
(A) Body weight at the start and end of the diet. (B) ADAMTS13 antigen (Ag) levels, as compared 
to a reference plasma pool, in plasma of WT mice at the start and end of the diet. Data are means 
± SEM of 9-11 experiments with * p < 0.05, ** p < 0.01 and *** p < 0.001 (Mann-Whitney U test). 
 
At the start of the diet, plasma VWF antigen levels were not different in the four groups 
(data not shown). After 15 weeks on HFD, VWF levels were significantly increased as 
compared to SFD feeding of both genotypes. On SFD, there was no significant 
difference between genotypes, whereas on HFD the VWF levels were lower for the 
Adamts13-/- mice (Figure 29A). Plasma levels of lactate dehydrogenase (LDH) activity 
were higher after HFD in Adamts13-/- mice reflecting more organ damage, but were not 
affected by genotype (Figure 29B). Hemoglobin and hematocrit levels were not 
different between WT and Adamts13-/- mice on SFD or HFD (Table 11). Obese as 
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compared to lean mice of both genotypes displayed enhanced hepatic macrophage 
content, as determined by quantitative analysis of F4/80 staining (Figure 29C). Platelet 
count was comparable for WT and Adamts13-/- mice at the start of the diet. At the end 
of the diet, platelet counts were reduced for obese as compared to lean WT as well as 
Adamts13-/- mice (Figure 29D), suggesting that obesity may represent a risk for 
enhanced platelet consumption or clearance. 
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Figure 29: Phenotype of wild-type (WT) and ADAMTS13 deficient (Adamts13-/-) mice kept on a 
standard fat (SFD) or high fat diet (HFD).   
(A) Endogenous plasma VWF Ag levels, (B) LDH activity and (C) hepatic macrophage content 
(F4/80 staining) of WT and Adamts13-/- mice at the end of the diet. (D) Platelet count at the start 
and end of the diet of WT and Adamts13-/- mice. Data are means ± SEM of 9-11 experiments with 
* p < 0.05, ** p < 0.01; †† p < 0.01, ††† p < 0.001 as compared to the start of the diet (Mann-Whitney 
U test). 
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Table 11: Blood cell analysis of WT and Adamts13-/- mice fed a SFD or HFD for 15 weeks. 
 
 SFD HFD 
WT Adamts13-/- WT Adamts13-/- 
n 5 11 8 9 
WBC (x103/µL) 8.27 ± 0.66 10.4 ± 0.70* 10.8 ± 1.1 8.99 ± 0.73 
Neutrophils (%) 14.7 ± 2.3 10.6 ± 0.96 9.56 ± 1.4 9.83 ± 1.8 
Lymphocytes (%) 79.9 ± 2.3 84.6 ± 1.4 85.04 ± 2.0 82.3 ± 2.4 
RBC (x106/µL) 8.70 ± 0.16 8.66 ± 0.29 9.31 ± 0.38 8.97 ± 0.21 
Hemoglobin (g/dL) 12.6 ± 0.13 12.6 ± 0.47 13.5 ± 0.55 12.9 ± 0.32 
Hematocrit (%) 13.9 ± 0.17 13.8 ± 0.51 14.8 ± 0.59 14.2 ± 0.34 
 
Data are means ± SEM of n experiments in each group. * p < 0.05 as compared to WT mice on 
SFD (Mann-Whitney U test). Abbreviations: SFD, standard fat diet; HFD, high fat diet. 
 
rVWF induces TTP symptoms in obese Adamts13-/- mice 
A previous study reported that injection of 2000 U/kg rVWF in Adamts13-/- mice 
induced TTP (3). However, we observed that this high dose rVWF also caused severe 
thrombocytopenia in WT mice (data not shown). Therefore, we determined the 
threshold dose of rVWF that significantly decreased platelet counts, but not below the 
level of thrombocytopenia (< 600 x 10³/µL). Therefore, decreasing doses of rVWF 
(2000 to 100 U/kg) were injected in lean Adamts13-/- mice and platelet counts were 
monitored between 24 and 120h after injection (data not shown). Doses of rVWF 
between 500 and 2000 U/kg caused severe thrombocytopenia (platelet counts 
between 65 and 343 x 10³/µL) after 24h in all mice, whereas up to 250 U/kg only a 
moderate decrease of platelet count was observed. Therefore, a dose of 250 U/kg was 
selected as threshold for further experiments, and platelet counts were measured 24h 
after injection. Using this approach, injection of rVWF in obese WT or Adamts13-/- mice 
was associated with lower platelet counts as compared to lean mice (Figure 30A). In 
obese Adamts13-/- mice, platelet counts after injection dropped by 96% (948 ± 46 x 
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103/µL at the end of the diet versus 35 ± 13 x 103/µL 24h after rVWF injection), as 
compared to a drop by 29% for lean Adamts13-/- mice (1,133 ± 40 x 103/µL versus 803 
± 113 x 103/µL). In contrast, platelet counts of lean or obese WT mice were not affected 
by rVWF injection. Thus, obesity in an Adamts13-/- background promotes induction of 
severe thrombocytopenia upon rVWF injection. In addition, plasma levels of LDH 
activity were significantly higher for obese as compared to lean Adamts13-/- mice or to 
obese WT mice (Figure 30B), indicating more severe organ damage in obese 
Adamts13-/- mice 24h after rVWF injection. Endogenous VWF antigen levels were 
higher in obese as compared to lean WT as well as Adamts13-/- mice, without marked 
effects of genotype (Figure 30C).  
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Figure 30: TTP characteristics after injection of rVWF in lean (SFD) and obese (HFD) WT or 
Adamts13-/- mice.  
 (A) Platelet count, (B) LDH activity and (C) endogenous levels of VWF antigen. Data are means 
± SEM of 9-11 experiments with * p < 0.05, ** p < 0.01 and *** p < 0.001 (Mann-Whitney U test). 
 
Hemoglobin (Figure 31A) and hematocrit (Figure 31B) levels were not different 
between obese and lean Adamts13-/- mice, not supporting hemolytic anemia or effects 
on hematopoiesis. Furthermore, analysis of schistocytes in blood smears (Figure 32B) 
did show an increase after HFD as compared to SFD feeding, but no difference 
between WT and Adamts13-/- mice (Figure 32A). Taken together, these data indicate 
that obesity is a risk factor for development of TTP in genetically predisposed 
Adamts13-/- mice, induced by the additional injection of rVWF.  
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Figure 31: Hemoglobin and hematocrit levels after injection of rVWF in lean and obese WT or 
Adamts13-/- mice.  
(A) hemoglobin levels, and (B) hematocrit levels for WT and Adamts13-/- mice on SFD or HFD. 
Data are means ± SEM of 9-11 experiments. No significant differences were observed  
(Mann-Whitney U test). 
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Figure 32: Schistocytes in blood smears after injection of rVWF in lean and obese WT or 
Adamts13-/- mice.   
(A) Quantitation of schistocytes (number per 500 red blood cells) in lean and obese WT and 
Adamts13-/- mice. (B) Blood smear (40x magnification) from an obese Adamts13-/- mouse after 
rVWF injection. Schistocytes, visualized by May-Grühnwald Giemsa staining, are indicated by 
white circles. Data are means ± SEM of 9-11 experiments with * p < 0.05 (Mann-Whitney U test). 
 
Hepatic macrophages contribute to severe thrombocytopenia  
HFD feeding was associated with enhanced hepatic macrophage content (Figure 
29C), which may contribute to enhanced clearance of platelets and platelet/VWF 
complexes. Therefore, we have depleted macrophages in the liver and spleen of lean 
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and obese WT and Adamts13-/- mice by i.v. clodronate treatment before rVWF 
injection. Reduction of macrophage populations in livers of all treated mice was 
confirmed by reduced staining and expression of F4/80 as compared to PBS treatment 
(Figure 33A, C). This was further supported by reduced expression of macrophage 
markers IL-1β, MRC-1 and TNF-α (Figure 33B).  
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Figure 33: Effect of clodronate treatment 48h before injection of rVWF on hepatic macrophage 
populations in WT and Adamts13-/- mice. 
(A) F4/80 staining of liver sections of obese WT (panels III and IV) and Adamts13-/- (panels I and 
II) mice treated with PBS (left panels) or clodronate (right panels). Scale bars represent 50 µm. 
(B) mRNA expression of macrophage markers F4/80, IL-1β, MRC-1 and TNF-α in the liver of lean 
and obese WT and Adamts13-/- mice injected with PBS or clodronate normalized to lean WT mice 
injected with PBS liposomes. (C) Quantitation of macrophages from F4/80 staining for injection 
of PBS (white bars) or clodronate (black bars). *, ** p < 0.05, p < 0.01 as compared to mice of the 
same genotype on the same diet injected with PBS; ## p < 0.01 as compared to obese WT mice 
injected with PBS; † p < 0.05 and ††† p< 0.001 (Mann Whitney U test). Data are means ± SEM of 
5 experiments. 
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Figure 34: Effect of macrophage depletion on TTP characteristics of lean and obese WT or 
Adamts13-/- mice.  
(A) Platelet count, (B) endogenous VWF antigen levels and (C) LDH activity at the end of the diet 
(white bars) and 24h after injection of clodronate or PBS (grey bars) and rVWF (only in panel A) 
(black bars). Data are means ± SEM of 5 determinations. * p < 0.05, ** p < 0.01, *** p < 0.001. 
(Mann-Whitney U test or Wilcoxon Rank test). Abbreviation: TP: thrombocytopenia. 
 
 
Platelet counts at the end of the diet were not significantly affected by treatment with 
either clodronate or PBS (Figure 34A). However, platelet counts 24h after injection of 
rVWF (250 U/kg) remained significantly higher in lean and obese Adamts13-/- mice 
when macrophages were depleted as compared to PBS controls. These differences 
were not observed for lean or obese WT mice. Thus without macrophage depletion 
(PBS), platelet counts of obese Adamts13-/- mice were significantly lower than for 
obese WT mice (Figure 34A). Treatment with clodronate caused a significant rise of 
endogenous VWF levels in lean as well as obese WT and Adamts13-/- mice as 
compared to PBS injected mice (Figure 34B). Hemoglobin and hematocrit levels were 
comparable for all mice (data not shown). LDH activity was not affected by diet only, 
but increased after depletion of the macrophages in all mice (Figure 34C). The 
prevalence of schistocytes in fresh blood smears of Adamts13-/- mice tended to be 
(non-significantly) higher upon clodronate versus PBS treatment for both lean (1.5 ± 
0.4/500 RBC versus 0.7 ± 0.1/500 RBC) and obese (0.7 ± 0.2/500 RBC versus  
0.4 ± 0.4/500 RBC) mice.  
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rVWF enhances platelet phagocytosis by macrophages  
When fluorescently labeled platelets were added in vitro to fluorescently labeled 
macrophages in the presence of rVWF and botrocetin, phagocytosis of platelets was 
observed (Figure 35A). The total amount of macrophages that phagocytosed platelets 
was not affected by rVWF (Figure 35B), whereas the proportion of phagocytosed 
platelets increased with rising concentrations of rVWF (Figure 35C, D). 
Subsequently, we isolated and fluorescently marked platelets from obese WT donor 
mice and injected them in obese Adamts13-/- mice before injection of rVWF. Twenty-
four hours later, liver and spleen were harvested to track the administered platelets. In 
mice with normal functioning macrophages, single platelets as well as platelet 
aggregates could be visualized particularly in the liver (Figure 36, I). Macrophage 
depletion strongly reduces platelet aggregate accumulation in the liver (Figure 36, II). 
Injection of rVWF triggered little platelet aggregate accumulation in the spleen (Figure 
36, III), unless mice were treated with clodronate in which more platelet aggregates 
accumulated in the spleen (Figure 36, IV).  
These preliminary data need to be confirmed by histological stainings and/or western 
blot analysis.  
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Figure 35: Phagocytosis of platelets by macrophages in the presence of rVWF.  
(A) Representative image of phagocytosis of platelets (green/yellow) by macrophages (red) 
(magnification 20x). (B) The proportion of macrophages (Mφ) that phagocytosed platelets. (C) 
The proportion of phagocytosed platelets. (D) The ratio of phagocytosed platelets to the total 
macrophage content in the presence of increasing concentrations of rVWF. Data are means ± 
SEM of 15 experiments. ** p < 0.01, *** p < 0.001 as compared to the absence of rVWF (Mann-
Whitney U test). 
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Figure 36: Effect of macrophage depletion on in vivo platelet distribution in obese Adamts13-/- 
mice.  
Washed platelets isolated from obese WT mice were fluorescently labeled by CMTMR-Orange 
and injected i.v. in obese Adamts13-/- mice 24h after clodronate injection (II and IV) or without 
macrophage depletion (I and III), followed by rVWF injection 24h later. Liver (I and II) and spleen 
(III and IV) were removed 24h after rVWF injection to track fluorescent platelets. Scale bars 
represent 50 µm.  
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DISCUSSION 
TTP is an extremely rare, but life-threatening disease caused by the absence of 
ADAMTS13 activity, the VWF cleaving proteinase, whereby microthrombi are formed 
in the microcirculation causing tissue damage and ultimately death (2). TTP patients 
may have a genetic predisposition, but an additional triggering factor is needed to 
evoke an acute TTP episode. Known triggers include pregnancy, HIV infection and 
alcohol abuse. However, in many cases the trigger remains unknown, and therefore 
the exact etiology of TTP remains unclear (1). Interestingly, obesity, which is a state of 
chronic inflammation, was found to be associated with higher ADAMTS13 levels in 
mice and man (6, 11). Nonetheless, obesity was suggested to be a possible risk factor 
for TTP (9). Although apparently contradictory, there are indications that obesity is 
indeed a risk factor for TTP. In the Oklahoma TTP cohort study, morbid obesity had a 
significantly higher prevalence in TTP patients (10), and ADAMTS13 levels were lower 
in obese TTP patients as compared to patients with a healthy BMI (16, 17). In contrast, 
in 21% of obese patients undergoing bariatric surgery non-inhibitory ADAMTS13 
autoantibodies were detected, whereas ADAMTS13 antigen and activity levels were 
comparable to lean subjects (18). Weight loss after bariatric surgery was associated 
with a reduction of anti-ADAMTS13 autoantibodies (19).  
Studies on TTP are hampered by the lack of suitable animal models; indeed mice 
deficient in ADAMTS13 do not spontaneously develop TTP. Furthermore, obese WT 
mice have enhanced ADAMTS13 levels. We previously reported that obese  
Adamts13-/- mice had a slightly lower platelet count and more hepatic microthrombi 
than obese WT or lean Adamts13-/- mice (20). However, because obese Adamts13-/- 
mice did not suffer from severe thrombocytopenia and did not show marked organ 
damage or blood schistocytes, they did not represent an improved model of TTP.  
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In this study, we show that obesity is indeed a risk factor for TTP in Adamts13-/- mice, 
as injection of a threshold dose of rVWF (250 U/kg) resulted in severe 
thrombocytopenia and more organ damage. Thus, when both risk factors, obesity and 
deficiency of ADAMTS13, are present, mice are more susceptible for TTP 
development upon triggering by rVWF. 
The human body produces and removes up to 1011 platelets daily in order to maintain 
a normal steady state platelet count. Multiple mechanisms may contribute to platelet 
production and clearance (reviewed in (21)). It was shown that macrophages play a 
crucial role in clearance of platelets and platelet/VWF complexes (22, 23). Indeed, 
increased clearance of platelet/VWF complexes by macrophages in liver and spleen 
contributes to the thrombocytopenia associated with von Willebrand disease type 2B, 
which is characterized by enhanced affinity of VWF for platelets (12).  
Due to the inflammatory state, obesity is especially associated with an increase in pro-
inflammatory M1 macrophages in both the adipose tissue (24) and the liver (25). Thus, 
whereas obesity is associated with enhanced ADAMTS13 levels in mice (5), it also 
causes more abundant macrophage populations. The expected protective effect of 
enhanced ADAMTS13 levels on TTP development by reducing microthrombi formation 
may therefore be blunted by higher macrophage content that may lead to enhanced 
platelet clearance. In order to further investigate a potential causative relation between 
enhanced macrophage content and reduced platelet counts in TTP, we have depleted 
hepatic as well as splenic macrophages by i.v. clodronate treatment. Clodronate 
treatment by itself had no effect on platelet counts in either lean or obese WT or 
Adamts13-/- mice. Reduced macrophage populations (clodronate) in lean and obese 
Adamts13-/- mice were indeed associated with higher platelet counts after triggering 
with rVWF as compared to PBS treatment. A causal relationship between both 
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observations is further suggested by a significant negative correlation between hepatic 
macrophage content and platelet counts (p = 0.001, r = -0.7 for Adamts13-/- mice). 
Taken together, these observations indicate that enhanced platelet clearance in control 
PBS-treated lean and obese Adamts13-/- mice involves interaction with injected VWF. 
This is not observed in WT mice possibly because of cleavage of UL-VWF by 
ADAMTS13. Endogenous VWF levels were significantly elevated after clodronate 
treatment of lean and obese mice, possibly reflecting reduced clearance after 
macrophage depletion. 
By both in vitro and in vivo approaches, we showed that addition of rVWF causes 
enhanced phagocytosis of platelets by macrophages. Increasing concentrations of 
rVWF induced significantly more platelet phagocytosis by the same number of 
macrophages in vitro. Thus, in the presence of high concentrations of VWF, each 
macrophage phagocytizes a higher number of platelets. This observation should be 
further confirmed by histological stainings for platelet and macrophage markers on liver 
and spleen sections from mice injected with rVWF and clodronate or control liposomes.  
Thus, in addition to microthrombi formation (26), enhanced platelet clearance by 
upregulated macrophage populations may also contribute significantly to severe 
thrombocytopenia in obese subjects with TTP. The stimulating role of VWF on platelet 
phagocytosis by macrophages may also be relevant in other pathologies with 
associated thrombocytopenia. In such pathologies, VWF-targeting treatment such as 
Caplacizumab (27) could be beneficial.  
The animal model for TTP used in this study (a nutritionally induced obese  
Adamts13-/- mouse injected with rVWF), albeit complex and time consuming, could be 
useful in studies to evaluate new pharmacological approaches.  
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In conclusion, our data indicate that obesity is a risk factor for TTP development in 
genetically predisposed mice, and that hepatic macrophages play an active role in 
platelet clearance leading to severe thrombocytopenia.  
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Chapter 7 
General Discussion 
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Second hit theory in TTP: a role for obesity? 
TTP is a life-threatening disease of which the most distinct characteristics are severe 
thrombocytopenia and formation of microthrombi in the microcirculation where the 
shear stress is high. The main cause of TTP is a deficiency or absence of ADAMTS13 
(activity < 5%), the VWF cleaving proteinase, leading to persistence of uncleaved ultra-
large hyperactive VWF multimers. These will bind to platelets, resulting in 
platelet/VWF-rich thrombi and thrombocytopenia due to the high platelet consumption 
(2, 56). It is thought that ADAMTS13 deficiency as such is insufficient to develop a TTP 
episode, since patients with congenital TTP only sporadically develop TTP attacks 
alternated with periods of remission. Therefore, it is postulated that a second hit, driving 
endothelial damage or activation, is needed to develop an acute TTP episode (130). 
Despite known triggers as pregnancy, HIV, several anti-platelet drugs such as 
ticlopidine and clopidogrel, and alcohol abuse, the triggering factor to induce 
endothelial damage/activation is still largely unknown. Hence, the exact 
pathophysiology remains unexplained, hampering prevention of TTP attacks in high-
risk subjects and development of specific treatments. Nowadays, acquired or 
congenital TTP is treated mainly by plasma exchange or infusion therapy, respectively, 
complemented or not by immunosuppressive therapy. Further research is needed to 
unravel the exact etiology of TTP. Since the prevalence of TTP is low, an experimental 
animal model would be useful. However, the existing TTP mouse models have major 
limitations, including complexity and lack of reproducibility. 
Although several studies, both in mice and men, proposed obesity as a potential risk 
factor for TTP (128, 131), this is associated with increased ADAMTS13 levels (124, 
125, 131). This is somewhat paradoxical, since higher ADAMTS13 levels should be 
protective instead of harmful for TTP development. Moreover, obesity is a state of low-
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grade chronic inflammation (110), whereas ADAMTS13 has anti-inflammatory 
capacities (75) (Figure 37).  
 
Figure 37: Paradoxical setting of obesity as risk factor for TTP. 
Whereas obesity is a state of low-grade chronic inflammation, it is associated with increased 
levels of the anti-inflammatory proteinase ADAMTS13. Although ADAMTS13 is shown to be 
protective against TTP development, obesity has been proposed as risk factor for TTP.   
Abbreviations: ADAMTS13: a disintegrin and metalloproteinase with thrombospondin-1 repeat, 
member 13; UL-VWF: ultra-large von Willebrand Factor; TTP: thrombotic thrombocytopenic 
purpura; EC: endothelial cell.   
 
To resolve a potential role of ADAMTS13 in obesity and TTP, we have addressed the 
following research questions: 
 Does ADAMTS13 play a role in adipose tissue development/expansion? 
 Does ADAMTS13 in an obese context promote microthrombosis? 
 Does ADAMTS13 play a role in NASH? 
 Does obesity represent a risk factor for TTP? 
 Do macrophages play a role in TTP-related thrombocytopenia?  
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These issues were addressed mainly with the use of diet-induced obese ADAMTS13 
deficient mice.   
ADAMTS13 in adiposity  
Since ADAMTS13 levels are positively correlated with BMI (124) and it was proposed 
as a potential player in angiogenesis (78, 79) and oxidative stress/inflammation (75, 
76), we investigated a potential role of ADAMTS13 in adipose tissue expansion. We 
did not find any relevant differences between WT and Adamts13-/- mice kept on SFD 
or HFD concerning body weight, weight of different fat depots, adipocyte size and 
density, inflammation, oxidative stress or angiogenesis related to obesity. Thus, 
despite its role in several obesity-related processes, we concluded that ADAMTS13 
has no functional role in adiposity in mice. This may be in agreement with the fact that 
ADAMTS13 is not expressed in adipose tissue or adipocytes (data not shown). 
Surprisingly, ADAMTS13 expression in the liver, the main organ of secretion, was not 
enhanced with obesity, whereas plasma ADAMTS13 antigen and activity levels were 
markedly elevated after a HFD. Furthermore, increased hepatic ADAMTS13 
expression in obese WT and ApoE-/- mice was described before (125).  
Interestingly, adiponectin levels were not decreased upon a HFD in Adamts13-/- mice, 
which is puzzling, because adiponectin has metabolically protective characteristics; its 
levels are generally negatively correlated with fat mass and ADAMTS13 has anti-
inflammatory properties (75). Therefore, it would be expected that adiponectin levels 
would decrease upon a HFD in Adamts13-/- mice and would be even lower than in 
obese WT mice. Adiponectin forms complexes with serum proteins such as TSP-1. 
Since obese subjects have lower levels of adiponectin, free TSP-1 levels may be 
increased, probably due to reduced complex formation (132). Since we did not 
measure TSP-1 levels in plasma of our mice, we cannot determine whether TSP-1 
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levels were lower in obese Adamts13-/- mice as compared to obese WT mice. Because 
ADAMTS13 contains TSP-1 domains (TSR), it is conceivable that adiponectin forms 
complexes with ADAMTS13. Moreover, we found a negative correlation between 
ADAMTS13 and adiponectin levels in WT mice (r = -0.6; p = 0.01).Thus, on the 
condition that complexes are cleared from the body, reduced complex formation of 
adiponectin with ADAMTS13 may in part explain the increase of ADAMTS13 in obese 
WT mice.  
 In human subjects, obesity is associated with production of non-inhibitory antibodies 
directed against ADAMTS13, but Lombardi et al. (129) did not observe differences in 
ADAMTS13 antigen and activity between lean and obese human subjects. This is in 
contrast to our own and other peer-reviewed data (124, 125). Lombardi et al. 
suggested that increased TSP-1 levels, because of decreased complex formation with 
adiponectin, would be responsible for the antibody production, since TSP-1 has 
structural homology with ADAMTS13. Moreover, a negative correlation between  
TSP-1 and ADAMTS13 was observed, whereas adiponectin and ADAMTS13 were not 
correlated, which is in contrast to our findings in mice.   
Hence, both adiponectin and TSP-1 may influence ADAMTS13 levels, but this remains 
enigmatic. The increased adiponectin levels in obese Adamts13-/- mice remain 
unexplained.  
Similarly as adiponectin levels, total cholesterol levels were increased in obese 
Adamts13-/- mice as compared to WT mice. Atherosclerosis is a consequence of 
hypercholesterolemia, which is frequently accompanied by obesity. Uptake of LDL by 
macrophages in the arterial wall leads to foam cell and plaque formation combined with 
secretion of inflammatory mediators. Atherosclerosis is a common comorbidity of 
obesity, which is also known as a state of low-grade systemic chronic inflammation in 
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which macrophages play an important role. The role of the ADAMTS13/VWF axis was 
previously described in systemic inflammation (75, 133). Additionally, Gandhi et al. 
reported that macrophage infiltration in the aortic sinus of ApoE-/-/Adamts13-/- mice was 
increased as compared to ApoE-/- mice. Interestingly, this effect was reversed in 
Adamts13-/-/VWF-/-/ApoE-/- mice. Besides infiltration of macrophages, also neutrophil 
infiltration was higher in the absence of ADAMTS13, whereas deficiency of VWF had 
opposite effects in ApoE-/- mice. Therefore, it was suggested that ADAMTS13 reduced 
macrophage and neutrophil infiltration by cleavage of UL-VWF, thereby affecting 
atherosclerotic lesions. Whereas Ghandi et al. did not report an effect of ADAMTS13 
on cholesterol levels in ApoE-/- mice (134), others observed positive correlations 
between ADAMTS13 and cholesterol levels, in both mice (135) and men (124). We 
did, however, not find a clear functional association between ADAMTS13 and 
cholesterol in our study, as total cholesterol levels were higher in obese Adamts13-/- 
than WT mice. Interestingly, a diet rich in cholesterol increases VWF levels (136). 
Therefore, increased ADAMTS13 levels after a HFD may be explained as reaction to 
increased VWF related to higher cholesterol levels. Indeed, both cholesterol as well as 
VWF levels were increased in obese WT mice as compared to lean WT mice (p < 
0.0001 and p = 0.003, respectively; pooled data from two diet studies, n = 40). 
Consequently, VWF and cholesterol levels in both lean and obese WT mice correlated 
positively (r = 0.3; p = 0.056). Hence, ADAMTS13 elevation could possibly be regarded 
as a protective mechanism against atherosclerosis and possibly also against TTP 
(Figure 38). Thus, obese subjects deficient in ADAMTS13 could be at higher risk for 
TTP development, since the increased VWF levels (as result of both elevated 
cholesterol levels and ADAMTS13 deficiency) are not counteracted by ADAMTS13.  
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To summarize, although we did not find a significant role of ADAMTS13 in adipose 
tissue expansion, this proteinase may be relevant in protection against obesity-related 
disorders such as atherosclerosis. The increased ADAMTS13 levels after a HFD in 
WT mice may probably be explained as a protective reaction mechanism to enhanced 
cholesterol and increased VWF levels.  
Figure 38: Increased ADAMTS13 in the obese context as protection mechanism against elevated 
VWF.  
High cholesterol leads to increased VWF levels. As reaction, ADAMTS13 levels are enhanced, 
which is protective against atherosclerosis, but also against TTP. Hence, obesity could be a risk 
factor for TTP in obese subjects deficient for ADAMTS13.   
Abbreviations: VWF: von Willebrand Factor; ADAMTS13: a disintegrin and metalloproteinase 
with thrombospondin-1 repeat, member 13. 
 
Role of the fibrinolytic system in hepatic microthrombosis in obese Adamts13-/- 
mice? 
Deficiency of ADAMTS13 in combination with obesity caused enhanced formation of 
thrombi in the liver. We measured TAT complex levels reflecting thrombin generation 
and representing a marker for a pro-coagulant state. We found a slight increase of TAT 
levels in plasma and in liver extracts upon HFD as compared to SFD feeding. In liver 
extracts, TAT levels were slightly, but significantly higher for lean WT than  
Adamts13-/- mice, whereas in plasma no significant differences were found between 
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the genotypes. However, thrombin generation causes fibrin-rich thrombi, whereas 
hepatic microthrombi in the obese Adamts13-/- mice are rich in VWF and platelets. In 
addition, fluorescent platelet-rich aggregates were observed in livers of obese 
Adamts13-/- mice injected with fluorescently labeled platelets (preliminary data of in 
vivo study). Noteworthy, these latter mice were triggered for TTP, in contrast to the 
mice of the diet-induced obesity experiment. Higher prevalence of hepatic platelet-rich 
thrombi in obese Adamts13-/- mice could possibly be explained by higher levels of 
leptin (p < 0.05) in obese mice, promoting platelet aggregation (137), combined with 
the absence of the antithrombotic proteinase ADAMTS13.  
In addition, we measured PAP complex levels in both plasma and liver extracts, but 
we did not find evidence of an increased activity of plasmin in our study. This is not in 
agreement with a compensatory role of plasmin in ADAMTS13 deficiency, as 
described by Tersteeg et al. (81). Nonetheless, the conditions in our study were 
different, as our mice did not suffer from TTP. In the study of Tersteeg et al.,  
Adamts13-/- mice were injected with high dose rVWF to induce TTP, simultaneous with 
plasminogen and streptokinase administration. Hence, it may be that more extensive 
endothelial damage is required for activation of the fibrinolytic system, and subsequent 
degradation of UL-VWF multimers. Therefore, increased PAP complex levels would be 
expected after induction of endothelial damage by injection of rVWF in obese 
Adamts13-/- mice, but this was not investigated. Tersteeg et al. hypothesized that 
plasminogen is activated during TTP attacks and that plasmin degrades VWF in 
recently formed microthrombi when α2-AP is depleted. Thereafter, plasmin can further 
degrade the remaining VWF (Figure 39).  
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Figure 39: Plasmin as compensatory proteinase for ADAMTS13? 
Plasmin can act as bypass for ADAMTS13 in case of deficiency during TTP attacks when α2-AP 
is depleted (A). In obese Adamts13-/- mice, platelet-rich hepatic thrombi were detected, but 
without marked activation of the fibrinolytic system. Probably because of less pronounced 
endothelial damage (B). 
Abbreviations: ADAMTS13: a disintegrin and metalloproteinase with thrombospondin-1 repeat, 
member 13; rVWF: recombinant von Willebrand Factor; α2-AP: α2-antiplasmin; UL-VWF: ultra-
large von Willebrand Factor multimers. 
 
ADAMTS13 does not affect development of liver steatosis  
Since ADAMTS13 is produced by the liver, its role in liver diseases was studied 
extensively, but data are somewhat controversial (138). We could not find a role of 
ADAMTS13 in liver steatosis using two different mouse models. The first model, a diet-
induced obese mouse, represents liver steatosis as a consequence of obesity, the 
most common form of NAFLD (139, 140). It shows typical signs of human NASH as 
hypertriglyceridemia, hyperlipidemia and insulin resistance. The MCD diet, on the other 
hand, is not related to obesity, but induces weight loss. Despite that liver injury and 
steatosis are histologically similar to humans, the MCD diet fed mice do not present 
with insulin resistance, a typical NASH characteristic (141-143). These mice actually 
showed improved peripheral insulin sensitivity. We observed a somewhat decreased 
platelet count after MCD as compared to MCC diet in Adamts13-/- mice, but VWF levels 
were unchanged. Additionally, LDH activity was comparable for Adamts13-/- mice on 
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either diet and clear TTP symptoms could not be identified in Adamts13-/- mice fed the 
MCD diet. Thus, these data do not support a role for steatosis in TTP development in 
this model. Nonetheless, Lombardi et al. suggested that since hepatic stellate cells are 
the main producers of ADAMTS13, NAFLD/NASH could affect ADAMTS13 levels. This 
hypothesis was based on a clinical case of TTP not induced by inhibitory antibodies 
nor by a genetic ablation of ADAMTS13, in a morbid obese subject suffering from 
NASH (144). However, we did not find differences in ADAMTS13 antigen levels 
between WT mice fed the MCC or MCD diet.  
Animal models to the rescue 
Since TTP is a very rare disease, databases and registries are scarce and patients are 
spread around the world, hampering clinical research.  
In the Oklahoma TTP cohort study, it was observed that the prevalence of morbid 
obesity was significantly higher in TTP patients (126) and that ADAMTS13 levels were 
lower when patients were obese (127, 145). This is in contrast with the higher 
ADAMTS13 levels we found in obese WT mice. Therefore, the increase in ADAMTS13 
antigen and activity in obese WT mice could be a potential protection mechanism 
against TTP (see Figure 38). Probably, this mechanism fails in genetically predisposed 
subjects resulting in a higher risk for TTP development. From a few observational 
studies, obesity was suggested as a risk factor for TTP. We investigated this by using 
lean and obese Adamts13-/- mice. Animal models are indeed valuable to gain insight in 
the cause, clinical course and outcome of TTP. However, Adamts13-/- mice do not 
show signs of TTP without extra triggering factors as Stx (61) or high dose human 
rVWF (64). Therefore, we attempted to develop an improved model using obese 
Adamts13-/- mice. Although the obese Adamts13-/- mice showed a lower platelet count 
and more hepatic microthrombi in comparison with lean Adamts13-/- or obese WT mice, 
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these findings did not allow to conclude that obesity is indeed a risk factor for TTP, nor 
to use the obese Adamts13-/- mouse as a new model for TTP. However, after injection 
of a threshold dose of rVWF in obese genetically predisposed mice, severe 
thrombocytopenia and organ damage were observed (Figure 40). Since this was not 
seen in lean mice, obesity may indeed be a risk factor for TTP development in 
Adamts13-/- mice. The injection of a threshold dose represents an improvement 
towards the previously used injection of high dose rVWF as this causes 
thrombocytopenia also in WT mice. Unfortunately, despite the severe 
thrombocytopenia and increased LDH activity levels, none of our obese mice 
developed end-stage TTP. 
Because of the 15 weeks diet, our model is quite time-consuming. Alternatively to diet-
induced obese, genetically obese mice (ob/ob) could be used. These are deficient in 
leptin, the satiety hormone, leading to uncontrolled food intake. Leptin stimulates 
energy expenditure by stimulating brown adipose tissue (146, 147) and modulating 
glucose and fat metabolism (148). It is unclear whether our results in the  
nutritionally induced obesity model would be the same in ob/ob mice. As it has been 
described that leptin promotes platelet aggregation, absence of leptin may delay 
thrombi formation and lead to decreased stability of the thrombus (137). The exact 
mechanisms of the effect of leptin on platelet aggregation and thrombus formation are 
still unclear, but since leptin-deficiency in obese subjects is very rare, a nutritionally 
induced obese mouse model is probably more representative.  
Because of the ADAMTS13 deficiency, the model is more representative for the 
hereditary form of TTP. Congenital TTP represents only 5% of all TTP cases (56), and 
therefore a model for acquired TTP could be more interesting. Lean WT mice injected 
with antibodies against ADAMTS13 before high dose rVWF injection were previously 
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used as model for acquired TTP (149). Possibly, similar approaches could be used in 
obese WT mice, but instead of high dose rVWF, the threshold dose should be injected. 
However, the injection of antibodies in addition to the diet and rVWF injection would 
further complicate the model. 
Rodents are the most used animals to study obesity and related comorbidities. Mouse 
models show several important similarities with humans concerning adipose tissue 
(150). Unlike murine obesity models, mouse models for TTP are difficult to acquire and 
to work with. Baboons, on the other hand, develop acute acquired TTP by injection of 
ADAMTS13 neutralizing antibodies without further triggering (65). Baboons are more 
closely related to humans and are therefore very useful as non-human primates. Lean 
baboons do not develop end-stage TTP after administration of ADAMTS13 antibodies, 
but induction of obesity could possibly aggravate the TTP symptoms. Obesity has not 
yet been induced in baboons in TTP research, but has already been applied in 
pregnancy studies (151, 152) or studies investigating complex genetic diseases like 
the metabolic syndrome and cardiovascular diseases (153). Therefore, it could be of 
interest to use obese baboons injected with ADAMTS13 neutralizing antibodies as 
animal model for acquired TTP. However, expensive housing requirements and ethical 
considerations will hamper the widespread use of such model. 
In conclusion, obese Adamts13-/- mice injected with a threshold dose of rVWF 
represent an improved TTP model, suffering from severe thrombocytopenia and organ 
damage. Despite the time-consuming diet, absence of several other TTP symptoms, 
non-clinical setting and genetic basis origin, this model has significant advantages as 
compared to existing mouse models or larger animal models.  
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Figure 40: Newly developed mouse model for TTP and its (dis)advantages. 
Obese Adamts13-/- mice injected with a threshold dose of rVWF present with TTP symptoms.  
Abbreviations: Adamts13-/-: ADAMTS13 deficient; rVWF: recombinant von Willebrand Factor; 
i.v.: intravenously; LDH: lactate dehydrogenase activity; TTP: thrombotic thrombocytopenic 
purpura. 
 
Macrophages: important in TTP pathophysiology? 
Obesity is a pro-inflammatory state characterized by an increase in pro-inflammatory 
macrophages in the adipose tissue (154), but also in the liver (155). These hepatic 
macrophages (Kupffer cells) are involved in clearance of both platelets and VWF (23, 
49). In our study, depletion of hepatic and splenic macrophages by clodronate resulted 
in normal platelet counts after injection of rVWF in obese Adamts13-/- mice, suggesting 
that macrophages may play a causative role in severe thrombocytopenia by clearance 
of platelet/VWF complexes. Thus, in addition to what is generally accepted (156), TTP 
related thrombocytopenia may be a consequence of platelet clearance by 
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macrophages combined with microthrombosis. It was, however, not possible to 
determine the quantitative contribution of either process to thrombocytopenia.  
To investigate a potential role of macrophages in TTP related thrombocytopenia, we 
used Adamts13-/- mice injected with clodronate liposomes followed by rVWF. 
Clodronate is delivered intracellularly by liposomes that will become phagocytosed by 
macrophages in the sinusoids. Phospholipases in the macrophages disrupt the 
liposomal phospholipid bilayers resulting in clodronate release specifically inside the 
macrophages (157) (Figure 41). 
 
Figure 41: Mechanism of macrophage apoptosis by clodronate.  
Clodronate liposomes consist of phospholipid bilayers separated by hydrophilic compartments 
containing clodronate (green) (A). Liposomes filled with clodronate are endocytosed by 
macrophages. Fusion of lysosomes (filled with phospholipases (blue)) with clodronate 
liposomes causes disruption of the bilayers resulting in clodronate release and apoptosis of the 
macrophage (B).  
Figure based on (157). 
 
It should be kept in mind that clodronate liposomes may have several limitations: 
1)  Whereas in our study i.v. clodronate injection resulted in a small, but not 
significant increase of platelet counts after 24h, it is possible that without VWF 
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injection, clodronate treatment could affect platelet counts after 48h or 72h (158-
160). Macrophages in the spleen and bone marrow may be important in the 
regulation of megakaryopoiesis and thrombopoiesis, processes stimulated by 
clodronate (161). Therefore, it is conceivable that in our study, clodronate also 
stimulates platelet production, leading to very high platelet numbers that will 
decrease after rVWF treatment. Hence, the normal platelet counts in obese 
Adamts13-/- mice after clodronate and rVWF injection could be misleading. This 
should be further investigated in separate experiments. 
2) Phagocytic uptake of liposomes has been ascribed to platelets as well. Male et 
al. showed that platelets are able to phagocytose liposomes with a diameter of 
74 nm (162). Since clodronate liposomes have a diameter between 150 nm and 
3 µm (163) they are unlikely to be encapsulated by platelets. Furthermore, 
because clodronate liposomes were injected intravenously, hepatic and splenic 
macrophages were effectively killed without affecting other organs, since 
clodronate does not cross the cell membrane of macrophages (157, 164). 
Additionally, free clodronate in circulation from dead macrophages has an 
extremely short half-life (157). Therefore, it can be assumed that clodronate did 
not affect platelets directly. 
3) Potential uptake of clodronate by phagocytic dendritic cells (165, 166) has not 
been evaluated in our study. 
Theoretically, the higher abundance of macrophages in the obese phenotype could be 
protective against microthrombi formation in obese Adamts13-/- mice, because 
macrophages clear VWF, particularly in the activated state. Hence, after macrophage 
depletion, both platelets and VWF are not efficiently cleared. In an ADAMTS13 
deficient setting, UL-VWF (unfolded due to the high shear forces in the arterioles and 
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capillaries) will remain uncleaved and hyperactively bind to platelets, resulting in 
microthrombosis. Therefore, since the macrophages phagocytose VWF in its active 
state (bound to platelets), they might play a protective role against microthrombi 
formation and consequently organ ischemia. However, this also results in severe 
thrombocytopenia due to platelet clearance by macrophages. Generally, the effect of 
platelet clearance by macrophages seems more explicit in mice of an Adamts13-/- 
background, particularly when injected with rVWF. Our in vitro data also indicated that 
platelet clearance by macrophages is enhanced by VWF. 
Nonetheless, the preliminary data of our in vivo study indicate that rVWF injection 
resulted in formation of platelet aggregates and presence of single platelets in the liver 
when macrophages were not depleted (Figure 42A). Therefore, this observation does 
not allow to propose a protective role of macrophages against microthrombi formation. 
Moreover, after clodronate injection in comparison with control mice, fewer hepatic, but 
more splenic platelet aggregates were found (Figure 42B). This platelet consumption 
in splenic microaggregates could probably explain the slight decrease of platelets we 
observed after rVWF injection in mice treated with clodronate.  
Noteworthy, in ITP patients, most platelets are accumulated in the spleen, whereas in 
mice the accumulation of sensitized platelets is primarily observed in the liver (159). 
Hence, our findings may not be entirely representative for humans due to species 
differences. 
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Figure 42: Role of macrophages in TTP.  
After injection of rVWF in obese Adamts13-/- mice, platelet counts were extremely low, probably 
due to microaggregation and platelet clearance in the liver by hepatic macrophages (A). 
Macrophage depletion prevented thrombocytopenia after rVWF injection. The limited platelet 
drop induced by rVWF could probably be explained by microaggregate formation in the spleen 
(B). Abbreviations: rVWF: recombinant von Willebrand Factor; Adamts13-/-: ADAMTS13 (a 
disintegrin and metalloproteinase with thrombospondin-1 repeat, member 13) deficient; i.v.: 
intravenously; Mφ: macrophages. 
 
Novel TTP treatments to prevent platelet-VWF interactions, such as the nanobody 
Caplacizumab (58), aptamers (167) or anfibatide (168) are very promising (55). These 
agents prevent the first step in platelet adhesion to the vessel wall, resulting in 
improved endothelial function (169) and decreased thrombi formation, hence less 
organ damage (58, 168). Although the most important effect of these drugs is inhibition 
of microthrombosis, platelet clearance by macrophages will probably also be affected, 
because platelets will not bind to VWF in the presence of these agents. Combined with 
decreased formation of platelet-rich thrombi, reduced platelet clearance will result in 
normal platelet counts.    
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Future perspectives  
The preliminary in vivo data showing hepatic or splenic microaggregates of fluorescent 
platelets and single platelets in obese Adamts13-/- mice should be investigated more 
extensively and quantitatively. Therefore, histological stainings and/or western blot 
analysis of platelet markers on liver and spleen tissue of obese mice injected with 
clodronate or PBS, followed by rVWF, should be performed. Preferably, these 
analyses should be carried out on tissues acquired from mice that were not injected 
with fluorescently labeled platelets obtained from donor mice. Furthermore, the effects 
of clodronate treatment on megakario-/thrombopoiesis in Adamts13-/- mice should be 
investigated. 
Finally, it will be important to demonstrate the validity of the newly developed mouse 
model. This could be done by treatment with inhibitors of the interaction between VWF 
and platelets. Furthermore, since this mouse model shows high rates of platelet 
clearance, it could also be useful for platelet clearance studies in other diseases.  
General conclusions 
1. Despite the increased levels of ADAMTS13 in obesity and its reported role in 
angiogenesis and inflammation, it does not affect adipose tissue expansion in a 
diet-induced obese mouse model. 
2. Obesity in combination with ADAMTS13 deficiency results in a slightly 
decreased platelet count accompanied by formation of platelet-rich hepatic 
thrombi. 
3. Although ADAMTS13 has been implicated in several liver diseases, it does not 
play a role in development of steatosis in our mouse models. 
4. Obesity is a risk factor for TTP in mice. Despite the absence of some TTP 
related symptoms and a disease onset different from human subjects, obese 
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Adamts13-/- mice injected with a threshold dose of rVWF can be useful as new 
model for TTP. 
5. After triggering for TTP, macrophages, particularly in the liver, are involved in 
platelet clearance, resulting, in combination with formation of platelet-rich 
hepatic microthrombi, in severe thrombocytopenia.  
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Thesis abstract 
TTP is a life-threatening disease characterized by severe thrombocytopenia and 
formation of platelet-rich thrombi in the microcirculation. It is caused by deficiency of 
ADAMTS13 activity, the VWF cleaving proteinase, in combination with an additional 
triggering factor. Altough it is associated with higher ADAMTS13 levels, obesity has 
been proposed as potential risk factor for TTP development. Using Adamts13-/- mice, 
we did not find evidence for a role of ADAMTS13 in adipose tissue development or 
liver steatosis. However, we found that obesity combined with deficiency of 
ADAMTS13 leads to enhanced hepatic thrombosis. Since Adamts13-/- mice do not 
develop TTP spontaneously, we injected a threshold dose of rVWF to trigger it and 
observed that obese mice are more sensitive, indicating that obesity indeed may be a 
risk factor for TTP. Obesity is a state of low-grade chronic inflammation associated with 
an increase of macrophage content in adipose tissues and liver. Since hepatic 
macrophages are important in platelet and VWF clearance, we depleted these cells, 
and observed that platelet counts were normalized in obese Adamts13-/- mice despite 
TTP triggering. Thus, the severe thrombocytopenia in TTP appears to be due to 
consumption of platelets in microthrombi as well as to platelet clearance by 
macrophages. These findings could be relevant for the development of new strategies 
for prevention or treatment of TTP.  
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Summary 
Thrombotic thrombocytopenic purpura (TTP) is a very rare, but life-threatening disease 
characterized by severe thrombocytopenia, micro-angiopathic hemolytic anemia 
(formation of microthrombi, schistocytes, low hematocrit) and less common by fever, 
neurological damage and kidney failure. TTP is caused by a deficiency or total absence 
of the proteinase ADAMTS13 (a disintegrin and metalloproteinase with 
thrombospondin-1 repeat, member 13) that can cleave hyperactive ultra-large von 
Willebrand Factor (UL-VWF) multimers thereby preventing thrombus formation. In 
addition to an ADAMTS13 activity of less than 5%, a secondary risk factor appears to 
be needed to evoke endothelial damage resulting in an acute TTP attack. Known 
triggers are pregnancy and inflammatory diseases, but in most cases the triggering 
factor remains unknown. Therefore, the precise etiology of TTP is still a matter of 
debate, hampering prevention of TTP episodes and adapted treatments.  
Obesity has been proposed as a potential risk factor for TTP development. However, 
the obese state is associated with increased systemic ADAMTS13 antigen and activity 
levels, which would be expected to protect against TTP. Moreover, obesity is a pro-
inflammatory state, whereas ADAMTS13 has anti-inflammatory potential.  
Because of the enhanced ADAMTS13 levels after a high fat diet (HFD) in mice, we 
proposed that ADAMTS13 could play a functional role in adipose tissue expansion. 
Therefore, both Adamts13-/- and WT mice were kept on a HFD or standard fat diet 
(SFD). Body weight gain and food intake, as well as weight of gonadal (GN) and 
subcutaneous (SC) fat depots, expression of inflammatory or oxidative stress markers 
in the adipose tissues, and obesity-related angiogenesis were not different between 
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WT and Adamts13-/- mice. Therefore, we concluded that ADAMTS13 does not play a 
functional role in adiposity and adipose tissue expansion in mice.  
Besides adipose tissues, we examined the liver (the major organ of ADAMTS13 
secretion) of lean and obese Adamts13-/- and WT mice. Histological staining for VWF, 
TSP-1 and fibrinogen revealed a higher prevalence of platelet-rich microthrombi in liver 
tissue of obese Adamts13-/- as compared to WT mice. Moreover, platelet counts in the 
obese Adamts13-/- mice were significantly lower than in their lean or WT counterparts, 
and the plasma contained higher levels of ultra-large VWF multimers (UL-VWF). Thus, 
ADAMTS13 deficiency in mice in combination with obesity acts synergistically in 
development of hepatic microthrombi and some symptoms of TTP (lower platelet 
count, more UL-VWF). This does, however, not represent a complete TTP phenotype.  
Adamts13-/- mice are healthy and do not present with clear TTP-related symptoms. 
Administration of Shiga toxin (Stx) or high dose recombinant VWF (rVWF) induces a 
TTP-like phenotype. However, such TTP mouse models are difficult to handle and not 
very reproducible. Therefore, we tried to develop a new TTP mouse model using obese 
Adamts13-/- mice, since these were likely to be more sensitive to TTP development. 
After injection of a threshold dose of recombinant VWF (rVWF) (250 U/kg) (the highest 
dose not causing thrombocytopenia in lean Adamts13-/- mice), we observed a platelet 
drop of 96% in obese Adamts13-/- mice. Moreover, these obese mice showed signs of 
organ damage, likely as a consequence of microthrombosis. Since these symptoms of 
TTP were not seen in lean Adamts13-/- or in obese WT mice, we conclude that obesity 
is a risk factor for TTP development in genetically predisposed (Adamts13-/-) mice. 
However, obese Adamts13-/- mice injected with a threshold dose of rVWF still have 
limitations as animal model for TTP, as they do not show schistocytosis or a decrease 
in hematocrit.  
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Obesity is a state of low-grade chronic inflammation primarily caused by an increase 
of pro-inflammatory macrophages in the adipose tissue, but also in the liver. Since 
macrophages in the liver and the spleen are involved in clearance of both platelets and 
VWF, we depleted these macrophages in obese Adamts13-/- mice before injection of 
rVWF, and observed that platelet counts were normalized. Moreover, a higher number 
of platelets was phagocytosed by macrophages in vitro after addition of rVWF. Hence, 
the severe thrombocytopenia in TTP may be the result of both platelet consumption in 
microthrombi and platelet clearance by macrophages.  
Future studies should further unravel the mechanism of platelet clearance by 
macrophages in TTP models. Our findings could be relevant for the development of 
new strategies for prevention or treatment of TTP. 
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Nederlandse samenvatting 
Trombotische trombocytopenische purpura (TTP) is een zeer zeldzame, maar 
levensbedreigende ziekte gekenmerkt door ernstige trombocytopenie, micro-
angiopathische hemolytische anemie (vorming van microtrombi, schistocyten, laag 
hematocriet) en minder vaak door koorts, neurologische schade en nierfalen. TTP 
wordt veroorzaakt door een tekort of totale afwezigheid van het protease ADAMTS13 
(a disintegrin and metalloproteinase with thrombospondin-1 repeat, member 13) die 
hyperactieve ultralange von Willebrand Factor (UL-VWF) multimeren kan splitsen en 
daardoor trombusvorming kan voorkomen. Naast een ADAMTS13 activiteit onder 5%, 
wordt gedacht dat een secundaire risicofactor nodig is om endotheliale schade of 
activatie uit te lokken met een acute TTP-aanval als gevolg. Gekende triggers zijn 
onder meer zwangerschap en ontstekingsziekten, maar in de meeste gevallen is de 
oorzaak onduidelijk. Daarom is de exacte etiologie van TTP niet uitgeklaard, wat het 
voorkomen van TTP-aanvallen en gerichte behandelingen bemoeilijkt. 
Obesitas werd voorgesteld als een mogelijke risicofactor voor de ontwikkeling van 
TTP. Vreemd genoeg zien we bij obesitas verhoogde systemische ADAMTS13 
antigen- en activiteitniveaus, waardoor men een bescherming tegen TTP zou 
verwachten. Daarenboven is obesitas een pro-inflammatoire toestand terwijl 
ADAMTS13 anti-inflammatoire eigenschappen heeft. 
De verhoogde ADAMTS13-niveaus na een vetrijk dieet (HFD) bij muizen wijzen op een 
mogelijke functionele rol van ADAMTS13 in vetweefselexpansie. Om dit te 
onderzoeken hebben we zowel Adamts13-/- als WT muizen op een HFD of standaard 
vet dieet (SFD) gezet voor 15 weken en de toename in lichaamsgewicht en 
voedselinname gemeten; we vonden geen verschillen tussen de genotypes. Verder 
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waren er geen relevante verschillen tussen WT en Adamts13-/- muizen wat betreft 
gewicht van gonadale (GN) en subcutane (SC) vetdepots, expressie van inflammatoire 
en oxidatieve stressmerkers in het vetweefsel, of obesitasgerelateerde angiogenese. 
Daarom besloten we dat ADAMTS13 geen functionele rol speelt in vetweefselexpansie 
bij muizen. 
Naast vetweefsel, onderzochten we de lever (het belangrijkste orgaan voor secretie 
van ADAMTS13) van magere en obese Adamts13-/- en WT muizen. Histologische 
kleuringen voor VWF, TSP-1 en fibrinogeen toonden een groter aantal microtrombi rijk 
in plaatjes/VWF in leverweefsel van obese Adamts13-/- in vergelijking met WT muizen. 
Bovendien was het bloedplaatjesaantal is deze Adamts13-/- muizen significant 
verlaagd in vergelijking met de magere of WT tegenhangers. De plasmawaarden van 
ultralange VWF multimeren (UL-VWF) waren daarenboven ook hoger. ADAMTS13-
deficiëntie in combinatie met obesitas bij muizen werkt dus synergistisch in het 
ontwikkelen van hepatische microtrombi. Alhoewel deze muizen daarbij tekenen van 
TTP (lager aantal bloedplaatjes, meer UL-VWF) vertoonden, waren de resultaten niet 
overtuigend genoeg om dit fenotype als TTP te definiëren. 
Adamts13-/- muizen zijn gezond en vertonen geen TTP-gerelateerde symptomen. 
Toediening van Shigatoxine (Stx) of hoge dosis recombinant VWF (rVWF) kunnen een 
TTP-gelijkend fenotype induceren in Adamts13-/- muizen. Deze bestaande TTP-
muismodellen zijn moeilijk in gebruik en niet altijd reproduceerbaar. Daarom hebben 
we getracht een nieuw TTP-muismodel te ontwikkelen, vertrekkende van obese 
Adamts13-/- muizen, gezien deze gevoeliger leken te zijn voor TTP-ontwikkeling. 
Hiervoor bepaalden we een threshold dosis van rVWF (250 U/kg) (de hoogste dosis 
die net geen thrombocytopenie veroorzaakt in magere Adamts13-/- muizen) om te 
injecteren in de obese muizen. Na injectie namen de bloedplaatjesaantallen in obese 
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genetisch voorbeschikte muizen af met maar liefst 96%. Bovendien vertoonden deze 
obese Adamts13-/- muizen tekenen van orgaanschade, waarschijnlijk als gevolg van 
microtrombose. Aangezien deze TTP-indicaties niet werden teruggevonden in magere 
Adamts13-/- of obese WT muizen, besluiten we dat obesitas een risicofactor is voor de 
ontwikkeling van TTP in muizen met een genetische aanleg (Adamts13-/-). De obese 
Adamts13-/- muizen geïnjecteerd met een drempeldosis van VWF zijn echter nog niet 
optimaal als diermodel voor TTP omdat deze muizen geen duidelijke schistocytose of 
een verlaagd hematocriet vertonen. 
Obesitas is gekend als een pro-inflammatoire toestand voornamelijk veroorzaakt door 
een toename van pro-inflammatoire macrofagen in het vetweefsel, maar ook in de 
lever. Aangezien macrofagen in de lever en de milt betrokken zijn bij de klaring van 
zowel bloedplaatjes als VWF, hebben we de macrofagen in obese Adamts13-/- muizen 
gedood vóór injectie van rVWF en merkten we op dat het bloedplaatjesaantal 
normaliseerde. Bovendien werd een groter aantal bloedplaatjes in vitro gefagocyteerd 
door macrofagen na toevoeging van rVWF. Het lijkt er dus op dat de ernstige 
trombocytopenie bij TTP een gevolg is van zowel bloedplaatjesconsumptie in 
microtrombi als van klaring van bloedplaatjes door macrofagen. 
Het zou zinvol zijn toekomstige studies uit te voeren om het onderliggend mechanisme 
van plaatjesklaring door macrofagen in TTP te ontrafelen. Dergelijke kennis zou nuttig 
kunnen zijn om TTP-aanvallen te voorkomen of te behandelen.
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